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Abstract
To investigate the regulation of flavin-containing monooxygenase 5 (FM 05) by 
xenobiotics in mouse liver, a method for isolating primary mouse hepatocytes was 
designed. Fmo5 expression was up-regulated by hormones (estradiol, progesterone), 
dietary supplements (lipoic acid) and other xenobiotics (rifampicin, ethanol) in primary 
mouse hepatocytes and HepG2 cells. Gene reporter assays showed that Fmo5 expression 
in HepG2 cells is mediated by pregnane-x-receptor (PXR) ligands.
To uncover more about the endogenous role of FMOs, two knockout mouse 
models, Fmol, 2, 4 (-/-) and Fmo5 (-/-), were studied. Fmol, 2, 4 (-/-) males weighed less 
and had less gonadal fat than their wild-type counterparts. The bodyweight o f the Fmol, 
2, 4 (-/-) females was greater than that of the wild-type females. Histology shows that the 
adipocytes in the Fmol, 2, 4 (-/-) male mice are 50% smaller than wild-type male 
adipocytes, and the liver histology shows the Fmol, 2, 4 (-/-) males had less fat in the 
liver compared to wild-type males. Fmol, 2, 4 (-/-) mice had higher plasma total-, HDL- 
and LDL-cholesterol than the wild-type mice. On a high-fat diet, the male Fmol, 2, 4 (-/- 
) mice gain weight and gonadal fat weight.
The Fmo5 (-/-) mice have a similar bodyweight and fat weight to the wild-type 
animals, but Fmo5 (-/-) mice have lower plasma HDL cholesterol and lower plasma iron 
than WT mice.
The results therefore show that a deficiency in FMOs interferes with endogenous 
fat metabolism.
Lipoic acid is an endogenous substrate of FM Ol, so to see if the inability to 
metabolise lipoic acid is the reason for the lower bodyweight and fat weight in Fmol, 2, 4 
(-/-) males, the mice were fed a 0.1% lipoic acid diet. All knock-out and wild-type mice 
lose a similar amount of weight. This implies that the metabolism of lipoic acid is not the 
fundamental endogenous role o f FMOs.
2
Contents
1 Introduction____________________________________________________________17
1.1 Liver structure and function___________________________________________ 17
1.1.1 Vasculature of the liver________________________________________________________18
1.2 The acinus-the functional unit of the liver________________________________ 19
1.2.1 Liver lobule and acinus_______________________________________________________ 20
1.3 Xenobiotic Metabolism________________________________________________21
1.4 Cytochromes P450 ___________________________________________________21
1.5 Flavin-containing monooxygenases (FMOs)______________________________22
1.6 Expression of FMOs_________________________________________________ 23
1.6.1 FMO catalytic cycle__________________________________________________________ 25
1.7 FMO developmental expression________________________________________26
1.8 Sex differences and hormonal effects on FMO expression___________________ 26
1.9 The effects of growth hormone on FMO expression________________________ 28
1.10 FMOs in diabetes____________________________________________________29
1.11 FMOs role in iron homeostasis_________________________________________30
1.12 Instances of FMO induction ___________________________________________30
1.13 FMOs and dietary components_________________________________________31
1.14 FMO, endogenous substrates and redox state_____________________________33
1.15 FM05 and its limited substrate portfolio_________________________________34
1.15.1 Substrates and inducers of FM 05_____________________________________________ 36
1.16 FM05 regulation by hormones_________________________________________37
1.17 Orphan Nuclear Receptors___________________________________________ 37
1.18 AhR, CAR and PPAR________________________________________________ 38
1.19 Pregnane X Receptor (PXR)__________________________________________ 39
1.19.1 Nuclear receptor mode of action and PXR ligands_______________________________ 40
1.20 Drug-drug and drug-diet interactions___________________________________41
3
1.21 Liquorice__________________________________________________________ 42
1.22 Objectives of this project_____________________________________________ 43
2 Materials and Methods  ________________________________________________ 45
2.1.1 Chemicals and Reagents______________________________________________________ 45
2.1.2 Culture of bacteria___________________________________________________________ 45
2.1.3 Small-scale isolation of plasmid DN A from bacteria_______________________________ 45
2.1.4 Medium-scale isolation of plasmid DN A from bacteria_____________________________ 46
2.1.5 Quantification of DNA by UV spectrophotometry_________________________________ 47
2.1.6 Agarose gel electrophoresis o f DNA fragments___________________________________ 47
2.1.7 Gel extraction________________________________________________________________48
2.1.8 Polymerase Chain Reaction (PC R)______________________________________________48
2.1.9 TOPO®/TA cloning___________________________ ;______________________________ 49
2.1.10 Bacterial transformation____________________________________________________49
2.1.11 Restriction endonuclease digestion of DNA____________________________________ 51
2.1.12 Ligation_________________________________________________________________ 51
2.1.13 Preparation of glycerol stocks________________________________________________51
2.2 Isolation and maintenance of primary mouse hepatocytes___________________52
2.2.1 Sterilisation of the perfusion apparatus___________________________________________ 52
2.2.2 Matrigel coating of culture p lates_______________________________________________ 52
2.2.3 Dissection __________________________________________________________________ 52
2.2.4 Two-step Perfusion of the Mouse L iver_________________________________________ 53
2.2.5 Purification of Mouse Hepatocytes______________________________________________56
2.2.6 Hepatocyte dosing regime_____________________________________________________ 56
2.2.7 Isolation of primary mouse hepatocyte lysates____________________________________ 57
2.2.8 Trypan Blue exclusion test_____________________________________________________ 57
2.3 Cell culture________________________________________________________ 59
2.3.1 HepG2 cell culture___________________________________________________________ 59
2.3.2 Transient transfection of HepG2 cells____________________________________________59
2.3.3 Isolation of total RNA from HepG2 cells or primary hepatocytes_____________________59
2.4 Down-stream analysis________________________________________________ 60
2.4.1 Dual-Luciferase reporter assay and pGL3 vectors__________________________________ 60
2.4.2 Protein concentration determination_____________________________________________63
2.4.3 SDS-PAGE_________________________________________________________________63
2.4.4 Coomassie Blue staining______________________________________________________ 64
2.4.5 Western blotting_____________________________________________________________ 64
4
2.5 Microarray________________________________________________________ 65
2.5.1 Cell treatment and preparation of RNA for microarray______________________________ 65
2.5.2 Microarray procedure________________________________________________________ 65
2.5.3 Real-time RT P C R _ _________________________________________________________ 67
2.6 Animal Husbandry___________________________________________________68
2.6.1 Mouse weighing______________________________________________________________ 69
2.6.2 Mouse diets_________________________________________________________________ 69
2.6.3 Dissection _________________________________________________________________ 69
2.6.4 Blood collection______________________________________________________________70
2.6.5 Blood plasma biochemical tests________  70
2.6.6 Liver histology_______________________________________________________________ 70
2.6.7 Adipose histology____________________________________________________________71
3 FMOS promoter cloning and analysis_____________________________________ 74
3.1 Identification of FMOS leader sequence_________________________________ 74
3.2 Amplification of the FMOS promoter region_____________________________ 74
3.2.1 FM05 cDNAs_______________________________________________________________ 75
3.2.2 Gel picture o f clone inserts____________________________________________________ 76
3.3 Conservation of the human FMOS promoter region_______________________ 77
3.4 FMOS promoter sequence analysis_____________________________________ 77
3.4.1 Human FM05 promoter compared to the mouse and chimp promoters________________ 78
3.4.2 Analysis of mouse and human FM05 promoter___________________________________ 83
3.5 Transfecting HepG2 cells_____________________________________________ 84
3.5.1 The promoter cloning and transfection strategy____________________________________ 85
3.6 Failure to obtain expression of human FMOS reporter gene constructs in primary
mouse hepatocytes_________________________________________________________ 86
3.6.1 Luciferase assay development-constructs at 24 and 48 hours_________________________ 87
3.6.2 Luciferase assay development-pGL3 control______________________________________ 88
3.7 Effects of xenobiotics on FMOS promoter reporter constructs and FM05 mRNA
expression________________________________________________________________ 89
3.8 Progesterone regulation of FMOS expression____________________________ 89
3.8.1 Progesterone effects on FM05 promoter constructs in HepG2 cells___________________ 92
3.8.2 Progesterone effects on FM05 mRNA in HepG2 and male mouse hepatocytes__________93
3.8.3 Induction of Fmo5 mRNA by progesterone in female mouse hepatocytes______________94
5
3.9 Rifampicin induces FMOS expression, and FM05 mRNA in both human and
mouse 95
3.9.1 Effects of rifampicin on FM05 promoter constructs in HepG2 ce lls__________________ 97
3.9.2 Effects of rifampicin on FM05 mRNA and reporter gene constructs__________________ 98
3.10 Ligand-independent effects of PXR on FMOS promoter reporter gene constructs 
99
3.11 Testosterone repression of the FMOS promoter but induction of FM05 mRNA 99
3.11.1 Effects of testosterone on the FM05 promoter and on Fmo5 mRNA________________ 101
3.11.2 Testosterone effects on FM05 mRNA in HepG2 and male mouse hepatocytes_______ 102
3.12 Dose-dependent mediation of FMOS by estradiol_______________ 103
3.12.1 Effects of 17|3-estradiol on FM05 promoter constructs in HepG2 cells______________105
3.12.2 Effects of estradiol on FM05 promoter constructs in HepG2 cells co-transfected with
mERa 106
3.12.3 17P-estradiol effects on FM05 mRNA in HepG2 and male mouse hepatocytes_______107
3.12.4 Effect of 17|3-estradiol on FM05 mRNA in female mouse hepatocytes _____________108
3.13 Hyperforin and its effect on FMOS promoter constructs_________ 109
3.13.1 The repression of FM05 promoter constructs by hyperforin in HepG2 cells__________ 110
3.13.2 The effect of hyperforin and hPXR or mPXR on the FM05 promoter_____________ 111
3.14 Lipoic acid and its effect on FMOS promoter constructs_________ 112
3.14.1 The effect of lipoic acid or ethanol on the FM05 promoter_______________________ 113
3.14.2 The effect of lipoic acid on FM05 mRNA_____________________________________114
3.15 Ethanol induces FMOS promoter constructs____________________________ 115
3.16 Conclusions______________________________________________ 115
4 Isolation and maintenance o f  primary mouse hepatocytes___________________120
4.1 Isolation of primary hepatocytes from mice____________________ 121
4.2 Cannulation______________________________________________ 122
4.2.1 Hepatocyte methods__________________________________________________________ 124
4.3 Liver removal____________________________________________ 126
4.4 Perfusion buffers__________________________________________ 126
4.5 Perfusion flow rate________________________________________ 127
4.6 Collagenase______________________________________________ 127
6
4.7 Maintenance of mouse primary hepatocytes-use of media_________________ 128
4.8 Plate coatings_______________________________________________________ 128
4.9 Plating density _________________________________________________129
4.9.1 Primary mouse hepatocytes plated onto collagen_________________________________130
4.9.2 Primary male mouse hepatocytes plated on Matrigel™ ___________________________ 131
4.9.3 Primary male mouse hepatocytes plated onto Matrigel™ and cell density_____________ 132
4.9.4 Primary male mouse hepatocytes-plating density________________________________ 133
4.10 Defining a differentiated system-examples of healthy cultured mouse hepatocytes 
134
4.10.1 Demonstration of healthy morphology_______________________________________ 135
4.11 Confirmation of a P450 response using phenobarbital_________________ 136
4.11.1 Induction of CYP2B in phenobarbital-treated primary mouse hepatocytes__________ 136
4.12 Investigating hepatocyte genetic response to glycyrrhetinic acid using microarray
137
4.13 Xenobiotic metabolism_______________________________________________ 137
4.14 Glycolysis__________________________________________________________ 137
4.14.1 Table of the genes up-regulated in glycyrrhetinic acid-treated hepatocytes__________ 139
4.15 Hypoxia and apoptosis_______________________________________________ 140
4.15.1 Diagram 1: The response of genes and their inter-relationship when primary male mouse
hepatocytes are treated with glycyrrhetinic a c id _________________________________________ 143
5 Investigation into FMO knock-out mouse models and implications fo r  the
endogenous role(s) o f  F M O s________________________________________________146
5.1 Weight analysis of male Fmol, 2, 4 (-/-) knock-out m ice___________________ 146
5.1.1 Picture of Fmol, 2, 4 (-/-) male mouse and WT male m ouse________________________ 147
5.2 Weight analysis of female Fmol, 2, 4 (-/-) knock-out mice__________________ 148
5.3 Food intake of Fmol, 2, 4 (-/-) knock-out and WT mice____________________ 148
5.3.1 Bodyweights of Fmol, 2, 4 (-/-) and WT m ice____________________________________149
5.3.2 Food consumption of Fmol, 2, 4 (-/-) and WT mice_______________________________ 150
5.3.3 Percentage weight gain of Fmol, 2, 4 (-/-) and WT m ice___________________________ 151
5.4 Fmol, 2, 4 (-/-) males have less gonadal fat than WT males_________________ 152
5.5 Fmol, 2, 4 (-/-) males have smaller hearts_______________________________152
7
5.5.1 Abdominal and kidney photos from Fmol, 2, 4 (-/-) and WT male m ice_______________153
5.5.2 Organ weights at 4 and 10 weeks of age-Fmol, 2, 4 (-/-) males_____________________ 154
5.5.3 Organ weights and gonadal fat weight__________________________________________ 155
5.5.4 Heart weights  _______________________________________________________156
5.6 Fmol, 2, 4 (-/-) males have less fat in the liver than WT males_____________ 157
5.7 Fmol, 2y 4 (-/-) males have smaller adipocytes than WT males_____________ 157
5.7.1 Liver histology in Fmol, 2, 4 (-/-) and WT males at 4 weeks of age _________________ 158
5.7.2 Liver histology in Fmol, 2, 4 (-/-) and WT males at 10 weeks of age _____________159
5.7.3 Liver histology in Fmol, 2 ,4  (-/-) and WT males at 22 weeks of age__________________160
5.7.4 Adipocyte histology-10 week m ales____________________________________________ 161
5.7.5 Adipocyte histology-22 week m ales____________________________________________ 162
5.7.6 Adipocyte volumes-normal diet________________________________________________ 163
5.8 Analysis of blood plasma lipids and solutes in Fmoly 2,4  (-/-) male mice 164
5.8.1 Total cholesterol and HDL cholesterol__________________________________________165
5.8.2 LDL cholesterol and triglycerides______________________________________________ 166
5.8.3 Blood plasma solutes at 9 and 15 weeks of age____________________________________167
5.8.4 Blood plasma solutes at 20 weeks of age_________________________________________ 168
5.9 On a high-fat diet Fmoly 2, 4 (-/-) mice gain body weight, fat mass and adipocyte
size 169
5.9.1 Bodyweight and organ weights on a high-fat diet_________________________________ 170
5.9.2 Adipocyte histology-high fat d ie t______________________________________________ 171
5.10 Plasma lipid and solute analysis in Fmoly 2, 4 (-/-) males on a high-fat diet 172
5.11 Liver histology on a high-fat diet in WT and KO mice_____________________ 172
5.11.1 Plasma lipid and solutes on a high-fat d ie t____________________________________ 173
5.11.2 Liver histology in Fmol, 2 ,4  (-/-) and WT males on a high-fat d ie t_______________ 174
5.12 Analysis of bodyweight, organ weight, plasma lipids and plasma solutes in Fmoly
2, 4 (-/-) males on a lipoic acid diet___________________________________________ 175
5.12.1 Bodyweight and plasma lipids on a lipoic acid d ie t_____________________________177
5.12.2 Plasma solutes on a lipoic acid diet__________________________________________ 178
5.12.3 Organ weights on a lipoic acid diet__________________________________________ 179
5.12.4 Liver histology in Fmol, 2 ,4  (-/-) and WT males on a lipoic acid d ie t______________180
5.13 Organ weight analysis of Fmol, 2, 4 (-/-) females_________________________ 181
5.14 Analysis of plasma lipids and solutes in Fmol, 2, 4 (-/-) females_____________ 181
8
5.14.1 Organ weights of Fmol, 2, 4 (-/-) females at 4 weeks of age______________________ 182
5.14.2 Plasma total and HDL cholesterol____________________________________________ 183
5.14.3 Plasma LDL cholesterol and triglycerides_____________________________________184
5.14.4 Plasma solutes _________________________________________________________185
5.15 Analysis of Fmol, 2, 4 (-/-) females on a high-fat diet______________________186
5.15.1 Bodyweight and plasma lipids of females on a high-fat d ie t______________________ 187
5.15.2 Organ weights of Fmol, 2, 4 (-/-) females on a high-fat d iet______________________ 188
5.16 Investigation into FmoS (-/-) mice on a normal d iet____________ ;__________189
5.17 Blood plasma lipids in FmoS (-/-) mice__________________________________189
5.17.1 Bodyweights of Fmo5 (-/-) and WT males and females__________________________ 191
5.17.2 Percentage weight gain of Fmo5 (-/-) mice____________________________________ 192
5.17.3 Plasma total and HDL cholesterol in male Fmo5 (-/-) mice_______________________ 193
5.17.4 Plasma LDL cholesterol and triglycerides in Fmo5 (-/-) m ice_____________________ 194
5.17.5 Plasma total and HDL cholesterol in female Fmo5 (-/-) m ice_____________________ 195
5.17.6 Plasma LDL cholesterol in female Fmo5 (-/-) m ice_____________________________ 196
5.17.7 Plasma solutes in Fmo5 (-/-) mice at 15 weeks of ag e___________________________ 197
5.17.8 Plasma solutes in Fmo5 (-/-) mice at 22 weeks of ag e___________________________ 198
5.18 Analysis of FmoS (-/-) mice on a high-fat d iet____________________________199
5.18.1 Bodyweight in Fmo5 (-/-) mice on a high-fat diet ______________________________ 200
5.18.2 Plasma lipids in Fmo5 (-/-) mice on a high-fat diet______________________________ 201
5.18.3 Plasma solutes in Fmo5 (-/-) mice on a high-fat d ie t_______________  202
5.19 FmoS (-/-) males on a lipoic acid d iet__________________________________ 203
5.19.1 Bodyweight and blood plasma lipids on a lipoic acid d ie t________________________204
5.19.2 Organ weights on a lipoic acid diet___________________________________________205
5.19.3 Blood plasma solutes on a lipoic acid d ie t____________________________________ 206
5.20 Discussion________________________________________________________ 207
5.21 Current work_____________________________________________________ 211
5.21.1 Fat regulatory and fat oxidation genes in WT and KO white adipose ______________213
5.21.2 The expression of Fmos in WT male adipose__________________________________ 215
5.21.3 Ventricle weights vs bodyweight or femur length ______________________________ 216
5.22 Conclusions_______________________________________________________ 217
References________________________________________________________________ 219
Appendix_________________________________________________________________ 242
9
List of Figures
1.15.1 Substrates and inducers of FM 05_______________________________________________  36
1.18.1 Nuclear receptor mode of action and PXR ligands__________________________________ 40
2.1.10.1 PCR parameters______________________________________________________________ 50
2.2.4.1 Blood supply and circulation in the human liver (Merck.com)_________________________ 54
2.2.4.2 Representation of liver perfusion ap p a ra tu s .___________________________________ 55
2.2.8.1 Trypan Blue Exclusion T e s t____________________________________________________  58
2.4.1.1 The pGL3 vectors by Promega__________________________________________________  62
3.2.1 FM05 cDNAs_________________________________________________________________  75
3.2.2 Gel picture of clone inserts_______________________________________________________ 76
3.4.1 Human FM05 promoter compared to the mouse and chimp promoters___________________  78
3.4.2 Analysis of mouse and human FM05 promoter______________________________________ 83
3.5.1 The promoter cloning and transfection strategy_______________________________________  85
3.6.1 Luciferase assay development-constructs at 24 and 48 hours___________________________  87
3.6.2 Luciferase assay development-pGL3 control_________________________________________  88
3.8.1 Progesterone effects on FM05 promoter constructs in HepG2 cells______________________  92
3.8.2 Progesterone effects on FM05 mRNA in HepG2 and male mouse hepatocytes_____________  93
3.8.3 Induction of Fmo5 mRNA by progesterone in female mouse hepatocytes_________________  94
3.9.1 Effects of rifampicin on FM05 promoter constructs in HepG2 ce lls_____________________  97
3.9.2 Effects of rifampicin on FM05 mRNA and reporter gene constructs_____________________  98
3.11.1 Effects of testosterone on the FM05 promoter and on Fmo5 mRNA__________________  101
3.11.2 Testosterone effects on FM05 mRNA in HepG2 and male mouse hepatocytes_________  102
3.12.1 Effects of 17|3-estradiol on FM05 promoter constructs in HepG2 cells________________  105
3.12.2 Effects of estradiol on FM05 promoter constructs in HepG2 cells co-transfected with
mERa 106
3.12.3 17P-estradiol effects on FM05 mRNA in HepG2 and male mouse hepatocytes_________ 107
3.12.4 Effect of 17p~estradiol on FM05 mRNA in female mouse hepatocytes _______________ 108
3.13.1 The repression of FM05 promoter constructs by hyperforin in HepG2 cells___________  110
3.13.2 The effect of hyperforin and hPXR or mPXR on the FM05 promoter________________ 111
3.14.1 The effect of lipoic acid or ethanol on the FM05 promoter_________________________  113
3.14.2 The effect of lipoic acid on FM05 mRNA_______________________________________  114
4.2.1 Hepatocyte methods____________________________________________________________  124
4.9.1 Primary mouse hepatocytes plated onto collagen____________________________________  130
4.9.2 Primary male mouse hepatocytes plated on Matrigel™ ______________________________  131
4.9.3 Primary male mouse hepatocytes plated onto Matrigel™ and cell density________________ 132
4.9.4 Primary male mouse hepatocytes-plating density____________________________________ 133
10
4.10.1 Demonstration of healthy morphology___________________________________________ 135
4.11.1 Induction of CYP2B in phenobarbital-treated primary mouse hepatocytes_____________  136
4.14.1 Table of the genes up-regulated in glycyrrhetinic acid-treated hepatocytes_____________  139
4.15.1 Diagram 1: The response of genes and their inter-relationship when primary male mouse
hepatocytes are treated with glycyrrhetinic a c id ____________________________________________  143
5.1.1 Picture of Fmol, 2 ,4  (-/-) male mouse and WT male m ouse___________________________ 147
5.3.1 Bodyweights of Fmol, 2 ,4  (-/-) and WT m ice______________________________________  149
5.3.2 Food consumption of Fmol, 2, 4 (-/-) and WT mice___________________   150
5.3.3 Percentage weight gain of Fm ol, 2 ,4  (-/-) and WT m ice______________________________ 151
5.5.1 Abdominal and kidney photos from Fmol, 2, 4 (-/-) and WT male m ice_________________  153
5.5.2 Organ weights at 4 and 10 weeks of age-Fmol, 2 ,4  (-/-) males________________________  154
5.5.3 Organ weights and gonadal fat weight_____________________________________________  155
5.5.4 Heart weights_________________________________________________________________  156
5.7.1 Liver histology in Fmol, 2 ,4  (-/-) and WT males at 4 weeks of age ____________________ 158
5.7.2 Liver histology in Fmol, 2, 4 (-/-) and WT males at 10 weeks of age____________________  159
5.7.3 Liver histology in Fmol, 2, 4 (-/-) and WT males at 22 weeks of age____________________  160
5.7.4 Adipocyte histology-10 week m ales______________________________________________  161
5.7.5 Adipocyte histology-22 week m ales______________________________________________  162
5.7.6 Adipocyte volumes-normal diet___________________________________________________ 163
5.8.1 Total cholesterol and HDL cholesterol_____________________________________________  165
5.8.2 LDL cholesterol and triglycerides_________________________________________________ 166
5.8.3 Blood plasma solutes at 9 and 15 weeks of age______________________________________  167
5.8.4 Blood plasma solutes at 20 weeks of age___________________________________________  168
5.9.1 Bodyweight and organ weights on a high-fat diet____________________________________  170
5.9.2 Adipocyte histology-high fat diet _________________________________________________  171
5.11.1 Plasma lipid and solutes on a high-fat d iet_______________________________________  173
5.11.2 Liver histology in Fmol, 2, 4 (-/-) and WT males on a high-fat d ie t__________________  174
5.12.1 Bodyweight and plasma lipids on a lipoic acid d ie t________________________________  177
5.12.2 Plasma solutes on a lipoic acid diet_____________________________________________  178
5.12.3 Organ weights on a lipoic acid diet_____________________________________________  179
5.12.4 Liver histology in Fmol, 2, 4 (-/-) and WT males on a lipoic acid d ie t________________  180
5.14.1 Organ weights of Fmol, 2, 4 (-/-) females at 4 weeks of age________________________  182
5.14.2 Plasma total and HDL cholesterol______________________________________________  183
5.14.3 Plasma LDL cholesterol and triglycerides_______________________________________  184
5.14.4 Plasma solutes______________________________________________________________  185
5.15.1 Bodyweight and plasma lipids of females on a high-fat diet ________________________  187
5.15.2 Organ weights of Fmol, 2, 4 (-/-) females on a high-fat d iet________________________  188
11
5.17.1 Bodyweights of Fmo5 (-/-) and WT males and females____________________________  191
5.17.2 Percentage weight gain of Fmo5 (-/-) mice_______________________________________  192
5.17.3 Plasma total and HDL cholesterol in male Fmo5 (-/-) mice_________________________  193
5.17.4 Plasma LDL cholesterol and triglycerides in Fmo5 (-/-) m ice_______________________  194
5.17.5 Plasma total and HDL cholesterol in female Fmo5 (-/-) m ice_______________________  195
5.17.6 Plasma LDL cholesterol in female Fmo5 (-/-) m ice________________________________ 196
5.17.7 Plasma solutes in Fmo5 (-/-) mice at 15 weeks of ag e______________________________ 197
5.17.8 Plasma solutes in Fmo5 (-/-) mice at 22 weeks of ag e_______________ _ ____________  198
5.18.1 Bodyweight in Fmo5 (-/-) mice on a high-fat diet  ______________________________ 200
5.18.2 Plasma lipids in Fmo5 (-/-) mice on a high-fat diet_________________________________ 201
5.18.3 Plasma solutes in Fmo5 (-/-) mice on a high-fat d ie t______________________________  202
5.19.1 Bodyweight and blood plasma lipids on a lipoic acid d ie t__________________________  204
5.19.2 Organ weights on a lipoic acid diet ___________________________________________  205
5.19.3 Blood plasma solutes on a lipoic acid d ie t_______________________________________  206
5.21.1 Fat regulatory and fat oxidation genes in WT and KO white adipose __________________ 213
5.21.2 The expression of Fmos in WT male adipose_____________________________________  215
5.21.3 Ventricle weights vs bodyweight or femur length_________________________________  216
12
Abbreviations
AhR Aryl hydrocarbon receptor
BSA Bovine serum albumin
C/EBP CCAAT/enhancer-binding protein
CAR Constitutive-activated receptor
CHD1L chromodomain helicase DNA binding protein 1-like
CYP Cytochrome P450
DPT 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine
ER Estrogen receptor
FAD Flavin adenine dinucleotide
FAS Fatty acid synthase
FBS Fetal bovine serum
FCS Fetal calf serum
FMO Flavin-containing monooxygenase
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GCR Glucocorticoid receptor
GH Growth hormone
GRE Glucocorticoid responsive element
GST glutathione ^-transferase
GTA Glycyrrhetinic acid
HBSS Hank’s buffered salt solution
HDL High density lipoprotein
HIF-1 Hypoxia induced factor-1
HNF Hepatocyte nuclear factor
HO Haem-oxygenase
HSD Hydroxysteroid dehydrogenase
IRS Insulin response sequence
IVC Inferior vena cava
KO Knock-out
LARII Luciferase Assay Reagent II
LB Luria-Bertani
LDL Low density lipoprotein
MW Molecular weight
NADPH Nicotinamide adenine dinucleotide phosphate
PB Phenobarbital
PBREM Phenobarbital response element
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PEP Phosphoenolpyruvate
PGC-la Peroxisome proliferators-activated receptor-y co-activator la
13
PPAR Peroxisome proliforator activated receptor
PRKAB2 AMP-activated protein kinase subunit beta-2
PXR Pregnane-x-receptor
RLU Relative light units
ROS Reactive oxygen species
RT Room temperature
RT-PCR Reverse transcriptase-polymerase chain reaction
RXR Retinoid-x-receptor
SDS Sodium dodecyl sulphate
SEM Standard error of the mean
SP1 Specificity protein-1
SRC-1 Steroid receptor coactivator-1
SSC Standard saline citrate
STAT Signal transducer and activator of transcription
TBE T ris-borate-EDT A
TCDD Tetrachloro-di-benzo-p-dioxin
TE Tris-EDTA
TMA Trimethylaminuria
UDPGT UDP-glucuronyl transferase
USF Upstream stimulatory factor
WT Wild-type
A word about human and mouse gene and protein nomenclature
A human gene is written in italics and capital letters e.g. FMO, whereas the human 
protein is written in capitals e.g. FMO. In mice the protein is also written in capitals e.g. 
FMO, but the gene is written in italics with the first letter uppercase and the following 
letters lowercase e.g Fmo.
14
Acknowledgments
I’d obviously like to thank Professor Elizabeth Shephard for all her support and guidance. 
I greatly appreciated her understanding over the first year or so. Who’d o f thought 
culturing primary mouse hepatocytes would be so tough?...
Many thanks to Dr Azara Janmohammed, who has been a great friend and a 
constant source of technical support and inspiration. Thank you Miss Asvi Francois and 
Mr Matthew Hancock who made the lab a fun and challenging place to be, I hope the 
next lab incumbents have strong constitutions, and like tea.
Thank you also to Mr Bilal Omar, whom I always enjoyed working with. It was 
great to have a fresh pair o f eyes and someone to bounce ideas around with.
Thank you Dr Mina Edwards, who knows better than most how difficult it was to 
isolate the hepatocytes, and who was good enough to keep me going when it looked like 
we’d never crack it. Many thanks to Professor Ian Phillips, Dr Anoop Kumar and Mr 
Phillip Gates who were all kind enough to give me technical support and information at a 
moments notice.
I’d also like to thank Miss Alison Bradley and Mr Andrew Niewiarowski who 
have become two of my closest friends and who have been good enough to listen to me 
through the good times and bad.
My parents and my brother have been so supportive, since I first decided that 
Bunsen burners and frothing coloured liquids in flasks was the career I wanted for 
myself. O f course modem science turned out not to be like that at all. Although I do 
suspect there’s only so much you can do with some dry ice and some coloured liquid. 
Thank you, I hope this thesis does you justice.
Finally, of course I’d like to thank Jim, for his support which has been immense, 
for listening to me harp on about mouse liver and for reminding me that a PhD was never 
supposed to be easy.
This research was very kindly funded by the Drummond Trust.
15
Chapter 1
Introduction
16
1 Introduction
1.1 Liver structure and function
The liver is the largest gland in the body and perhaps the most versatile organ. It is 
involved in many major physiological functions which can be divided into lipid 
metabolism, carbohydrate metabolism, protein metabolism, producer o f bile, 
detoxification and excretion. Detoxification of course involves xenobiotic metabolism 
which is discussed in more detail below.
The human liver is comprised of several cell types where hepatocytes represent 
90% of the tissue volume and 70% of the total cell population. The liver has a dual blood 
supply and is served mostly by the portal vein, which drains from the intestines, and by 
the hepatic artery. The portal vein, hepatic artery, bile duct and lymphatics enter the liver 
at a single point, the porta hepatis. Once inside the liver these vessels run in a connective 
tissue matrix and the assemblage is called the portal tract. This branches out to form the 
“portal tree”. Each branch of the tree contains all four types of vessel. The hepatic vein 
also branches out amongst the liver and intermingles with the vessels from the portal tree 
(Rhoades, 2003).
Terminal portal venules and hepatic arteries deliver their blood to sinusoids 
formed by fenestrated endothelial cells. The functional part of the gland, the parenchyma, 
consists o f hepatocytes, here the blood flows through the sinusoids, making contact with 
these cells. Unbound xenobiotics in the sinusoidal blood get taken up into the hepatocytes 
either by active transportation or by diffusion. This mode of transport very much depends 
upon how large the compound is, its charge and its lipophilicity. Having made contact 
with the hepatocytes the blood drains into the central vein and then to the hepatic artery. 
Blood leaves the liver via the hepatic veins, which join the ascending vena cava 
(Rhoades, 2003). The vasculature of the liver is shown in Figure 1.1.1.
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1.1.1 Vasculature of the liver
The vasculature o f  the human liver and integration o f  bile ducts from the pancreas and 
gall bladder (excerpt from M erck.com).
1.2 The acinus-the functional unit of the liver
The acinus represents the functional unit of the liver and zones within the acinus centre 
around the blood supply. The acinus is the egg-shape delimiter around the terminal 
branches of the hepatic artery and portal vein (Figure 1.2.1). The area around the terminal 
portal vein and arteriole is the periportal zone. The area around the central vein is termed 
the perivenous or centrilobular zone. It is here that monooxygenase activity 
predominantly occurs (Bengtsson et al., 1987; Vaananen, 1986). There are phenotypic 
differences between hepatocytes as you move through the acinus. Genes are differentially 
expressed in the periportal and perivenous zones of the liver. This zonation appears to be 
dynamic, affected by the levels of oxygen, nutrients, hormonal signals (Jungermann and 
Katz, 1982) and xenobiotics (Buhler et al., 1992; Rich et al., 1989). The perivenous cells 
have the highest level of phase I and phase II enzymes, and genes from these cells also 
seem more sensitive to induction from xenobiotics (Baron et al., 1981; Buhler et al., 
1992; Gooding et al., 1978). Hepatocytes that were isolated using digitonin-zonation 
showed that cytochrome P450 enzymes were more susceptible to induction from the 
perivenous compared with the periportal area (Bars et al., 1992). The zonation for the 
phase II enzymes, such as glutathione ^-transferases and the UDP-glucuronyl 
transferases, appears to be less stark than that for phase I enzymes. This can often make 
the perivenous area more susceptible to damage because the phase II enzymes may not 
fully compensate for the high turn-over of toxic intermediates produced by the phase I 
enzymes (Bengtsson et al., 1987; Kera et al., 1987).
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1.2.1 Liver lobule and acinus
Two representations o f  the liver lobule and the acinus (both excerpt from M erck.com ).
20
1.3 Xenobiotic Metabolism
Xenobiotic metabolism is carried out by enzymes all over the body, but the main 
concentration of these enzymes is in the liver. Chemical reactions they preside over 
include oxidation, reduction, hydrolysis, conjugation and condensation. The result of 
these reactions can determine if a drug has a pharmacological or toxicological effect.
Xenobiotic metabolism can be split into two phases. Phase I enzymes 
functionalise the drug by uncovering or adding a reactive ‘handle’ for phase II enzymes 
to act upon. Phase II reactions essentially detoxify the drug, resulting in a hydrophilic 
product that can be excreted in the urine or bile.
There are several groups involved in phase I metabolism, the main two groups 
being the cytochromes P450 (P450) (the most prolific of the two) and the flavin- 
containing monooxygenases (FMO), both o f which are discussed below. Other enzymes 
are involved such as peroxidases, amine oxidases, dehydrogenases, xanthine oxidases, 
but to a lesser degree.
1.4 Cytochromes P450
The major group of enzymes involved in xenobiotic metabolism are the cytochromes 
P450 (P450). These are a superfamily of haem-containing mixed-function oxidases, 
found bound to the endoplasmic reticulum in many cells. The mixed-function oxidase 
reaction conforms to this stoichiometry:
NADPH + H+ + 0 2 + RH —» NADP+ +H20  +ROH 
Where RH represents an oxidisable drug and ROH is the hydroxylated metabolite. 
The overall reaction is catalysed by the P450 enzyme, which requires the presence of 
molecular oxygen, NADPH and NADPH-cytochrome P450 reductase.
The largest concentration of P450s is in the liver, although they are found 
throughout the body, most notably in the small intestine, kidney, skin (Murray et al.,
1988) and lung (Hall et al., 1989). They are involved in the phase I metabolism of a 
massive variety of xenobiotics, although at most only 15 P450 enzymes are thought to be 
involved in exogenous metabolism. Besides xenobiotic metabolism P450s play a large
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endogenous role. They are involved in cholesterol biosynthesis, vitamin D metabolism, 
bile acid metabolism and biosynthesis and catabolism of steroids ((Nelson, 1999).
There are four main P450 families involved in xenobiotic metabolism (CYP1-4), 
each with several sub-familes (e.g. CYP2A, CYP2B) and isoforms (e.g. CYP2B6). 
CYP2C9, CYP2D6 and CYP3A4 account for 60-70% of all phase I metabolism of drugs.
CYP3A4 is the most highly expressed P450 isoform in the human liver, 
approximately 30% of the total P450 content in the liver is represented by CYP3A4. 
Even more importantly it metabolises around half of the clinically important drugs in use 
today. This also means it is very important in the etiology of drug-drug interactions.
The human CYP3A4 family consists of 3 members; CYP3A4, CYP3A5 and 
CYP3A7 (Nelson et al., 1996). CYP3A7 is predominantly expressed in foetal liver 
(Komori et al., 1990) and metabolises retinoic acid (Chen et al., 2000). CYP3A4 is 
inducible by barbiturates, glucocorticoids and rifampicin in humans. It has the broadest 
substrate specificity of any P450 and is able to act upon compounds from acetaminophen 
(MW 151) to cyclosporine (MW 1201) (Combalbert et al., 1989). It is also able to 
metabolise pesticides (e.g. parathion) (Butler and Murray, 1997) and non-ionic detergents 
(Hosea and Guengerich, 1998).
CYP3A4’s expression is under the control of several transcription factors, the 
most important of which are members o f the orphan nuclear receptor family enabling 
CYP3A4’s expression to be changed in response to environmental stimuli (see Section 
1.17).
1.5 Flavin-containing monooxygenases (FMOs)
This small family of monooxygenases is the other prominent group of enzymes involved 
in phase I metabolism. FMOs were discovered in the 1960s in hepatic microsomes, not 
long after P450s were characterised, and were described as NADPH- and oxygen- 
requiring enzymes, able to metabolise dimethylaniline to its A-oxide (Ziegler and Pettit, 
1966).
FMOs are flavoproteins containing a single FAD (Poulsen and Ziegler, 1979) and 
are important for the metabolism of a massive variety of dietary compounds, synthetic
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environmental toxicants, natural plant alkaloids and therapeutics (Cashman, 2003). They 
are able to act upon such a range of xenobiotics because the energy required to drive the 
reaction is already available to the enzyme because the FAD moiety is already bound to 
oxygen as a peroxyflavin (Massey, 1994) (Figure 1.6.1). This intermediate is stable from 
minutes to hours in vitro at 4°C and so presumably this is the predominant form of FMO 
in the cell, waiting to bind a substrate (Jones and Ballou, 1986). Thus the tight fit of a 
substrate usually needed to lower the activation energy of a catalysed reaction is 
superfluous.
There are 5 functional human isoforms, FMO 1-5, which preferentially act upon 
substrates containing nucleophiles such as nitrogen, sulphur, selenium and phosphorous. 
FMOs are expressed ubiquitously, found associated with the endoplasmic reticulum, but 
there are distinct differences between tissue, sex, developmental stage and species.
1.6 Expression of FMOs
FMOl is the main liver isoform in mammals such as pig, rabbit, rat and mouse 
(Cherrington et al., 1998; Gasser et al., 1990; Lattard et al., 2002; Lawton et al., 1990), 
the exception being humans. In human liver the dominant isoform switches from FMOl 
in the foetus to FM03 in the days following birth (Dolphin et al., 1996; Koukouritaki et 
al., 2002). The expression of FM03 is also switched on at this time in mice (Cherrington 
et al., 1998). Although the expression of FMOl is switched off in humans after birth, it 
remains highly expressed in other organs, hence FMO l in adult humans is extra-hepatic. 
FMOl is expressed in human foetal and adult kidney (Dolphin et al., 1996; Krause et al., 
2003; Zhang and Cashman, 2006), as well as human lung (Dolphin et al., 1996; Krueger 
et al., 2002a), brain (Zhang and Cashman, 2006), and intestine (Yeung et al., 2000). In 
mice FMOl mRNA is found in the lung, kidney and brain (Janmohamed et al., 2004).
FM02 is highly expressed in the lung of rabbits (Williams et al., 1984) and rhesus 
macaque (Yueh et al., 1997). FM02 mRNA expression is the highest amongst the 
isoforms in human lung (Zhang and Cashman, 2006), however it is not expressed in the 
lung as a functional enzyme in most humans because o f nonsense or frame-shift 
mutations in Caucasians and Asians (Dolphin et al., 1998; Furnes et al., 2003; Krueger et
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al., 2002b). FM02 mRNA is also found in human kidney and intestine (Zhang and 
Cashman, 2006), as well as mouse brain and kidney (Janmohamed et al., 2004).
FM03 is thought to be the most important isoform in the human liver and is 
highly polymorphic. Mutations result in a dysfunctional enzyme which can reduce the 
enzyme’s ability to A-oxygenate trimethylamine (TMA) (Dolphin et al., 1997). Un­
metabolised, TMA is highly odorous and people who have a defective FM03 are said to 
suffer from Tish-odour syndrome’ or trimethylaminuria. FM03 is highly expressed in 
human liver and at low levels in human kidney and lung (Zhang and Cashman, 2006). 
FM03 is also highly expressed in female mouse liver (Falls et al., 1995), and mRNA is 
seen at low levels in mouse kidney, lung and brain (Janmohamed et al., 2004).
FM 04 protein has not been observed, but low mRNA levels in mouse kidney, 
brain, liver and lung have been found (Janmohamed et al., 2004). In humans FM04 
mRNA is expressed at its highest levels in liver and kidney and to a lesser extent in foetal 
liver (Zhang and Cashman, 2006).
FM05 is expressed in the liver of humans (Overby et al., 1995), rabbits (Atta- 
Asafo-Adjei et al., 1993), guinea pigs (Overby et al., 1995) and mice (Cherrington et al.,
1998). The mRNA level in the liver is higher than any other FMO in humans (Zhang and 
Cashman, 2006) and mice (Janmohamed et al., 2004). But due to the lack o f a suitable 
probe substrate, the contribution of FM05 to xenobiotic metabolism is unclear. FM05 
levels are also high in mouse kidney, lung and brain (Janmohamed et al., 2004). In 
human foetal liver FM05 mRNA levels are highest amongst the FMO isoforms. FM05 
mRNA is also seen at lower levels in human kidney, small intestine, lung and brain 
(Zhang and Cashman, 2006).
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1.6.1 FMO catalytic cycle
The binding o f  NADPH and oxygen (a-d) to form the hydroperoxyflavin, this step 
happens relatively fast. FAD-OOH oxygenates the substrate (e). NADP and w ater are 
released and are the rate-lim iting steps ( f  and g). Step h shows the possible mode o f  
release o f  reactive oxygen species (ROS). Taken from (Schlaich, 2007).
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1.7 FMO developmental expression
The developmental expression in humans describes FMO l as the dominant foetal liver 
isoform (Dolphin et al., 1991). FMO l is highly expressed in the human embryonic liver, 
and is down-regulated shortly after birth (Hines and McCarver, 2002). FM03 is 
expressed at very low levels in human embryonic liver, but is up-regulated and detected 
in most individuals between l -2 years of age, although its expression is highly variable 
(Koukouritaki et al., 2002). In mice FMOl is found in the placenta between 12 and 18 
days of pregnancy (Ishida et al., 2007). Also in mice both Fmol and Fmo5 are expressed 
at high levels in the newborn liver, with expression reaching a peak at 5 weeks, then 
declining with age (Janmohamed et al., 2004). FMOl protein and mRNA is found at day 
25 of gestation in the rabbit, but approximates to 10% of the adult amount. This rises 
rapidly after birth, where at 3 weeks it is 70-80% of the adult concentration (Larsen-Su et 
al., 2002). FM02 which is highly expressed in the lung, increases during mid-late 
gestation in rabbits, a pattern that mirrors the increased levels of circulating progesterone. 
At parturition (where there are also higher levels of progesterone) FM02 is increased in 
the kidney. The sub-cutaneous application of progesterone or dexamethasone also 
increases the FM02 protein level in the lung as well as in the kidney (Lee et al., 1995). 
The same researchers found that FMOl was induced over the period of mid-late gestation 
in rabbit liver. FMOl mRNA levels were increased four-fold in response to progesterone 
or glucocorticoids. This study confirmed the findings of other experimenters (Devereux 
and Fouts, 1975).
In humans the switch over from FMOl in the foetal liver to FM03 in adult liver 
clearly has parallels in the switch over from CYP3A7 to CYP3A4, the major human liver 
P450 isoform.
1.8 Sex differences and hormonal effects on FMO expression
There are distinct sex-related differences in FMO expression in rodents, which are not 
seen in humans. What complicates the issue is that the hormonal control of FMO also 
displays species differences.
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In the mouse FMOl is the predominant form in male liver, in the female liver it is 
FM03. This is because of the repressive effects of testosterone on FM03 in the mouse. 
Treatment of castrated male mice with flutamide, an anti-androgen, increased FM03 in 
the liver to female levels (Kloss et al., 1982). In the males, castration increased FM03 as 
well as FMOl, whilst the re-introduction of testosterone only repressed FM03 (Falls et 
al., 1997). FMOl increased upon the treatment of intact males with 17(3-estradiol, a slight 
increase in FM03 was also observed (Falls et al., 1997). In ovariectomised females, the 
treatment with testosterone reduced hepatic FMO (FM03) to male levels. Ovariectomy 
alone in females slightly reduced hepatic FMO activity, pointing to an inductive effect by 
female sex hormones. However, the subsequent addition of 17p-estradiol or progesterone 
resulted in no discemable effect on FMO levels (Falls et al., 1997). Gonadectomy in male 
and female mice had no effect on the expression of FM05, implying a sex-independent 
expression profile (Falls et al., 1997).
In adult mouse liver FM05 mRNA is the most highly expressed, in both males 
and females. FM03 is second, but only in the female, followed by FMOl, which is 
expressed 5 times less than FM05 (Janmohamed et al., 2004). In the kidney FMOl 
mRNA is twice the level in males as in females and FM05 is expressed six times more 
abundantly in the male than female kidney (Janmohamed et al., 2004). FM03 levels in 
mouse kidney are barely detectable in both males and females. The relative amount of 
FM03 protein in mouse kidney is low, and similar in males and females (Ripp et al.,
1999).
In male rat liver FM03 increases with age, so that FM03 is the predominant form 
in the adult (compared to adult male mouse which is FMOl). FMOl remains at a 
constant level with age. In young female rat liver it is FMOl which is most highly 
expressed, but is un-detectable after 10 weeks of age, so that FM03 becomes 
predominant in the adult, as its expression remains relatively unchanged (Lattard et al., 
2002). The total activity of FMOs was seen to increase in male rat livers from 1 to 3 
months of age, while FMO 1-dependent activity remained the same over this time (Das 
and Ziegler, 1970). Studies using gonadectomy and hormone replacement point to 
positive regulation of FM03 in male rat liver by testosterone, whilst in female rat liver 
there is a negative effect upon FMOl by 17(3-estradiol (Dannan et al., 1986). In primary
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male rat hepatocytes the activity o f FMOl is repressed 56% after the treatment of the 
cells with 17p-estradiol for two weeks. Male sex hormones have no effect upon activity 
(Coecke et al., 1998). In the male rat kidney the expression profile is similar to that in the 
liver, where FMOl remains at the same expression level with age whereas FM03 
expression increases after 6 weeks of age. A similar pattern is seen in female rat kidney 
to that in male kidney, which differs to that in female rat liver. FMOl was repressed in 
female liver, but remains consistent in female kidney (Lattard et al., 2002).
In late gestation rabbit lung FMO (FM02) is induced, but rabbit liver FMO 
(FMOl) is not (Devereux and Fouts, 1975; Williams et al., 1985). This induction of 
FM02 coincides with increased plasma progesterone and cortisol levels. The sub­
cutaneous treatment of rabbits with progesterone leads to an up-regulation o f FM 02 in 
the lung (Lee et al., 1995).
To summarise, in mice testosterone is a negative regulator o f FM03 in the liver, 
whereas in rats it is a positive regulator of hepatic FM03. Estradiol is a negative 
regulator o f FMOl in female rat liver but in female rat kidney FMOl is not repressed. 
FM02 appears to be under some regulation by progesterone in rabbit lung. In humans 
sex-dependent differences in FMO expression are not observed. Subsequently the FMO 
profile across sex, species, age and tissue is perplexing.
1.9 The effects of growth hormone on FMO expression
It is thought that the secretion o f sex hormones is under the control of the hypothalamic 
pituitary axis. Growth hormone has ultimate control over sex-differences in P450 
expression. Hence the expectation would be that FMOs, given the degree o f hormonal 
regulation they are under, would be receptive to changes in growth hormone levels. As it 
is there is little demonstration of this.
In cultured rat hepatocytes growth hormone had no effect on the levels o f FMOl 
(Coecke et al., 1998). In the Mini:Nts mouse, a transgenic mouse showing lower 
circulating levels o f growth hormone, FMOl expression in the liver was changed little 
from that of a WT mouse (Tani et al., 1999).
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HNFla and HNF4a enhanced FMOl promoter activity (Luo and Hines, 2001). In the 
embryonic liver o f the HNF4a null mouse, the expression of both Fmol and Fmo5 are 
completely repressed (Battle et al., 2006). The upstream-stimulatory factor and Spl have 
been shown able to bind to the promoter of human growth hormone (Lemaigre et al.,
1989). C/EBPa has also been shown to be under direct control o f growth hormone 
(Rastegar et al., 2000), and C/EBPa in turn regulates Hnf3p which controls Hnf4 
(Samadani et al., 1995).
1.10 FMOs in diabetes
The increased activity o f FMOs in drug-induced diabetes was first described in 1987 
when the Af-oxidation of imipramine (an FMOl substrate) was increased in 
streptozotocin-induced mouse liver (Rouer et al., 1988). Following this thiobenzamide 
metabolism was observed to be two-fold higher in streptozotocin-induced rats and mice 
(Rouer et al., 1988) and a two-fold increase in activity specifically o f FMOl was 
described in streptozotocin-induced rats (Wang et al., 2000). In liver biopsies o f type II 
diabetics, FM05 is repressed with the implication of its involvement in stress-response 
(Takamura et al., 2004).
Obviously any changes in the level of metabolising enzymes is important in many 
pathologies as patients respond differently to therapies, with the possibility o f adverse 
drug reactions. Hence this change in FMO level could be important in drug therapy in 
diabetics.
A more recent study showed that FMO activity was again induced 2-fold in 
streptozotocin-induced rats, but also that FMO activity became equivalent o f the control 
on addition of insulin (Borbas et al., 2006), insulin alone had no effect. The activity of 
FMO correlated closely with glucose levels and the level of cytochrome b5. Cytochrome 
b5 has long been associated as an electron transfer component in oxidative reactions in 
the metabolism of fats, steroids and xenobiotics (Schenkman and Jansson, 2003).
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1.11 FMOs role in iron homeostasis
Iron salts in the diet are absorbed and bound to intraluminal mucin in the duodenum. To 
cross the cell membrane, the iron is released from mucin and associated with integrins on 
the luminal surface of the cell membrane (Conrad and Umbreit, 1993). The iron is then 
transferred to mobilferrin and also a larger complex called parraferritin (Conrad et al.,
1990). This large 520 kDa iron-binding protein is made up of mobilferrin, integrin and 
FMO (Umbreit et al., 1996). Mobilferrin and calreticulin are highly homologous (Conrad, 
1993) and FMO was found bound to calreticulin in rabbit lung (Guan et al., 1991; Rojiani 
et al., 1991). The parraferitin complex has ferrireductase activity, reducing Fe (III) to Fe 
(II) using NADPH. The FMO portion of parraferritin is implicated in an ability to act as 
the ferrireductase, since the complex was also able to metabolise methimazole, a classic 
FMO substrate (Umbreit et al., 1996).
In two patients with sideroblastic anaemia there was a marked reduction in 
ferriductase activity along with a reduction in FMO protein in lymphocyte extracts and an 
increase in mobilferrin. This could imply that a disruption in FMO and mobilferrin 
concentrations could cause sideroblastic anaemia (Barber et al., 2000).
Haemochromatosis is a disorder where the duodenum hyperabsorbs iron. In mice with 
transgenic haemochromatosis, surprisingly haem-oxygenase was lowered, whereas CYP 
oxidoreductase was induced. Fmo3 was up-regulated in the liver, but in 
haemochromatosis mice and WT mice treated with iron-dextran, Fmo3 was down- 
regulated (Muckenthaler et al., 2003).
1.12 Instances of FMO induction
Cytochrome P450s are classically thought of as inducible, i.e. P450 gene transcription is 
increased in response to environmental or toxic insult. FMOs do not appear to be 
modulated environmentally; hence FMOs are described as refractory to dietary or 
chemical induction.
Although FMOs are not thought inducible by xenobiotics there is limited 
evidence o f this. In rat liver, FMOl was induced over three-fold upon the addition of the
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polycyclic aromatic hydrocarbon 3-methylcholanthrene, an aryl hydrocarbon receptor 
(AhR) ligand. The level of thiobenzamide ^-oxidation (an FMO 1 catalysed reaction) was 
also seen to increase (Chung et al., 1997).
In another AhR-mediated example, a microarray studying the gene expression 
changes in AhR (+/+) versus AhR (-/-) male mouse liver, found that on addition o f the 
AhR ligand, TCDD, Fmo2 and Fmo3 were induced 4-fold and over 6-fold respectively 
(Tijet et al., 2006).
Hyperforin is the active component o f St John’s Wort, a dietary supplement used 
for the alleviation o f depression (Muller et al., 1998). Hyperforin is a potent pregnane-x- 
receptor (PXR) ligand and therefore its use has implication in drug-diet interactions 
(Moore et al., 2000; Wentworth et al., 2000). In a microarray where HepG2 cells were 
dosed for 24 hours with 1 pM hyperforin, FM05 was induced about 3-fold, this 
observation was confirmed with RT-PCR (Krusekopf and Roots, 2005).
In a microarray using RNA from primary human hepatocytes dosed with 33 pM 
rifampicin (a PXR ligand) for 3 days, both FM04 and FM05 were induced over 3-fold 
(Rae et al., 2001), along with other metabolising enzymes such as CYP2A6, CYP2B5, 
CYP2C9 and non metabolising enzymes such as UDP glycosyltransferase 1A, 
monoamine oxidase B, and glutathione-S-transferase PI. CYP3A4 had the greatest fold 
induction, over 55 times.
FM 02 in rabbit lung and liver were induced by dexamethasone and progesterone 
correlating with increased plasma steroid levels during pregnancy (Lee et al., 1993). 
FMOl mRNA was increased four-fold upon treatment with dexamethasone in rabbit liver 
(Lee et al., 1995).
1.13 FMOs and dietary components
Guinea pigs fed an ascorbic acid-deficient diet had 61% hepatic FMO activity o f the 
controls, whilst guinea-pigs on ascorbic acid-deficient and reduced diet had 17% of the 
activity of a guinea-pig on a normal diet (Brodfuehrer and Zannoni, 1987). One of the 
first papers indicating that FMOs could be influenced by diet found that rats fed on total 
parental nutrition for 7 days had a 75-80% decrease in FMO activity (Kaderlik, 1991). In
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rats fed a semi-synthetic diet, there was a smaller decrease in FMO activity, which was 
induced on addition of rat chow extract. Ziegler surmised that FMO is already maximally 
induced on a normal chow diet by the components of plants (Cashman et al., 1995). 
Kaderlik found in un-published observations that rat chow contains 290 nmoles/gram of 
FMO substrates.
Dietary indole-3-carbinol, a naturally occurring component of cruciferous 
vegetables, when dosed to male rats results in an 8-fold reduction o f FMOl in liver and 
almost total inhibition of FMOl expression in the small intestine (Larsen-Su and 
Williams, 1996).
In plants there are 26 FMOs, and like plant P450s they have evolved to be highly- 
substrate specific and are involved in the synthesis of biologically active secondary 
metabolites. Whereas in animals, both FMOs and P450s are less specific and have a 
much wider substrate specificity in xenobiotic metabolism (Donaldson and Luster, 1991). 
One o f the substrates that plant FMOs biosynthesise are glucosinolates (Hansen et al., 
2007). The glucosinolates give cruciferous vegetables (eg broccoli) their distinctive 
flavour by the release of isothiocyanates (Halkier and Gershenzon, 2006).
Isomers o f conjugated linoleic acid are found naturally in dairy products and 
ruminant meats. Synthetic isomers o f conjugated linoleic acid are currently being touted 
as fat loss and insulin-sensitivity improvement pills, of which there is some evidence 
(Gaullier et al., 2007; Syvertsen et al., 2007). Female mice fed dietary trans 10, cis 12- 
conjugated linoleic acid develop fatty livers and show reduced expression of fatty acid 
oxidation genes such as carnitine palmitoyl transferase la (77%), acetyl CoA oxidase 
(50%) and PPARa (65 %). Fmo3 was grouped in with these genes, and was reduced 
97%, although there is no evidence for FM03 being a fatty acid oxidation gene. The 
mouse liver microsomal activity of FMO was also reduced (40%) as was overall P450 
activity (67%). The treatment with cis 9, trans 11-conjugated linoleic acid also decreased 
Fmo3 and P450 expression 61% and 38% respectively (Rasooly et al., 2007).
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1.14 FMO, endogenous substrates and redox state
Trimethylaminuria, often referred to as ‘fish-odour syndrome’, is caused by a 
missense mutation in FM03 (Dolphin et al., 1997). Trimethylamine is an endogenous 
compound which is also present in the diet. It is predominantly found in fish as the 
trimethylamine-N-oxide which is reduced by gut bacteria to the amine. Endogenous 
trimethylamine is formed from the break-down of choline by gut bacteria (Lowis et al., 
1985) and is metabolised to the JV-oxide, predominantly by FM03 (Lang et al., 1998). 
Trimethylamine is extremely odorous whereas the N-oxide has little or no odour. This is 
the best-characterised ‘endogenous’ substrate for an FMO isoform. There are also a 
handful of other endogenous substrates.
It has been suggested that methionine is the most toxic amino acid (Benevenga, 
1974) and it is metabolised to an 5-oxide by FMOl, 2 and 3 in rabbit liver and kidney 
microsomes (Duescher et al., 1994) in rat liver and kidney microsomes (Krause et al., 
1996) and human liver microsomes (Ripp et al., 1999). Whether the metabolism by 
FMOs to methionine sulfoxide represents a detoxification reaction is unknown given that 
the toxicity of methionine sulfoxide is also unknown. However given that methionine 
sulfoxide is probably more water soluble than methionine itself it may be more readily 
excreted. However the Km for methionine is quite high, rabbit cDNA-expressed FMO 1, 2 
and 3 gave a KM of 48, 30, and 6.5 mM, respectively (Duescher et al., 1994). Whereas the 
human liver microsomal KM ranged from 0.03 to 5 mM (Ripp et al., 1999). The free 
plasma methionine concentration in healthy humans has been shown to be approximately 
23 pM (Potgieter et al., 1997) so it is unlikely that the ability of FMOs to metabolise 
methionine is physiologically relevant.
Cysteamine is 5-oxygenated by FMOs to cystamine. This may be a detoxification 
mechanism, since cysteamine at concentrations as low as 39 pM, is toxic to cells possibly 
by the production of hydrogen peroxide (Jeitner and Lawrence, 2001). Cysteamine is 
transported into cells as a mixed disulfide with cysteine, which is needed to maintain high 
cellular glutathione levels. Thus in an indirect way FMO may control hydrogen peroxide 
levels within the cell as well as genes regulated by H2O2 because cysteamine increases
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hypoxia induced factor-1 (HIF-1) expression, which in turn increases redox-sensitive 
transcription factors and thus the general redox state (Khomenko et al., 2004).
Lipoic acid is a vital cofactor for a-ketoglutarate and pyruvate dehydrogenases. It 
is also taken as a supplement because o f its antioxidant properties (Bustamante et al., 
1998) and as a therapeutic agent (Smith et al., 2004b). FMOl metabolises lipoic acid and 
lipoamide through <S-oxygenation with a Km of 2pM (Taylor and Ziegler, 1987).
It is interesting that the two previous examples o f endogenous substrate have 
some sort of relationship with reactive oxygen species (ROS) or anti-oxidant ability. 
Since FMO is present at such high concentrations in the endoplasmic reticulum (up to 
10% of total protein in rabbit lung (Williams et al., 1985), it seems that the production of 
ROS as a side-effect o f the FMO catalytic cycle could be important. Hydrogen peroxide 
production by purified rabbit lung FMO (FM02) was 41% of the total NADPH oxidised 
(Tynes et al., 1986). Superoxide anion radical production has been measured in purified 
pig liver FMO (FMOl) the level being about 4% of the total NADPH oxidised 
(Rauckman et al., 1979). The impact of this ROS production by FMO has never been 
elucidated. Of course the previous experiments were all done in vitro, so the 
measurements obtained may bear no resemblance at all to the in vivo situation. 
Interestingly in a microarray o f ob/ob mice, Fmo5 was reduced 1.4 fold and was grouped 
in with redox-sensitive genes (Liang and Tall, 2001).
1.15 FM05 and its limited substrate portfolio
With regard to transcription, FM05 mRNA has recently been shown to be 
expressed in the human liver to a higher extent than FM03 mRNA, FM03 is the enzyme 
predominantly involved in human hepatic xenobiotic metabolism (Zhang and Cashman, 
2006). Equivalent levels of FM03 mRNA to FM05 mRNA have also been seen in the 
female mouse liver (Janmohamed et al., 2004). What is unclear is FM 05’s contribution 
to xenobiotic metabolism. This is due to a lack of suitable substrate with which to 
measure FM05 activity. FM05 shows little or no activity towards classic FMO 
substrates such as trimethylamine (FM03), imipramine (FMOl) and methimazole 
(FMOl and FM03). The known substrates of FM05 are shown in Figure 1.15.1. A
34
recent paper has delved more deeply into the mouse FM05 metabolising capabilities 
(Zhang et al., 2007). FM05 metabolised phenothiazine analogs 5-DPT and 8-DPT, 
which are tertiary amines (as were FMOl and FM03). The catalytic activity o f FM05 for 
8-DPT was nearly 50 times and 6 times lower than FMOl and FM03 respectively. S- 
methyl-esonarimod was also a substrate for mouse FM05 which has been described 
previously for human FM05 (Ohmi et al., 2003). Mouse FMOl was also a substrate for 
S'-methyl-esonarimod with a similar KM to that of FM05 (3.82 and 3.23 pM 
respectively).
FM05 has been reported to metabolise methimazole with a very low efficiency 
(Overby et al., 1995), as well as to catalyse benzydamine A-oxidation with a Km of 2 mM 
(Lang and Rettie, 2000). A-oxidation of A-octylamine has also been shown and is able to 
reach an activity of 26 nMol of NADPH oxidised min'1 nMol FMO'1 by human 
recombinant FM05 (Overby et al., 1995). Ranitidine is also a substrate o f human 
recombinant FM05 (as are FMOl and FM03) but is not an efficient producer o f the N- 
and S-oxides (Chung et al., 2000).
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1.16 FM05 regulation by hormones
FM05 is often thought of as gender-independent, but there is evidence o f hormonal 
regulation of FM05 in the literature. Apart from the example mentioned previously 
where FM05 mRNA is expressed to a much higher degree in male rather than female 
mouse kidney (Janmohamed et al., 2004), there are several other examples of hormonal 
regulation.
A breast cancer cell line stably expressing progesterone A or B receptors was 
dosed for 18 hours with 20 nM progestin. FM05 was induced 9-10 fold only in 
progesterone B receptor cells (Miller et al., 1997). Both forms o f the receptor mediate the 
effects of progesterone, but the B receptor to a higher degree.
In human breast cancer tissue using RT-PCR, FM05 was induced in estrogen 
receptor-a (ERa) positive cancers (Bieche et al., 2004). Breast cancer growth is regulated 
by estrogen, mediated through the ERa receptor. Patients that have ERa in their breast 
tumours may respond to anti-endocrine drugs such as tamoxifen. Interestingly patients 
who had FM05-overexpressing tumours had a longer relapse-free survival, although this 
didn’t retain significance when a more rigorous statistical regression analysis was used.
1.17 Orphan Nuclear Receptors
Orphan nuclear receptors are ligand-activated transcription factors. Their ligands are 
small and lipophillic, describing a large proportion of xenobiotics. Several orphan nuclear 
receptors mediate the induction and repression of P450 enzymes.
In the absence of a substrate, P450s are expressed at quite a low level basal ly but 
their expression is increased in the presence of their substrate or other inducers. The 
members of the CYP1A, CYP2B, CYP2C, CYP3A and CYP4A gene subfamilies are 
highly inducible. Initially, phenobarbital (PB) was seen to increase total P450 
concentration in rats (Conney et al., 1960). This was later attributed to the transcriptional 
induction of P450 genes by PB (Adesnik et al., 1981). Other inducers (PB-like inducers) 
were found able to up-regulate transcription of CYP2A, CYP2B, CYP2C and CYP3A 
genes (Waxman and Azaroff, 1992) this is now attributed to the nuclear receptors who
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mediate enzyme induction. Drugs do not only induce drug-metabolising enzymes or 
transporters, there is a pleiotrophic response, including the up- and down-regulation of 
many genes and systems (Okey, 1990; Waxman and Azaroff, 1992).
Cytochrome P450 induction in response to xenobiotics is mediated by four main 
transcription factors: the aryl hydrocarbon receptor (AhR), the constitutive androstane 
receptor (CAR), the pregnane-x-receptor (PXR) and the peroxisome proliferator- 
activated receptor (PPAR). The most important of these four is the PXR, which is 
described in detail below; PPAR, CAR and AhR are discussed briefly.
1.18 AhR, CAR and PPAR
Polycyclic and halogenated aromatic hydrocarbons, as well as various organochlorinated 
compounds, are able to cause immunosuppression, tumorogenesis and cardiovascular 
disease in humans. These effects are thought to be mediated via the AhR. The AhR is a 
basic ligand-dependant helix-loop-helix transcription factor. Ligand activation results in 
the cytosolic AhR relocating to the nucleus to dimerise with AhR nuclear translocator 
(AhRNT). Together they are able to transcriptionally activate the genes CYP1A1, 
CYPJA2, CYP2B1 as well as the phase II enzymes glutathione 5-transferase (GST) and 
UDP-glucuronyl transferase (UDPGT).
CAR is the ‘constitutive’ receptor because it is able to transactivate response 
elements in the absence of ligand (Baes et al., 1994). CAR forms a heterodimer with the 
retinoid X receptor (RXR) (RXR is also able to form a heterodimer with PXR and 
PPAR). CAR predominantly mediates the activation of CYP2B genes. CAR is able to 
mediate the expression of CYP2B1 and CYP3A1 in rat primary hepatocytes and in vivo 
in the liver (Smirlis et al., 2001). It is also able to transactivate the PXR-responsive 
response elements in CYP3A4 (Goodwin et al., 2002). Phenobarbital is a well-known 
inducer of drug metabolism in mammals including man. The phenobarbital responsive 
element module (PBREM) was found upstream of the rat CYP2B. Only CAR was able to 
activate the PBREM-dependant reporter gene (Honkakoski et al., 1998).
The PPAR also forms a heterodimer with RXR. Its ligands include clofibrate the 
cholesterol-reducing drug and other peroxisome proliferators. So-called because they
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were observed to cause peroxisome proliferation in rodents, although not in humans. 
PPAR is thought to be involved in the regulation of CYP4A genes.
1.19 Pregnane X Receptor (PXR)
The PXR gene is expressed mainly in the liver and intestine, it plays a key role in the 
induction and constitutive expression of CYP3A isoforms. PXR forms a heterodimer with 
the retinoid X receptor (RXR) and binds the consensus motif AG(G/T)TC(A/C) in the 
promoters of many genes including human and rodent CYP3A genes, thus mediating 
CYP3A expression (Lehmann et al., 1998). It is also clear that PXR is able to mediate the 
expression of CYP2B genes (Goodwin et al., 2001).
Whilst pregnenolone 16a-carbonitrile is a known inducer of CYP3A in rats and 
mice, and activates rat and mouse PXR, rifampicin induces CYP3A and activates PXR in 
humans and rabbits. PXR sequence homology appears to explain the species differences 
regarding CYP3A induction. The DNA binding domain shares 95% homology, the 
ligand-binding domain shares approximately 75-80% homology between species (Jones 
et al., 2000). Figure 1.19.1b shows the species specificity of PXR ligands for mouse or 
human PXR. It has been shown that PXR is able to bind to response elements such as 
DR4 (direct-repeat 4, a copy of the consensus motif is repeated twice separated by 4 
unspecified nucleotides) within the phenobarbital response element o f the CYP2B1 
promoter as well as the DR3 site in the PXRE of CYP3A1 (Smirlis et al., 2001). PXR is 
also able to mediate CYP2B6 expression in humans (Goodwin et al., 2001) as well as that 
of CYP2C8 and CYP2C9 (Gerbal-Chaloin et al., 2002).
PXR may have a role in modulating drug metabolising enzymes in foetal liver, 
and requires HNF4a to do so. An HNF4a response element was found in PXR, and this 
was required to activate the PXR promoter in primary mouse foetal hepatocytes (Kamiya 
et al., 2003). HNF4a was also shown to have an important role in the PXR and CAR- 
mediated induction of CYP3A4. In Hnf4a-mx\\ mice, CYP3A4 expression was decreased 
and had a reduced capacity to be induced by rifampicin (Tirona et al., 2003).
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1.19.1 Nuclear receptor mode of action and PXR ligands
Part (a) shows the nuclear receptor mode o f  action, where PXR binds a substrate and 
undergoes a structural change allowing it to bind to RXR its heterodimer. Together they 
bind to response elements in the promoter o f  target genes and up-regulate transcription. 
Part (b) is a representation o f  the species specificity o f  PXR ligands and the substrates 
which are more likely to bind mouse PXR or human PXR (Kliewer et al., 1998).
X e n o b i o t i c
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More recently the maximal induction of CYP3A4 by rifampicin was shown to 
require the co-transfection of both HNF4a and PXR as well as the co-activators 
peroxisome proliferators-activated receptor-y co-activator la  (PGC-la) and steroid 
receptor coactivator-1 (SRC-1) in HepG2 cells. Induction observed via the addition of 
HNF4a appeared to be mediated through PXR as opposed to any direct interaction with 
the CYP3A4 promoter (Li and Chiang, 2006).
1.20 Drug-drug and drug-diet interactions
Drug-drug interactions represent approximately 3-5% of adverse drug reactions (Leape, 
1995). One drug affects the toxicity or efficacy of another. Co-administration of 2 or 
more drugs could mean that the combination causes an increase in efficacy of one, 
possibly to toxic levels. Conversely, the combination can nullify the effect o f the drugs, 
resulting in a lack o f efficacy, which can also be detrimental to a patient. As more drugs 
are developed and multiple drug therapies are more often used, side-effects and drug- 
drug interactions are bound to increase.
Drug interactions generally occur through the modulation o f metabolising 
enzymes via induction or inhibition. Inhibition decreases metabolism of drugs and can be 
competitive, non-competitive or uncompetitive. Induction leads to an increase in the 
amount of P450 expressed, enhancing the rate of metabolism. Understanding more about 
the underlying causes o f drug interactions may reduce the number o f adverse drug 
reactions and result in improved therapeutic regimes.
The number of food-drug interactions is incalculable. An interesting subset of 
food-drug interactions on which to focus would be herbal products/complementary 
medicines and their associated drug interactions. The use of complementary medicines 
has increased a great deal over the last 20 years. Their use and production is largely 
unregulated, and they are promoted as ‘natural’ and therefore harmless. The public do not 
view herbals as ‘drugs’, although they are not exempt from interactions, since they are 
metabolised in the same way as prescription drugs. Problems tend to arise when a 
patients’ use o f an herbal product is not made known to their GP when going for 
treatment, and a severe adverse drug reaction could be the consequence.
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The Dietary Supplement Health and Education Act (DSHEA) (Dietary 
Supplement Health and Education Act (DSHEA). 42 USC 287C-11. 1994) defines a 
dietary supplement as "a product (other than tobacco) that is intended to supplement the 
diet and that bears or contains one or more of the following dietary ingredients: a vitamin, 
a mineral, a herb or other botanical, an amino acid, a dietary substance for use by man to 
supplement the diet by increasing the total daily intake, or a concentrate, metabolite, 
constituent, extract or combinations of these ingredients."
Herbal products and dietary supplements are very popular. It is estimated that 
20% of Americans regularly take dietary supplements, yet only a third of those inform 
their doctor (Kennedy, 2005). An FDA testimony puts the consumption level much 
higher. In the year 2000, dietary supplements, including vitamins, were consumed by 158 
million Americans which is more than half the US population (US Food and Drug 
Administration. Statement by Joseph A. Levitt before the U.S. House of Representatives).
1.21 Liquorice
Liquorice has been used for thousands of years to treat ailments ranging from coughs and 
sore throats to hepatitis and stomach ulcers. Recently studies indicate that glycyrrhetinic 
acid (GTA) can be used to reduce the thickness of subcutaneous thigh fat (Armanini et 
al., 2005) and can delay the development of autoimmune disease (Horigome et al., 2001).
The main ingredient, glycyrrhizin is hydrolised to the active principal GTA by 
intestinal flora and absorbed by the gut. A hemi-succinate derivative carbenoxolone was 
synthesised and used widely in the 1950s as a treatment for stomach ulcers. A large 
proportion of the patients suffered from hypertension and hypokalemia, and it was 
thought that this was merely an ‘allergic reaction’ which resolved itself once the dose was 
reduced. It is now known that GTA is a non-specific 11 p-hydroxysteroid dehydrogenase 
(11P-HSD) inhibitor. There are two isoforms of 1 lp-HSD, type 1 and type 2. Type 2 is 
highly expressed in the renal cortex and salivary glands and has dehydrogenase activity. 
It catalyses the conversion of active cortisol to inactive cortisone, protecting the 
mineralacorticoid receptor from cortisol and enabling it to bind aldosterone. 1 lp-HSDl is 
mainly expressed in the liver and adipose tissue. It is a reductase and catalyses the
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conversion of cortisone to cortisol. Cortisol has a variety o f tissue-specific effects which 
may contribute to the phenotype o f simple obesity, type II diabetes and the metabolic 
syndrome. In the liver, cortisol induces gluconeogenesis, and in adipose tissue it 
increases adipocyte differentiation. It impairs insulin signalling and decreases insulin 
secretion, i f  cortisol production can be turned off, as in the inhibition o f 1 lp-HSDl, it 
will preserve insulin sensitivity and decrease hepatic glucose output, whilst slowing 
increasing adiposity.
1.22 Objectives of this project
FMOs have long been compared to P450 enzymes, but much less is known about the 
former than the latter. Although many o f the endogenous roles o f P450 enzymes have 
been elucidated, it is as yet unclear what the endobiotic role of FMOs are.
With the use of Fmol, 2, 4 (-/-) and Fmo5 (-/-) mice the project will investigate 
phenotypic differences in these KO mice. These studies should give a much better 
understanding of the endobiotic role of FMOs and possibly indicate differences in role 
between the individual FMO isoforms.
Although it is well known that several P450 enzymes are inducible by xenobiotics 
through various nuclear hormone receptors, this has never been demonstrated in FMOs. 
We hope to culture primary mouse hepatocytes and use these to study more closely the 
effects of xenobiotics on FMOs, through the use of reporter gene asssays, and thus 
discover whether nuclear receptors such as PXR have a role to play in any subsequent 
FMO induction.
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Materials and Methods
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2 Materials and Methods
2.1.1 Chemicals and Reagents
All chemicals used, apart from those used in tissue or cell culture, were purchased from 
Sigma Co. unless otherwise stated and were of analytical grade. Restriction 
endonucleases were purchased from NBL Gene Sciences. Reagents used for cell or tissue 
culture were purchased from Gibco BRL (Invitrogen) and were o f tissue culture grade. 
Details o f companies can be found in the appendix.
2.1.2 Culture of bacteria
LB medium (per L: lOg bactotryptone, 5g yeast extract, 5 g NaCl) (BIO 101, Anachem) 
or LB agar medium (per L: lOg bactotryptone, 5g yeast extract, 5 g NaCl, 15g agar) (BIO 
101, Anachem) were made by adding capsules to water (40 capsules/L) and autoclaving. 
Before use, ampicillin was added at a final concentration of 50 pg/mL. The LB agar 
medium was left to cool until ‘hand hot’ and poured into 82mm Petri dishes 
(30mL/plate). The plates were allowed to set at room temperature and stored at 4°C. 
Bacteria were streaked onto the plates and incubated at 37°C overnight. A single colony 
was used to inoculate 5 mL of LB-ampicillin media and incubated for 6-8 hours at 37°C 
with shaking (300 rpm). This ‘starter culture’ was used immediately for small-scale 
isolation of DNA (see below) or used to inoculate LB-ampicillin media (25 mL) which 
was incubated for 12-16 hours at 37°C with shaking (300rpm).
2.1.3 Small-scale isolation of plasmid DNA from bacteria
The QIAfilter Miniprep kit (Qiagen) was used for small-scale isolation o f plasmid DNA. 
Buffers PI, P2, N3, PB, PE and EB are all contained within the kit.
I mL of the 5 mL starter culture from above was spun (8,000 rpm, 3 minutes) and 
the supernatant removed. The resulting pellet was re-suspended in buffer PI (50mM Tris- 
Cl (pH 8.0), lOmM EDTA, 100 pg/mL RNase A) and the cells lysed by buffer P2 
(200mM NaOH, l%SDS). Buffer N3 was added, the tube inverted 4-6 times and the
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samples centrifuged (13,000 rpm, 10 minutes). The protein layer forms the pellet and the 
supernatant was applied to the QIAprep Spin column. This was centrifuged (13,000 rpm, 
30 seconds) and the flow-through was discarded. The spin column was washed with 0.5 
mL of buffer PB and again centrifuged (13,000 rpm, 30 seconds). The spin column was 
washed again with buffer PE and centrifuged (13,000 rpm, 30 seconds). The flow­
through was discarded and the spin column centrifuged again to remove all trace of 
ethanol. To elute the DNA 50 pi of buffer EB (lOmM Tris, pH 8.5) was added to the 
filter of the column and left to stand for 1 minute, then centrifuged (13,000 rpm, 30 
seconds).
2.1.4 Medium-scale isolation of plasmid DNA from bacteria
The QIAfilter Midiprep kit (Qiagen) was used for the following procedure to isolate a 
larger amount of plasmid DNA. Buffers PI, P2, P3, QBT, QC and QF are all contained 
within the kit.
The 25 mL culture obtained above was centrifuged (Sorvall, S-3000 rotor) 
(6000rpm, 15 minutes). The resulting bacterial pellet was thoroughly re-suspended in 4 
mL of buffer PI (50 mM Tris-Cl (pH 8.0), 10 mM EDTA, 100 pg/mL RNase A) and the 
cells lysed in 4 mL buffer P2 (200mM NaOH, 1%SDS). The tube was inverted 4-6 times 
to mix the lysate and then incubated at room temperature for 5 minutes. 4 mL of chilled 
buffer P3 (3M potassium acetate, pH 8.0) was added to neutralise the lysate, and the tube 
was inverted 4-6 times to mix. A white precipitate forms and the lysate was immediately 
poured onto a filter cartridge (included in the kit) and incubated (10 minutes, room 
temperature). During this time a QIAtip (included in the kit) was equilibrated with 4 mL 
buffer QBT (750mM NaCl, 50mM MOPS (pH 7.0), 15% isopropanol, 0.15% Triton® X- 
100).
The protein layer from the lysate naturally rises to the top of the cartridge and the 
cleared lysate was filtered into the equilibrated QIAtip and allowed to filter through the 
column. The resin in the QIAtip selectively binds plasmid DNA. The column was washed 
twice with 10 mL buffer QC (1M NaCl, 50mM MOPS (pH 7.0), 15% isopropanol) which 
removes cellular metabolites and RNA.
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Plasmid DNA was eluted from the column with 2 mL buffer QF (1.25M, 50mM 
Tris-Cl (pH 8.5), 15% isopropanol) into a 30 mL plastic tube (Starstedt). 3.5 mL of 
isopropanol was added to the eluant to precipitate the plasmid DNA. The mixture was 
centrifuged (Sorvall, SS-34 rotor) (11,000 rpm, 30 minutes, 4°C). After removing the 
supernatant, 2 mL of 70% ethanol was added to wash the DNA pellet. The tube was 
centrifuged again (14,000 rpm, 10 minutes). The supernatant was removed and the 
plasmid DNA pellet was allowed to air-dry then was re- suspended in an appropriate 
volume o f TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
2.1.5 Quantification of DNA by UV spectrophotometry
The concentration of DNA was quantified using the NanoDrop spectrophotometer 
(NanoDrop). I pi of water was applied to the platform and used to calibrate the 
NanoDrop, then 1 pi of TE buffer was used to ‘blank’ the sample. The TE droplet was 
removed from the platform and a DNA solution (1 pi) was applied. The sample 
absorbances were measured at 260nm. An optical density (OD) o f 1 at 260nm is 
equivalent to 50 pg o f DNA.
2.1.6  Agarose gel electrophoresis of DNA fragments
l g o f agarose was melted in 100 mL of l x TBE (10 x TBE: 0.89M Tris-base, 0.09M 
Boric acid, 20mM EDTA, pH 8.0) in a microwave until the agarose was completely 
dissolved. Once the liquid was ‘hand-hot’ 5 pi of ethidium bromide (stock o f 10 mg/mL, 
Fisher) was added. The liquid agarose was poured into a gel mould with an appropriate 
comb. Once set, the gel was placed into an electrophoresis tank filled with l x TBE. A 
DNA size marker, 10 pi of Hy peri adder I or IV (Bioline), was pipetted into the gel and 
electrophoresed with any DNA samples subsequently added to the gel.
DNA samples were mixed with l x loading buffer (6 x loading buffer: 0.25% 
bromophenol blue, 0.25% xylene cyanol, 30% (v/v) glycerol) and applied to the wells of 
the gel. The gel was run at 100 volts until sufficient separation of DNA fragments had 
occurred. After electrophoresis, the gel was photographed on a UV transilluminator.
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2.1.7 Gel extraction
Gel fragments were excised with a sharp scalpel from an agarose gel (1% w/v) and put 
into a colourless Eppendorf tube. Three volumes of buffer QG were added to 1 volume of 
gel (e.g. 300 pi to 100 mg o f gel) and the Eppendorf tube incubated (50°C, 10 minutes) 
with sporadic vortexing until the gel slice melted. The buffer containing the melted gel 
was applied to a QIAquick spin column and centrifuged (13,000 rpm, 1 minute). To 
remove all trace of agarose 0.5 mL of buffer QG was added to the column and 
centrifuged (13,000 rpm, 1 minute) and the flow-through discarded. To wash, 0.75 mL of 
buffer PE was applied to the column and centrifuged (13,000 rpm, 1 minute) again 
discarding the flow-through. To remove any residual ethanol, the column was spun again 
for 1 minute. 30 pi of buffer EB was applied to the column and left to incubate for one 
minute. Columns were put into clean Eppendorf tubes and the DNA was eluted by 
centrifugation (13,000 rpm, 1 minute).
2.1.8 Polymerase Chain Reaction (PCR)
All PCR reactions were carried out in a Genius PCR machine (Techne). Primer sequences 
can be found in the appendix. The BIO-X-ACT™ DNA polymerase from Bioline was 
used.
The PCR consisted of 10 ng of template DNA, l x OptiBuffer buffer (a non-Tris 
incubation buffer, Bioline) 0.2mM dNTP mix and 0.5 pM reverse and forward primers 
plus 0.5 units of the BIO-X-ACT™ DNA polymerase. The volume of the reaction was 
made up to 50 pi with sterile water. The negative control for each reaction was made in 
the same way but didn’t include template DNA. Amplification parameters are shown in 
Figure 2.1.10.1. The annealing temperatures were 65°C since the calculated Tm of each 
primer was much higher than this. The amplified products were viewed by agarose gel 
electrophoresis.
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2.1.9 TOPO°/TA cloning
The TOPO®/TA cloning kit (Invitrogen) was used. The single deoxyadenosine (A) 3’ 
overhangs on the PCR product left by the BIO-X-ACT™ DNA polymerase are used to 
ligate to the linearised TOPO® vector which contains 3’ deoxythymidines (T) at each 
end. Ligation is carried out by topoisomerases that are covalently bound to the vector.
In a 0.5 mL Eppendorf, 4 pL of a freshly prepared PCR product was gently mixed 
with l pi o f salt solution (contained in kit) and l pL o f TOPO® vector. This was 
incubated at room temperature for 5 minutes.
2.1.10 Bacterial transformation
M achl-Tl™  or DH5a™ (both Invitrogen) competent cells were thawed on ice. 50 pL of 
cells were mixed with 2 pL of a ligation reaction (see sections 2 .1.9 and 2.1.12). The 
mixture was incubated on ice for 30 minutes, then incubated at 42°C for 30 seconds, and 
put back on ice. Provided with the competent cells was SOC medium (Formulation per 
1L: 2% tryptone, 0.5% yeast extract, 10 mM sodium chloride, 2.5 mM potassium 
chloride, 10 mM magnesium chloride, 10 mM magnesium sulphate, 20 mM glucose) 250 
pL was added to the bacteria. Cells were incubated with shaking (1 hour, 37°C, 300 rpm). 
20 pL of the bacterial culture was plated onto an LB-ampicillin plate. Plates were 
incubated overnight (37°C).
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(a)
Programme 1 1 cycle
95°C 5 mins
~ 65°C 30 secs
68°C 1 min/Kb
Programme 2 30 cycles
95°C 5 mins
65°C 30 secs
68°C 1 min/Kb
Programme 3 1 cycle
68°C 5 mins
(b)
Tm = 69.3 + (0.41 x (%G+C)) -  650/length in nucleotides
Tml + Tm2 
Annealing temperature = 2
2.1.10.1 PCR parameters
The PCR programme (a) is shown. The extension temperature for BIO-X-ACT™ was 
68°C. The annealing temperature was 65°C. The Tm of each primer was calculated, and 
Tm values for both primers were used to calculate the annealing temperature (b).
50
2.1.11 Restriction endonuclease digestion of DNA
Restriction endonuclease digestions were carried out in l .5 mL Eppendorf tubes. Plasmid 
DNA and reaction buffer (lx) were added to the tube. The volume was made up to 25 or 
50 pi with sterile water, depending on the amount o f DNA to be digested. Finally the 
restriction endonuclease enzyme ( l unit per pg o f DNA) was added to the tube, and the 
reaction mixture was incubated at 37°C for at least l hour. When two different restriction 
endonucleases were required, both enzymes were added to the reaction containing a 
compatible reaction buffer.
2.1.12 Ligation
The fragments cloned using the TOPO™ kit were cut from the TOPO™ vector and 
ligated into the pGL3 Basic (Promega) vector. Ligation was carried out using the Quick- 
Stick ligase kit (Bioline). 9 pL of a promoter fragment was added to 1 pL of the digested 
pGL3 Basic vector to a maximum of 100 ng, and made up to 14 pL with sterile water. 
Quick-stick ligase (1 pL) plus QS buffer (5 pL) (contained in kit) was added to the DNA 
and mixed thoroughly. The reaction mixture was incubated for 5 minutes at room 
temperature. The ligated fragment is now ready for bacterial transformation.
2.1.13 Preparation of glycerol stocks
For long-term storage o f bacterial cultures, 0.85 mL of culture (grown overnight, 37°C) 
was mixed with 0.15 mL of glycerol (100%, autoclaved) in a 1.5 mL Eppendorf tube, and 
immediately stored at -70°C.
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2.2 Isolation and maintenance of primary mouse hepatocytes
2.2 .1 Sterilisation of the perfusion apparatus
The perfusion apparatus was filled with 70% ethanol and left overnight. The morning on 
which hepatocyte isolation was planned, the apparatus was rinsed thoroughly three times 
with sterile water.
2.2.2 Matrigel coating of culture plates
All well-plates were coated with Matrigel™ Basement Membrane Matrix (BD 
Biosciences) the morning of hepatocyte isolation. The Matrigel™ was diluted 1:9 with 
Williams E media then a sufficient amount of this dilution was pipetted into each well 
(e.g. 200 pL in a well from a 12-well plate). This solution was spread evenly over the 
well with a cell scraper (Coming) and left to set (1 hour, 37C). Just before the 
hepatocytes were plated, any Matrigel™ that hadn’t set was rinsed off with Williams E 
media.
2.2.3 Dissection
All dissection equipment was cleaned and autoclaved before use. Hepatocytes were 
isolated from male C57BL-6 mice at least 6 weeks old, who had access to food ad 
libitum.
Mice were anaesthetised by combining ketamine (5.7 mg/mL) and xylazine (2.6 
mg/mL) and injecting 0.1 mL/20g body weight intraperitoneally. Once the mouse failed 
to respond to stimuli, the abdomen was swabbed with alcohol (70% v/v ethanol) and the 
mouse immobilised on the dissection mat. The abdomen of the mouse was opened 
through a U-shaped incision and the intestines swept to the left o f the torso. Using a 
‘vein-lifter’ a ligature (size 3 Mersilk, Ethicon) was loosely tied around the inferior vena 
cava (IVC) below the junction to the kidney. A small hole was cut in the I VC below the 
ligature and the cannula (24G gavage needle, Popper and Son) filled with heparin 
(50U/mL) was inserted. Air bubbles in the cannula would seriously impair perfusion. The
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heparin reduces clotting in the liver that may also affect perfusion. It was important not to 
insert the cannula too far into the vessel as this could damage the liver. The ligature was 
tightened and knotted. A diagram of the vasculature of the liver is shown in Figure 
2.2.4.1.
2.2.4 Two-step Perfusion of the Mouse Liver
Before dissection of the mouse, approximately 50 mL of Buffer 1 (Hanks Balanced Salt 
Solution (without CaCl2 and MgCl2), containing 50 mM EGTA, 125 g glucose) with the 
temperature maintained at 37°C, was circulated around the perfusion apparatus. This was 
done to remove bubbles in the system. Buffer 1 had 95% 0 2 and 5% C 0 2 bubbled 
through it for 15 minutes prior to the perfusion. After this time the pH was re-instated to 
pH 7.4 with the addition of HC1 (1M, sterile). Arepresentation of the apparatus is shown 
in Figure 2.2.4.2.
The tubing from the perfusion apparatus was connected to the cannula that was 
inserted into the IVC of the mouse. Buffer 1 was then pumped through the liver at a rate 
of 2 mL/min. As soon as the perfusion apparatus was connected to the cannula, the portal 
vein was snipped and the perfusion flow rate increased to 7 mL/min. To prevent the 
buffer perfusing the heart and hence the rest o f the body, the diaphragm was cut and the 
IVC clamped just below the heart. The liver should bleach of colour almost immediately 
and take on a light beige colour. The abdomen would be rinsed with distilled water to 
clear out the blood. Perfusion with Buffer 1 would take approximately 7 minutes. During 
this time collagenase H (0.8 U of collagense/ mL, Roche) was added to pre-warmed 
Buffer 2 (100 mL of Hanks Balanced Salt Solution (with CaCl2) plus 1.74 mM CaCl2, 
0.72 % w/v BSA and 125 g glucose) and mixed well.
The buffer was changed from Buffer 1 to Buffer 2, and the perfusion was 
continued for approximately 8-10 minutes, or until the liver became soft and had a glassy 
appearance. Occasionally massaging the liver very gently between thumb and fore-finger 
aided the digestion of the liver by preventing clot formation. Once the liver was soft it 
was removed from the mouse taking care not to cut through the intestines, as this could 
result in contamination of the cells.
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2.2.4.1 Blood supply and circulation in the human liver
The cannula is inserted at the lower end o f  the inferior vena cava (light grey arrow). From 
here the perfusion buffer flows into the liver and out o f  the hole cut in the portal vein 
(dark grey arrow). To prevent the buffer flowing throughout the body, a ligature is placed 
around the inferior vena cava below the heart (black line, top o f  diagram). Excerpt from 
Merck.com.
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2.2.4.2 Representation o f  liver perfusion apparatus
Pre-warmed perfusion buffer 1 or 2 in the reservoir has gas (95% O2 , 5% CO2) bubbled 
through it. It is pumped from the reservoir to the heating jacket at a flow rate of 7 
mL/min, where its temperature is maintained at 37°C. From here it travels to the mouse 
liver through tubing connected to the cannula inserted in the mouse inferior vena cava.
55
2.2.5 Purification of Mouse Hepatocytes
The liver was transferred to ice-cold William’s E (WE) media (containing 7% v/v FBS 
(fetal bovine serum), 10 mL/L insulin tranferrin selenium (10X), 30 mM pyruvate, 300 
pg/mL gentamicin) and the cells dispersed by carefully scraping the Glissons capsule 
with 2 round-ended forceps. The digestion was successful if this was easily done. The 
cells were further dispersed through a large-bore pipette and filtered through a 70 pm 
nylon filter (Falcon). The remaining suspension was diluted to 20 mL with ice-cold WE 
(as above) and centrifuged (50 x g, 4°C, 2 minutes). The supernatant was poured away 
and the remaining pellet was re-suspended in 20 mL ice-cold WE (as above). 
Centrifugation and re-suspension was repeated twice. After the final centrifugation the 
pellet was re-suspended in 25 mL of WE (containing 7% FBS, 10 mL/L ITS, 30 mM 
pyruvate, 5nM dexamethasone, 300 pg/mL gentamicin) ready to be plated out. The 
suspension was kept on ice whilst the cells were counted and the viability determined 
using the Trypan Blue exclusion test (see below). 1 mL/well of the suspension was plated 
onto Matrigel™ coated 12-well culture plates (see section 2.2.2) at a density o f 0.5 
million cells per mL. The plates were incubated at 37°C, with 95% O2 and 5% CO2 for 2- 
3 hours depending on how well the cells had attached to the plate. After this time the 
media and dead cells were removed from the plates and replaced with fresh media 
typically omitting FBS so as not to interfere with further dosing experiments.
2.2.6 Hepatocyte dosing regime
After 2-3 hours incubation, the media was removed from the wells and replaced with 
fresh culturing media without FCS but containing the compound of interest. The plates 
were incubated at 37°C, with 95% O2 and 5% CO2 for 24 hours. Total protein lysates 
were isolated as described in Section 2.2.7. The isolation o f total RNA was carried out as 
described in Section 2.3.3.
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2.2.7 Isolation of primary mouse hepatocyte lysates
Cell lysates from primary mouse hepatocytes were isolated by scraping the cells from the 
plate using a cell scraper (TPP), and rinsing the plate with phosphate buffered saline 
(PBS, Gibco). This mixture o f PBS and cells was transferred to clean Eppendorfs and 
centrifuged (12,000 x g, 15 minutes) to get a cell pellet. The remaining PBS was removed 
from the pellet and the pellet allowed to drain. It was reconstituted in 40 pL o f 1 x TE, 
mixed well and then the cells lysed by sonication at the lowest setting for 2  seconds. 
These cells lysates were subsequently used for protein gels and Western blotting.
2.2.8 Trypan Blue exclusion test
If a cell is alive its cell membrane is intact and it is able to exclude Trypan Blue. The 
opposite is true for dead cells. Hence live cells appear white and dead cells, which have 
taken up Trypan Blue, appear blue.
200 pL of well-mixed cell suspension was added to 200 pL o f Trypan Blue stain 
(0.4% w/v). This was mixed and applied under a cover slip on top of a haemocytometer. 
The cells in the large central square on the haemocytometer were counted. Cells on the 
top and left border were included and those on the bottom and right border were 
excluded. If fewer than 100 cells were counted, cells in more squares were counted. The 
number of squares counted was taken into account (see Figure 2.2.8.1).
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(a)
(b)
Cell number per mL =  Cell count_____
No. of large squares counted x 2 x 104
For cell viability the total number of cells were counted along with the number of blue 
(dead) cells.
Number of live (white) cells = total number of cells -  number o f dead (blue) cells
Viability -  Number of white cells
Total number o f cells x 100
2.2.8.1 Trypan Blue Exclusion Test
A picture o f the grid on a haemocytometer is shown (a). The calculations to determine 
cell number and viability are shown in (b)
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2.3 Cell culture
2.3.1 HepG2 cell culture
HepG2 cells (passage number 9 or 10) were obtained from the European Collection of 
Cell Culture (ECACC) and seeded onto tissue culture flasks (MG Scientific) and grown 
in an incubator (Heraeus®, Kendro) at 37°C with 5% CO2 until the cells were 70-75% 
confluent. Cells were washed twice with PBS ((lx) 137 mM NaCl, 2.7 mM KC1, 10 mM 
Na2 HPC>4 , 1.8mM KH2PO4), detached with 4 mM EDTA in 1 x PBS and pelleted by 
centrifugation (1900 rpm, 2 minutes, room temperature). The pellet was re-suspended in 
fresh complete medium and seeded onto 24-well plates (Nunc). To ensure that the cells 
were 70-75% confluent at the time of transfection, they were plated 48 hours beforehand. 
HepG2 cell culture was carried out by Dr. Mina Edwards.
2.3.2 Transient transfection ofHepG2 cells
The HepG2 cells were plated into 24-well plates at a density of 4 x 104 per well. For 
transfection the cells were 70-80% confluent. For each well, 0.5 pg of DNA was diluted 
in 100 pL of Opti-MeM® and to this 2.5 pL of Lipofectamine LTX was added. This 
solution was mixed gently and incubated at room temperature for 25 minutes to form the 
DNA-Lipofectamine LTX complexes. The growth media from the plates was removed 
and to each well 0.5 mL of complete media and 100 pL of the DNA-Lipofectamine LTX 
complexes were added. The solutions were mixed by gently rocking the plate and the 
complexes were left for 24 hours before treatment with the selected xenobiotics. After a 
further 24 hours the cells were isolated for use with the Dual-Luciferase reporter assay 
(see below).
2.3.3 Isolation of total RNA from HepG2 cells or primary hepatocytes
After the cells (primary mouse hepatocytes or HepG2 cells) had been treated for 24 hours 
with an appropriate xenobiotic, the cell total RNA was isolated using the RiboPure™ kit
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(Ambion). After removal of the media (without washing the cells) TRI™-reagent (phenol 
and guanathionate) ( 2 0 0  pi per well in a 1 2 -well plate) was added to the cells allowed to 
cover the plate. TRI™-reagent completely detaches the cells, and this homogenate was 
removed and transferred to clean Eppendorf tubes. The tubes were frozen (-70°C) until 
RNA isolation could be carried out. At this time the tubes were allowed to thaw at room 
temperature (RT) and 100 pL of bromochloropropane was added to each mL of 
homogenate and vortexed for 15 seconds. The mixture was incubated (RT, 5 minutes) 
then centrifuged (12,000 x g, 10 minutes, 4°C). 400 pL o f the upper aqueous phase was 
pipetted into a new centrifuge tube and 200 pL of ethanol (100%) was added and 
vortexed. The samples were transferred to filter cartridges and spun in collection tubes 
(12,000 x g, 30 seconds, RT). The flow-through was discarded and 500 pL o f wash 
solution was added to the filter cartridge. This was centrifuged (12,000 x g, 30 seconds, 
RT), and the flow-through discarded. The whole washing sequence was repeated, and the 
filter cartridges were centrifuged a final time to remove residual wash solution. The filter 
cartridges were transferred to clean collection tubes and 100 pL of Elution Buffer added 
to the filter. They were left to incubate (RT, 2 minutes), then were centrifuged for 30 
seconds. The eluant contained the RNA.
2.4 Down-stream analysis
2.4.1 Dual-Luciferase reporter assay and pGL3 vectors
The Dual-Luciferase® reporter assay kit was purchased from Promega. It utilises a 
Firefly and Renilla luciferases. The pRL-TK vector contains the Renilla (.Renilla 
reniformis) luciferase reporter gene (Rluc) upstream of which is the herpes simplex virus 
thymidine kinase (HSV-TK) promoter. The pGL3 Basic vector contains a multiple 
cloning site upstream of the firefly (Photinus pyralis) luciferase reporter gene (luc+) (See 
Figure 2.4.1.1). The ability of any fragments cloned into this site to drive expression of 
this reporter gene can be measured. The cells were simultaneously transfected with the 
pRL-TK vector containing Renilla luciferase to act as an internal control.
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Luciferase Assay Reagent II (LARII) is the substrate for firefly luciferase, and its 
activity is measured first. Stop & Glo® Reagent is added to the same tube, this is used to 
measure the activity of the Renilla luciferase. It also quenches the luminescence produced 
from firefly luciferase so the two measurements do not interfere.
Cells are lysed using lysis buffer contained within the Dual-Luciferase® reporter 
assay kit, by adding it to the cells (200 pi per well in a 24-well plate) and rocking the 
plate for 15 minutes to allow for complete lysis. The lysate (20 pi) was transferred to a 
96-well plate and LARII was added (100 pi) before measuring the luminescence.
The plate was read at 520 nm absorbance on a Pherastar plate reader. This first 
step measures the firefly luciferase then Stop and Glo reagent (100 pi) was added to the 
same wells and the Renilla luciferase is measured. Relative light units (RLU) are the 
values obtained when the firefly luciferase measurement is divided by the Renilla 
luciferase measurement.
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2.4.1.1 The pGL3 vectors by Promega
Promoter fragments were cloned into the pGL3-Basic vector. The pGL3-Basic vector was 
also used as a negative control. The pGL3-Control vector was used as the positive control. 
The pRL-TK vector was co-transfected with each plasmid to act as an internal standard for 
each transfection reaction.
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2.4.2 Protein concentration determination
The DC Protein Assay (BioRad) was used. This is a colourimetric assay based on the method 
of Lowry (Lowry et al., 1951). BSA (1.4 mg/mL) was used as a standard. A standard curve 
was produced by making 6  BSA concentrations in duplicate ranging from 2pg to 20pg and 
adjusted to 100 pL with water. Any protein samples (cells lysates) were also duplicated, and 
made by adding 2 pL of total protein to 98 pL o f water. 500 pL o f Reagent A (alkaline 
copper tartrate solution) was added to each sample including the standard samples and 
allowed to incubate at room temperature for 5 minutes. 4 mL o f Reagent B (Folin reagent) 
was also added to each tube and immediately vortexed. The reactions were incubated for 20 
minutes at room temperature. During this time, samples and standards became blue. The 
absorbance of each sample was measured at 750 nm in a spectrophotometer. The BSA 
protein standard was drawn, and used to calculate the protein concentration of the test 
samples.
2.4.3 SDS-PAGE
Total protein from primary mouse hepatocytes or HepG2 cells were visualised on a 10% 
SDS-polyacrylamide gel. The separating gel (50 mL) consisted o f 16.7 mL Protogel (30% 
w/v acrylamide, 0.8% bisacrylamide, National Diagnostics), 12.5 mL Tris-HCl (pH 8 .8 ), 
0.1% (v/v) SDS and 19.8 mL water. 0.5 mL ammonium persulphate (10% v/w) and 50 pi 
TEMED (BioRad) was also added. This mixture was quickly poured into a gel mould and 
overlaid with 0.1% (w/v) SDS. The gel was allowed to set overnight. The following morning 
the SDS layer was poured away and in its place a 3% stacking gel was overlaid. To make the 
stacking gel, 1.3 mL Protogel was added to 2.5 mL stacking buffer (0.5M Tris-HCl, 0.4% 
(w/v) SDS, pH 6 .8 ) and 6.1 mL water. To this, 50 pL ammonium persulphate and 10 pL of 
TEMED were added. The gel was allowed to set for 1 hour.
Protein samples were mixed with loading buffer (6 x, Invitrogen) and denatured for 3 
minutes at 99°C. B-mercaptoethanol was added to each sample to a final concentration of 
20% (v/v). Samples were briefly vortexed and centrifuged, then loaded onto the gel. The gel 
was electrophoresed in running buffer (0.025M Trizma base, 0.192M Glycine, 0.1% w/v 
SDS) at 25 mA until the protein samples had moved through the stacking gel, then the 
voltage was increased to 35 mA until completion.
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After electrophoresis the gel was stained with Coomassie Blue staining (see below) 
solution or a Western blot was carried out.
2.4.4 Coomassie Blue staining
The gel was placed in Coomassie Blue staining solution (0.25% w/v Coomassie brilliant blue 
dye, 45% methanol, 10% glacial acetic acid) until such a time that the gel was stained 
completely blue. The gel was put in de-staining solution (45% methanol, 10% glacial acetic 
acid) until protein bands stained blue could clearly be seen. The gel was transferred to 3M 
Whatman paper and dried using a gel dryer.
2.4.5 Western blotting
The proteins separated by SDS-PAGE were fixed to a nitrocellulose filter by western 
transfer. To do this the nitrocellulose filter, several 3MM Whatman papers and 4 blotting 
pads were pre-soaked in transfer buffer (25 mM Tris, 192 mM Glycine, 20% v/v methanol). 
The SDS-PAGE gel was placed on the nitrocellulose filter, and sandwiched between the 
Whatman papers and blotting pads and put into a blotting cassette. The cassette was put in a 
transfer tank filler with transfer buffer. A constant current of 100 mA was run through the 
tank overnight (room temperature) to transfer the proteins to the nitrocellulose filter. The 
following morning the current was increased to 2 0 0  mA for 1 hour to ensure the transfer of 
proteins.
For immunoblotting the filter was soaked for 1 hour in blocking solution (0.2 % w/v 
milk protein, 20 mM Tris-HCl (pH 7.5), 0.15 M NaCl). The filter was washed in TTBS (20 
mM Tris-HCl, 150 mM NaCl, 0.1 % v/v Tween-20) 3 times for 5 minutes each time. The 
primary antibody (Santa Cruz) was diluted 500-5000 times (depending on the original titre of 
the antibody) in a solution containing 0.2 % w/v milk protein, 20 mM Tris-HCl (pH 7.5) and 
150 mM NaCl. The filter was soaked in the primary antibody for 1 hour then the antibody 
was removed and the filter washed again in TTBS ( 3 x 5  minutes). The secondary antibody, 
which recognises the primary antibody is alkaline phosphatase conjugated. It was diluted in 
the blocking solution at 1:1000. The filter was incubated in the secondary antibody for 1 hour 
then rinsed in TTBS ( 3 x 5  minutes).
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To visualise the amount of primary antibody bound to the nitrocellulose filter, the 
Alkaline Phosphatase Conjugate Substrate kit (BioRad) was used. Briefly, for 25 mL of 
solution, 24 mL water, 1 mL of AP development buffer, 0.25 mL of AP colour reagent A, 
and 0.25 mL colour reagent B was combined. The nitrocellulose filter was immersed in the 
solution and agitated gently for 1 0  minutes or until the colour development was complete.
2.5 Microarray
2.5 .1 Cell treatment and preparation of RNA for microarray
12-well plates of hepatocytes were dosed. Half o f the wells on each plate were treated with 
glycyrrhetinic acid (10 pM), half with the vehicle, 70% ethanol. The plates were incubated at 
37°C, with 95% O2 and 5% CO2 for 24 hours. The media was removed and 200 pL of TRI- 
reagent from the RiboPure kit (Ambion) was added to each well as explained in Section 
2.2.7.
The RNA concentration was measured and 5 pL run on a l % agarose gel to confirm 
RNA integrity. The samples were then sent away to the MRC Microarray Facility at the 
MRC Mammalian Genetics Unit at Harwell. I visited the facility and carried out the 
following procedures.
2.5.2 Microarray procedure
The microarray slides used were the RNG-MRC Mouse set 25k, printed by MRC Microarray 
Facility at Harwell.
The Roche cDNA Synthesis kit was used to produce the first and second strand 
cDNA. lOpg of total RNA were added to 2pL of T7 Oligo [dT] 24 primer (l 00 pmol/pL) and 
made up to 2 1.5 pL with double-distilled water. This mixture was incubated at 70°C for 10 
minutes then placed immediately on ice. To this tube, 8  pL of Reverse Transcriptase buffer, 
4 pL DTT, 2.5 pL Reverse Transcriptase Enzyme mix and 4 pL dNTP mix were added. This 
was incubated for l hour at 42°C then put on ice. To generate the second strand, the first 
strand cDNA (40 pL) was added to second strand synthesis buffer (30 pL), dNTP mix ( l .5 
pL), second strand synthesis enzyme mix (6.5 pL) and distilled water (72 pL). This mixture
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was incubated at 16°C for 2 hours. Then T4 DNA Polymerase (20 pL) was added to this 
mixture and incubated (5 minutes, 16°C). The reaction was stopped by adding 17 pL EDTA 
(0.2 M, pH 8.0). The cDNA was then applied to a Qiaquick PCR purification column and 
eluted in 50 pL of water. The cDNA is run on a 1% agarose gel for quality control and then 
labeled by randomly primed Cy incorporation using Klenow fragment of DNA polymerase 1.
Klenow Labelling was carried out using random primers and klenow from Bioprime 
kit (Invitrogen). The sample cDNA (20 pi) was added to Random primer/Reaction buffer 
mix (20 pL). This is boiled for 5 minutes and cooled on ice. While on ice the following was 
added [lOx] dNTP mix (low dC) (5 pL); 1 mM Cy5-dCTP or Cy3-dCTP (2 pL); Klenow 
(high conc.) (1.5 pL); H2O (1 pL). The reaction mixture was incubated at 37 °C for between 
1 and 18 hours and the reaction stopped with 0.5 M EDTA (pH 8.0)(5 pL). Each labeling 
reaction was applied to a Sephadex G50 spin column to remove 90% of the unincorporated 
nucleotide. The eluents from Cy-3 & Cy-5 tubes are combined and read on the NanoDrop to 
determine incorporation of labelling. The blocking agent Cotl (lpg/pL , 10-20 pL) was 
added and Poly(dA) ( 8  pg/pL, 2 pL) is added as a “packer” to increase the concentration in 
the hybridisation solution. The sample was evaporated to dryness in a speedvac, then re­
suspended in 50 pL microarray hybridization solution. This was incubated at 85°C for 5 
minutes then at 42°C for 30 - 60 minutes prior to placing on the array. Meanwhile the array 
slide is placed into a hybridisation cassette (Coming) and 15 pL of water is put in each end 
of the chamber to ensure humidity. The chamber is sealed and placed in an oven at 42°C for 
30-60 minutes.
The samples were spun for 2 minutes at 13000 rpm then labelled mixture carefully added 
onto the slide (avoiding picking up any solid matter). The coverslip & cassette lid were added 
and hybridised at 48°C overnight.
The slides were washed by placing slides (in rack) in a container with 1 L of Wash 
solution A ([2x] SSC) until the cover slip falls off. The rack was transferred rapidly to a 
container with 1L Wash solution B ([O.lx] SSC, 0.1% SDS) & mixed vigorously for 5 
minutes. Again the rack was transferred rapidly to a container with 1L Wash solution C 
([O.lx] SSC) and mixed vigorously for 2 minutes. The slides were quickly moved into a 50 
mL Falcon tube using forceps whilst taking care not to touch the surface o f the array. The 
slides were placed in a tube with the labelled end in the bottom of the falcon tube (this means
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that any debris is spun away from the array, not over it) and spun for 5 minutes at 600 rpm at 
room temperature. The array was then scanned using the Perkin Elmer ProScanArray HT 
confocal scanner, and the data extracted using the Imagene version 6.0 software from 
Biodiscovery.
2.5.3 Real-time RT PCR
Having isolated the RNA as described in Section 2.3.3, using the Ambion RNAeasy kit the 
RNA concentration was measured using the NanoDrop (Section 2.1.5). To accurately 
measure the RNA within the samples real time RT-PCR was carried out. This procedure 
varies little from RT-PCR but a fluorescent probe, SYBR green is incorporated into the 
double stranded DNA as it is amplified. The fluorescence is measured and plotted at the end 
of each cycle, this is the cDNA copy number, those that rise above the background 
fluorescence are recorded and known as the threshold cycle (Ct). This value is used in an 
equation to calculate the quantity of cDNA taking the original quantity into account.
Firstly cDNA must be made from total RNA using Superscript First-strand cDNA 
Synthesis System for RT-PCR (Invitrogen). Oligonucleotide primers are used to bind to a 
complementary sequence in the RNA. A recombinant reverse-transcriptase enzyme 
recognises the primer-RNA hybrid and synthesises a complimentary strand of DNA along the 
RNA template, resulting in a double stranded RNA-DNA molecule. To yield the RNA, high- 
temperature separates the two and the RNA template is degraded at a lower temperature with 
RNAse. Oligo(dT) primer was used for the reverse transcription because Oligo(dT) selects 
only RNA transcripts carrying a polyadenylation signal o f at least 16 adenine nucleotides. 
This reduces the likelihood of amplifying any genomic DNA that might be present.
Solution A contains total RNA (lpg), Oligo(dT) (0.5 pg), dNTPs (ImM), DEPC-H2O 
(up to 9 pL), this was incubated (65°C for 5 minutes) and then put on ice (5 minutes). 
Solution B contained RT-buffer (IX), MgC^ (5mM), DTT (lOmM) and RNAse OUT 
(RNAse inhibitor 40 units). 9 pL of Solution B was added to Solution A and incubated (42°C 
for 2 minutes). 1 pL (50 units) of Superscript II reverse transcriptase enzyme was added and 
the reaction mixture was incubated (42°C for 50 minutes), then 70°C for 15 minutes. The 
mixture was left on ice for 5 minutes then 1 pL (2 units) of RNAse H was added and the
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mixture was incubated at 37°C for 20 minutes. The yield of cDNA was determined by 
spectrophotometry using a NanoDrop (Section 2.1.5).
The real time RT-FCR reactions carried out in this study were done on a Stratagene 
Mx3000P machine using the Quantace Sensimix dT Kit with SYBR Green. The reactions 
were prepared in a total volume of 25 pL. cDNA (0.5 pg), gene-specific forward primer (500 
nM), gene-specific reverse primer (500 nM), SYBR Green solution (IX), Sensimix solution 
(IX) (containing Taq DNA polymerase, dNTPs, and 3mM MgCh) and water (to 25 pL).
Below are the PCR conditions:
Condition Temp Time
Initial denaturation 94°C 1 0  minutes
Denaturation 94°C 30 seconds
Annealing 63 °C 30 seconds
Extension 72°C 30 seconds
40 cycles
A melting curve analysis was carried out after the completion o f each PCR run in 
order to detect the presence of non-specific products which might themselves contribute 
fluorescence. If fluorescence from non-specific products was above the background level it 
might interfere with proper interpretation of the expression level o f the target gene. The 
melting curve analysis consisted of heating the PCR products to 94°C and immediately 
measuring the fluorescence emitted from the sample. The temperature was then lowered by 
1°C and the fluorescence measured again. This process was repeated until the temperature 
reached 55°C. Typically amplified PCR product melted between 70-90°C and primer dimers 
melted between 55-60°C. Real time RT-PCR data was interpreted from the raw data plots by 
the method of Liu and Saint using an internal reference gene (Liu and Saint, 2002).
2.6 Animal Husbandry
Fmol, 2, 4 (-/-), Fmo5 (-/-) mice and C57BL/6 (wild-type) mice were housed according to 
Home Office regulations in a 12 hour light/dark cycle in cages of two or more mice. They 
were fed on a normal chow diet and water ad libitum unless otherwise stated. Animals were
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weaned at 3 weeks and kept in male or female only cages, unless the animals were to be used 
for breeding, when they were kept one male to two females.
2.6.1 Mouse weighing
The ages of the mice were calculated so that their ages would correspond to each other. 
Animals were weighed twice a week for up to 20 weeks from the age o f weaning. The mice 
were weighed individually on a Heraeus balance at 1 lam (+/- one hour) on the appropriate 
day.
2.6.2 Mouse diets
Mice were fed a standard chow diet unless otherwise stated. Standard chow diet was obtained 
from Harlan Teklad Global 18% total protein rodent diet, containing 18% protein, 5% fat and 
56% carbohydrate. At 14 weeks of age, 6  WT males, 7 WT females, 3 Fmo5 (-/-) males, 3 
Fmo5 (-/-) females, 5 Fmol, 2, 4 (-/-) males and 6  Fmol, 2, 4 (-/-) females were placed on a 
high-fat diet for 7 weeks. After this period of time the mice were culled and dissected (see 
below). The high-fat diet was obtained from Special Diet Services UK SDS DIO 35% kcal FAT 
diet containing 35% of calories from fat.
At 6  weeks of age 6  WT males, 5 Fmol, 2, 4 (-/-) males and 3 Fmo5 (-/-) males were 
placed on a normal chow diet containing 0.1% (w/w) a lipoic acid. Every effort was made to 
make the feed in a sterile manner. Any apparatus used was swabbed with 70% ethanol and 
rinsed with autoclaved de-ionised water. Typically lOOg of feed was made by grinding 99.9 g 
of normal chow pellets in a coffee grinder, adding O.lg of lipoic acid powder (Sigma) and 
mixing well. Pellets were re-formed by adding 20 mL of autoclaved de-ionised water and 
mixing to form a pulp. Pellet shapes were made by rolling the feed pulp in the palm of the 
hand. The pellets were left to harden by heating in an oven at 35°C overnight.
2.6.3 Dissection
At an appropriate age, male and female Fmol, 2, 4 (-/-), Fmo5 (-/-) mice and C57BL/6 (wild- 
type) mice were killed by CO. The mice were then weighed, their length measured, then they 
were dissected and major organs were removed. These were the liver, kidneys, spleen, heart,
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gonadal fat and brown adipose which were also weighed, and aliquots stored both at -70°C 
and in RNAlater™ at -20°C. The frozen tissues were initially snap frozen in a dry ice-ethanol 
bath and the liver and gonadal fat used later for histological analysis (Section 2.6.6), whilst 
the RNAlater stored tissues were used to generate RNA and study the expression levels of 
the FMOs using real-time RT-PCR (Section 2.5.3).
2.6.4 Blood collection
The blood was collected from the mice between 9.30am and 12.00 midday to minimise the 
effects of circadian rhythm. The mice were then incubated for 10 minutes at 37°C to make it 
easier to collect the blood. After this time the mice were put in a restrainer and the tail tip 
snipped at a 45° angle, from this the blood was collected in Starstedt heparin-coated tubes. 
The blood was spun (8000rpm, 10 mins, 4°C) and the upper plasma layer removed into clean 
tubes and frozen (-70°C).
2.6.5 Blood plasma biochemical tests
The blood plasma was sent to the MRC Mammalian Genomics Unit, Harwell in Oxfordshire. 
The samples were analysed using an ion selective electrode contained within an Olympus 
Diagnostic Systems AU400 Automated Clinical Chemistry Analyzer. The samples were 
measured as described by Hough (Hough et al., 2002).
2.6.6 Liver histology
Small amounts of liver from the WT, Fmol, 2, 4 (-/-) and Fmo5 (-/-) mice were cut from 
frozen tissue and left to freeze at -70°C for 20 minutes in a cryo-mould filled with 
TissueTech (Samura). During this time the cryostat (Leica CM 1850) was brought up to 
temperature. For liver and heart this was -16°C. After being frozen, the tissues in TissueTech 
were put into the cryostat at -16°C to bring the tissues up to temperature also. The tissue 
frozen in TissueTech is now taken out of its mould and fixed onto a platform that is inserted 
into the cryostat. The section thickness was selected (12 pM) and the tissue was cut into 
these 12 pM sections which are immediately ‘fixed’ onto slides by the process of attraction.
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To stain for total lipids, liver sections were stained in Oil Red O. This was made by 
dissolving Oil Red O (Sigma) in isopropanol overnight, then adding to a 1% w/v solution of 
dextran and filtering through a Whattmann filter Size 2. Slides were put into the Oil Red O 
stain for 15 minutes, rinsed in tap water then stained in Hematoxylin (Gil’s type 1, Sigma) 
for 30 seconds then rinsed in tap water until the nuclei turned blue (approximately 1 minute). 
Photographs were taken with an Orbit micropublisher colour digital camera using an 
Axioskop 2 plus-Zeiss confocal microscope.
2.6.7  Adipose histology
Paraffin embedded tissue sectioning was employed for the investigation of the 
cellular structure of white adipose tissue in the Fmol, 2, 4 (-/-) mice as cryo-sectioning is not 
cold enough to maintain the structure of fat. Adipose was first fixed in neutral buffered 
formalin (NBF) containing formaldehyde 40% (v/v) (100 mL), sodium phosphate (4g), 
sodium chloride (6 g) and water to 1 L, and stored at 4°C until used.
Tissue samples that were to be paraffin embedded were first dehydrated through a 
series of alcohols. This ensures that the hydrophobic paraffin can infiltrate the tissue 
properly. An approximately 50 mg tissue portion was incubated with 5 mL of room 
temperature alcohol as follows:
Distilled Water 30 minutes
50% Ethanol 45 minutes
70% Ethanol 45 minutes
90% Ethanol 45 minutes
100% Ethanol 1 hour
100% Ethanol 1 hour
Xylene 15 minutes
Xylene 15 minutes
Following dehydration the tissue samples were incubated in liquid paraffin (58°C 
overnight). The following day the tissues were transferred to clean liquid paraffin and 
incubated (1 hour at 58°C). Tissues were then embedded in liquid paraffin set into blocks at 
room temperature where they set. The blocks were sectioned (10 pM) using a Leica 2325
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microtome and floated on 37°C water to remove wrinkles, and then transferred to slides. The 
sections were allowed to dry and stored at room temperature until staining.
Haematoxylin stains nuclei a deep blue colour and Eosin stains the cytoplasm a light 
pink colour. The Haematoxylin-Eosin staining procedure employed was a modification of the 
method of Culling (Culling et al., 1974). The staining procedure involves three steps; the 
hydration of the tissue, the staining, and finally dehydration of the tissue.
Hydration Staining Dehydration
Xylene 5 mins Haematoxylin (Gil’s) 5 mins 50% Ethanol 30 secs
Xylene 5 mins Water (running tap) 5 mins 70% Ethanol 30 secs
100% Ethanol 5 mins 70% Ethanol 30 secs 90% Ethanol 30 secs
100% Ethanol 5 mins Eosin Y alcoholic 2  mins 100% Ethanol 1 min
90% Ethanol 5 mins Water (running tap) 1 0  secs 100% Ethanol 1 min
70% Ethanol 5 mins Xylene 1 min
Water (tap) 5 mins Xylene 1 min
The slides were mounted in DPX, a xylene based mounting medium and cover-slipped.
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3 FM05 promoter cloning and analysis
3.1 Identification of FM05 leader sequence
Sequence information for the full human genome is freely available from the Ensembl.org 
website. From here four clones of the human FM05 promoter were designed. The start site 
o f transcription was confirmed by using the DBTSS website (http://dbtss.hgc.jp). This 
information was checked by aligning all available FM05 cDNA clones to find any 
differences to the published sequence such as alternative splice sites (Figure 3.2.1), none of 
which were found.
The human FM05 gene lies on chromosome 1 region lq 2 1.1. It is 39,084 bp long and 
is located between chromodomain helicase DNA binding protein 1-like (CHD1L) and the 5'- 
AMP-activated protein kinase subunit beta-2 (PRKAB2) gene. The mouse Fmo5 gene is 
between the same two genes on chromosome 3 region F2.2, and is 23,679 bp in length.
3.2 Amplification of the FM05 promoter region
Sequences were amplified by PCR using primers designed from the published sequence (see 
Appendix). To influence the choice of primers and the position of the resulting constructs, 
the FM05 promoter was analysed for possible transcription factor binding sites (see Section 
3.4).
The PCR-amplified sequences were cloned into TOPO™ vectors. The insert was then 
removed using restriction enzymes Bgl II and Kpn I  and ligated into the pGL3 Basic vector 
(Promega) which had been digested with the same two enzymes. The pGL3 Basic vector 
contains a firefly luciferase gene, and the FM05 promoter fragments were cloned upstream 
of this. The four FM05 clones, -531, -1031, -1723 and -2443 were named by the length of 
the fragment, each clone starting at the same point within exon 1 (See Figure 3.5.1 for 
cloning strategy). The resulting clones were analysed by restriction enzyme digestion and 
agarose gel electrophoresis to ensure that the promoter fragments were the correct sizes 
(Figure 3.2.2). The clones were further analysed by determining their DNA sequence. No 
differences from the published sequence were found.
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3.2.1 FM05 cDNAs
FM 05 cDNAs from various tissues plotted alongside each other and the exon structure o f  
FMQ5.
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3.2.2 Gel picture of clone inserts
To confirm that the four F M 0 5  promoter fragments have been cloned into the pGL3 vector, 
the clones are digested using restriction enzymes Bgl II and Kpn I. The resultant plasmid and 
inserts were run on a 1% agarose gel alongside Hyperladder 1 (Bioline), a DNA size 
indicator.
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3.3 Conservation of the human FMOS promoter region
Using the University College Santa Cruz (UCSC) Genome Browser website 
(http://genome.ucsc.edu/cgi-bin/hgGateway) and the Vista Genome Browser website 
(http://pipeline.lbl.gov/cgi-bin/gateway2 ), the similarity between the human, chimp and 
mouse FMOS promoters was analysed. Figure 3.4.1 shows the conservation between the 
human and mouse and the human and chimp FM05 promoters. Shown in Figure 3.4.1a is 
FMOS and its proximity to CHD1L, which starts at base 145,181,000, only 17500bp from the 
translation initiation site (ATG) of FMOS. What can also be seen is the lack o f conservation 
between human and chimp sequences in two places, between 145,166,700 and 145,168,400 
as well as between 145,170,835 and 145,171,945 (Figure 3.4.1b). This implies a recent 
evolutionary event in this area. These insertions in the human genome are 3200 bp and 7335 
bp from the FM05 translation initiation site respectively. Part (a) o f this figure shows that 
from 145,166,060 there is no similarity between rodent and human sequences. This is 
approximately 2500bp upstream from the FM05 translation initiation site. Whilst human and 
chimp sequences are mostly highly conserved, the conservation between mouse and human 
sequences is limited to the first 500bp of the promoter, as shown in the top row of Figure 
3.4.1c. The specifics of this conservation are studied more closely in Figure 3.4.2.
3.4 FM05 promoter sequence analysis
As shown in Figure 3.4.1 there is a lack of conservation between the rodent and human 
FM05 promoter sequences beyond the first 2500 bp, upstream from the translation initiation 
site. This 2500 bp of sequence was analysed using the Match program 
(http://sdmc.lit.org.sg/ERE-V2/index) (Matys et al., 2003). Both human and mouse 
promoters were examined, and in Figure 3.4.2 some o f the possible regulatory sequences 
have been annotated. As was observed using the Vista program (Section 3.3), conservation 
between the two promoters is limited to the first 500 bp upstream from the translation 
initiation site. These conserved areas focus around key regulatory elements such as Spl 
sites/GC boxes and TATA boxes. Within the first 500 bp are two Spl sites situated at -150 
bp and -194 bp from the translation initiation site. Both are conserved in the human and 
mouse. The core sequence is GGGCG the so-called GC box. Spl recognises and binds to GC
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(a) Human compared to mouse
Start o f  FM05 
1
1451650001 1451700001 145175000|
Start o f  CHD1L 
11451800001
JA * . H J
Direction o f  transcription
(b) Human compared to chimp
Start o f  FM()5 
1
1451650001 145170000| 145175000|
Start o f  CHD1L 
1
1451800001
<----------------------------------------------Direction o f  transcription
(c) Mouse and chimp compared to human-the first 1500bp of the prom oter
1500 bp
1451635001 145164000| 145164500| 1451650001
Mouse vs 
human
Chimp vs 
human
VVi
/ V ,  A.
3.4.1 Human FM05 promoter compared to the mouse and chimp promoters
The promoter sequences are compared using Vista Genome Browser. The peaks indicate 
similarity to human sequence, the more and higher the peaks the greater similarity. Numbers 
above the peaks indicate the position in the chromosome. Parts (a) and (b) show the 
proximity o f  FMC)5 and CHD1L. Part (c) compares the first 1500 bp o f  human FM()5 
promoter to the mouse and chimp sequences.
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boxes, initiating transcription. A third Spl site is found much further upstream (-1007) in the 
human sequence which is not conserved with the mouse.
TATA boxes (the core sequence o f which is TATAA) are sequences recognised by 
the TATA box binding protein which bends the DNA sequence 80° forming an initiation 
complex for RNA polymerase II. Two potential TATA boxes one in the human sequence (- 
116) and one in the mouse sequence (-128) are highlighted in Figure 3.4.2.
There are also potential C/EBP sites in both mouse and human sequences the core 
recognition sequence of which is ATTCGGCAAT (Osada et al., 1996). The first possible 
C/EBP site (-100 bp) is not conserved with the mouse sequence, but the second (-134 bp) is. 
The third potential C/EBP sequence is based -255 bp upstream in the mouse sequence and is 
partially conserved with the human sequence. The fourth and fifth potential C/EBP sites lie at 
-413 and -454 bp from the start of transcription and both are partially conserved with the 
mouse promoter. Two further C/EBP sites (neither of which are conserved with the mouse 
sequence) lie -1043 bp (within the second promoter construct) and -1270 bp upstream, the 
second overlapping with one of three potential insulin response sequences (IRS). The C/EBP 
factors are highly expressed in the liver. They modulate genes involved in gluconeogenesis 
and response to insulin as well as factors in control of liver-function such as insulin-like 
growth factor (Nolten et al., 1994). C/EBPa has been shown to bind to insulin response 
sequences (Ghosh et al., 2001) the core sequence o f this is T(G/A)TTTTG, of which there are 
three possible sites in the FM05 promoter sequence. The first lies -264 bp from the ATG in 
the mouse sequence. This sequence differs slightly from the core sequence, containing the 
nucleotides GTTTTCT, where the C is usually a G/A. The TTTTC part is conserved with the 
human sequence. The next potential IRS sites lie side-by-side. The first (-1261) differs from 
the core sequence reading GTTTTTAT, having an additional T, the second (-1269) matches 
the consensus sequence exactly (GTTTTAT). This second IRS site overlaps with a potential 
C/EBP site (-1270). Neither IRS sequence shows conservation with the mouse sequence. The 
similarity between the consensus sequences is presumably the reason why C/EBPa has been 
shown to bind to the IRS. Two other potential IRS sequences lie much further upstream (- 
2218 and -2304), neither of which are conserved with the mouse sequence.
There are also potential hepatic nuclear factor-3 (HNF-3) and HNF-4 binding sites 
within the mouse Fmo5 upstream sequence. It has recently been shown that HNF4a is 
essential for the induction of CYP3A4 (Tirona et al., 2003) and CYP2C9 (Chen et al., 2005)
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via PXR and CAR. HNF3 has been shown to control genes implicated in glucose-induced 
insulin release (Wang et al., 2002). The consensus sequence for HNF3 is 
TATTGAC/TTTA/TG, whilst that for HNF4 is A /GTG A /G C/A CT/CTT/A G G C/A  (Carter et 
al., 1993).
Another potential regulatory sequence present in the FM05 promoter is that o f  
upstream stimulatory factor (USF). This consensus sequence consists o f  an E-box 
(CANNTG) followed by AC (Vostrov et al., 1995). There are two possible USF consensus 
sequences in the human FM05 promoter (-490 and -680) and one in the mouse sequence (- 
490) which reads AGAGCACCTGCTTG, and is conserved with the human sequence.
A recombination signal (CCCACCC) repeated four times is just  within the first 
construct (-531) o f  the promoter sequence, lying -591 from the ATG. A recombination event 
may be the reason for the lack o f  similarity between human and mouse sequences beyond 
this point in the promoter.
Many half-sites for the pregnane-x-receptor (PXR) (yellow) and estrogen receptor 
(ER) (green) have been highlighted in Figure 3.4.2. The ER consensus sequence is 
GGTCAnnnTGACC, but no full sites were found in the FM05 promoter. The same applies 
to full PXR consensus sequences, but there are several half-sites (highlighted). The 
glucocorticoid receptor (GCR) binds to the glucocorticoid responsive element (GRE) 
(consensus: GG TACANNNTGTTCT) which consists o f  two GRE ‘half-sites’ (TGTTCT). 
There is a possible GRE located in the mouse Fmo5 promoter -51 Obp from the translation 
initiation site. The sequence is partly conserved with the human sequence. As well as the 
main role o f  GCR to sense changes in circulating steroid levels, it has been shown that GCR 
and CAR are able to modulate cytochrome P450 gene expression together (Pascussi et al., 
2003).
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3.4.2 Analysis o f mouse and human FM05 prom oter ___  ___
Pregnane-x-receptor half sites Other regulatory sequences are in JVirjj or j | |  or highlighted
half sites Primers and exon 1 in grey * shows nucleotide conservation between sequences
HUMAN FM05 - 2 4 7 5  GTCTAGTAATAGCATGAGTAACTGAGTTGAGTCTGTATATTAATTTGGATGTATCAAGTTATTTTTCAATGAA 
MOUSE FM05 TTTGATATTAGAATGCCTACTCCAGCTTGTTTCTTAGGACCATTTTCTTGAAAAATTGTTTTCCAACTGTTTA
GAAATTGACTTACTTGCAAATTGTCAGCTAGGCAAGAGAGAGAACATTTGAGTCAAGGTTTAAAACATTGTATAAGTAATTTTAATACAA
c t c t g a g g t a g t g t c t g c c t t t g t c a c t g a g g t g g t t t t a c t g t a t g c a g c a a c a t g c t g g g g c c t g t t t a t g t a t c c a g c c t g | ^ M t  
* * - * * * * * *  * * *  * * *  * * * *  * * * **
IRS
c M M M a t a t t t g c t a t a t t c a a a a g c a a t t a a t t a t a a g a c a c a a t t g a a g t a g g g g g a c a t t a a a a t a a a a t t a c a t t g t t a a c t a
TATGTCTTTTGGGGGAAATTGAGTCCATTGATGTTACTTCCTGTTATTTTTGTTGTTAGAGTCTGAATTATGTTTGTGTGGCTATCT^H  
* * * * *  * * *  * * *  * * * * *  * *
IRS
CATTTTAAA AG TAA TTCTTG CATTA TTTG TAAA AC^H BCAGTAGGAGGAAATTAATACTCAGTTTATAAAAGTATTCATGTTTTCCTT 
^ g a H ^ t g a a a g a t t a c t t t c t t g c t t t t t c a g t g t c c a t g a t g t a t c t t c c t g t g t c c t t t c c c t c c t c c t t c t c t g t g g a a c t  
*• * * * * * *  * * * * * *  * * * *  * * *  * *
TAGGCATTTCTTCTAGCGCATTCAAA-ATTATCCAATTTACAA-GTAATTCATTTTAAGTTAACTTCTAGCATATAAAATGGTTGTG-TT 
TAGGTACCTACAACATGGCAGACATGCAATAGGTATTGTGCTGTGTGTATGACCCCTGAATTACTCACGACTGTTACAAACTTTACGATT 
* * * * *  * * * * * * *  * * * * * * * * *  * * * * * * * * * * * * *  * * *
TATA box TATA box
GAAACA— c t g t c t t c a g a a t t t t a t t t t t a a a a g a t a c t a t t - ^ P B H H t t c a c a ^ ^ H g t t g a a t g c t t t t g t g a a a g a t a t  
g t a g c a a a t a a g t t t c c c a a t g g t a a g t c c g ^ ^ B t a t c a c B I ^ B g t t t a c a c g t g g g g c a g c t g g c t t c c a c t g c t a t c c t t c a g c c
* *  *  *  * *  *  *  *
TAGTCTTTAAAATATTTTACAGGCTGGCCTTGTTGGCTCATGCCTGTAATCCCAGCACTTTGGGAGGCCAAG-GCAGGTGGATCAC— TT
A A G A C T C A A G T T ^ H ^ ATTACAAGACGTGGCCTCCTAAGAGAGATAGTTATTGAATGTACGTAAGCAAAATGCAGACTTAGCAAAATA 
* *  * *  * * * * * * * * *  * * *  * * * * * *  * *  * *  * * * *  * * *  *
Primer -1723
GAGCCCAGGAGTTCAAGACCAGCTTGAGCAACATAGTGAAACCTCATTTCTACAAAAAATACAAAAATT ACCAGGTGTGGTGGCAC
AAATTAGGAAATAAGAAAACATAATAGGATCCAGAGAGATGACTCAGACGTCAAGAACHBBCTGGTGGTGGAGAAGAGGTGGGTTCAG 
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ * ★ ★ ★ ★ * ★ * * * * ★
a c a g c t g t a g t c c c t a c t c a g a a g g c t g a g g t g g g a g g g t a g a t t g a g c c c a g g a g a t a g a g g c t g c a g t g a g c c a B ^ H g c a c c a c t g
GTTGCTGGTAACCCAACGGCAACTATACAAATAGAAATACAAAGAGAACCATCTGAACTCCAGCTCCAGGAGATCAGGCATAGTCTCCTG
2 4 0 2
2 3 1 2
2 2 2 2
2 1 3 2
2 0 4 2
1 9 5 2
1 8 6 2
1 7 7 2
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CACTCC-AGCCCAAGTGCCAGAGTGAGACCCTGTTTCAAAAAAAAAAAAAAGTTCGACAGTTCCAAAACACATTAATGTTAATTAGAGTC
g c c t c t g a a g g t g c a t g c t g t t a a g a c a c a c a t a c a g g c a a a a g a c t c a t a c t c c t a a g a t a a a B H | g t c t t c t t t a a g a t t a c a a t g
★ ★ ★ ★ ★ ★  k k k k k ★ k k *
TGCTAAGTTGCTATAAATACAACAAAAAATTCAATGGCACAAACAAAATATCAG-TTGCCTCTCATGAAAAAGTCCAAGATTAGCAGGTG  
t g a t a a — t g c t c t t a c t g t g a c a g t t a t a g a c a t t g t g g a c a c a g t t H ^ B g g t t a a t c t t c a t t g t c a g c t t g g c a g a c t g t a g a a t
k k k k k ★ k k k ★ ★ ★ ★ k k k k ★ ★ ★ ★ ★ ★
Ap-1
CAGATTGGAAG— AGCAAAATTGACTCAGGG§§BiTAGAAGGAG----------------AGCAAGGATCCAAGGCATGAGCCACAATCCATGCCTCT
CACCTAGGAGATTGGTGGGCACAACTTTGGGAATGTCTGTGAGAGCATCTCCAGAGAGAATTCAGTGCA-GGGCAG--ACCCAAACTGAT 
* *■ * *** * *** **** ** * ★ ** *•* ** * * ** * * * * ** * *** * *
TACAACCCCTCACATCTGTCAAATAGAACCCTTGTCTGGATGGGCCCTTGTTCTAAC^^Hg CCTGAAATCTTGTATCTGTTATATTGG  
TATAGGCAGTTCAATCC— CATATGGACTTGGAGGCTCCATGCACCCACGATGTGGTAGAGTGTCATAGGTTCCCACTCTTCCTGTTTGC 
* *  * * * * * *  * *  * *  * *  * * *  * * * * * * * * * * * * *  * * *■ * * * * * *
C/EBP IRS IRS
t g g t t c t a c a t g a c t t t a t a t t t g a a a a g t t a c a t t t t a B H ^ B * t g t a t t t t t g g t t ^ * t a t a a c t g t g t g a a a g c a c t
TGTGTTTCCATTCATGTA GACACCGTACTTGGCAGGAGTCTTTCTGAGACAGCAAAGGATTCT---------------- CCAAGTCAATGAATT
** * * * * * * ** * * * * * *■ * * * *** * *■ * ** * * *■ * ** ** * * *
A TTA A AA ATAC TTTTATTTC G TTAA-AA TTAC CTG TTTATG TTTTG G TC TCCTC Cp^H T — CTGTAAGCCCCTCTGAGTAGGAAACAA
ATTTTAAGCAGTT— ATTTAATAAACAACTG CTTAG TTAAAAAG CAGTTCA^^H gAGGTAACAGCTGGTGTTAAGAAAAAAAGAACAA
*  *  *  ★ ★  ★ ★ ★ k k k k k k k k  k k k k k k k ★ *  *  k k k k k k k k
Primer -1031
t a c a t t c c t c a c t a t a c t c c a g c a c t c a g c t c a g t g c a t g g g g a t t t a a a a g t a a a t t t c t t c c a g a a g t g t a g a t t c t t a g a t c c a g M
CAGAGAAGTGAGGGAATGGGAGAA— GGGCTTGTTGCAAAATCCCTCAGGAGAGAGTTGTGT GTGATGGGGAGCCCTTGCTGGAGCC
k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k k
C/EBP GC box Spl
t g t g a g g a g g g g a g g a g a c J g g t a t a ^ ^ H g c c g g | ^ H B B B g g g g g c a g g a t c a t c t t a a g g a a g g a g a c c a c t a c t a c t a c t g c
AGCCTGCTGGGGTTGCATGGCTGGCCTCCCTGCCTTGCTCCGAGTTTTC— CAACTG CACGCTGGA^^HTCATAGTCATGCTTGCTTC
k k k k k k k k k k k k k k k k  k k k k k k k k k k k k k
t g c c c t c c t c ^ H H a c c t t g c c t c g t t c a c a a g a c a g g a g g a g a g a a a a a g c a a a a a g t t g g a a a a a a a a a a a a a a a a a g t a a g a t a a a
CTGGGTTGGCTCAGAGGGTTACATAATTGATTTCCTTTATGTCATTTGAA— CTATATACAGTAAACCCTCATGTTGACCATTAGGCTGG
★ k k k k k k k k k k k k k k k k k k k k k k k k k
- 1 5 9 2
- 1 5 0 2
- 1 4 1 2
- 1 3 2 2
- 1 2 3 2
- 1 1 4 2
- 1 0 5 2
- 9 6 2
- 8 7 2
t a g c c a g a c a a c c t t g g c a ^ H B a c c c g g c c c t a g g a g t t a a a a a a a g t a a t a a t a a t a a c a t c a a c c c c t g a c c t a a a c t a c t t g t g t
AAGGGAGATA-CTGAACCCTGAACCTTCAGAGCCAAGGATCTGCGTTGGTCGCAACCAAACCGTGTTGAGCAAAGTCAGTACACCGGAGT
- 7 8 2
- 6 9 2t a t - c t g t g a a t t c c t g a c a c t g t a t g a a a a a a g c a t t g t a g c c c B | ^ | c a c g t — t t c c c a c t c t t g t t t g a t g t a t c a c g a c c M
AGTGTTATGCAAGGCCGATAAGGCTTCAGACACAATTCATGCCTTCTGCAAATGTACATTTACATACTGCTGTGGTGCATGAATGCTATA 
*  *  * *  *  *  * *  * * * * * *  *  *  *  *  *  * *  * *  * *  * *  *  * *  * *  * *  *  *  *
Primer -531 RecombinationU SF
H M M M c c t t a a a g t t g t a a g c c t t t a a a a a g g c c a a g a a t t t c t t t t t c g g g g a g c t c g g c t c t t a a g a c g c g a g t c t - g c c g a
GCTATCTGACAGTTTTACCCGATTTTACATTTGAAAAATTTTTVAGTTACATTTAACTGCCCCCCAACCCTCTCTCHHBt H B H B
*  * *  *  * * *  *  *  *  *  * *  *  *  * *  * *★ A A A A A★ A A A  A A A  A
signal Imperfect IRS
c g c t c c c g g c c g a ^ M — jAACCTCTTCCTTTTTTAATTCGGTGTCTGAGGAGTTTTGTCTGTGGCTCATCCTGCTACAATCTG-----------
^ ^ m M ^ M CGTCAGCTGAGCACACTGCAATATCAAATTCCTACTGAGGT^ M H GCTCAAAGATCTGGTCTCTGAAGAGCGGAGAGG 
*  *  * * *  * *  *  * *  * * * * * * *  *  *  * * *  * *  *  * * * * * *
GCR USF c /E B P
m e  T T T TT T C C C T T C AC— T T T G A A C ^ ^ ^ ^ ^ ^ ^ ^ m GTAGGTGTTCATTTAAGCA— TTTGGAGTAGi
AG iC AG G ACA SB^H ^^H AA G G G ACTC TG G G AAG TG AAC TTTCTTC TTAATG CG G AG CCA G G G TTG CTT-CTG AA G G G CTG AG TT
★ A A A A A A A A A A A A A A A
API C/EBP
TAGGAAGTGTTTGTCAl^^^mi
A A A A  A A A A
p300
T AGC CGGCCC T T AT C AAT T T G AAAC AAAAAC -
★ A A A
A A A A A A ★ A A
GCR
GGATGCA G A A G | | ^ B ^ ^ ^ H ^ ^ m i GGGTTTCAGA
G A A C A A A C A C T G A A A G A m M B ^ ^ H ^ T G G A G C C T G G A G G  
* *  * * *  * * *  *  * * * * * * *  * * * * * * * *  * * * * * *  *  *  * * *  *  *  * * *  *  *  *  *  * *
TATA box HNF3B IRS C/EBP HNF3B
GAAAGTAATTGAGAGTGCTGGCAAC--AGCAGCTGAAATATAGAGAAGTTGTAGGA T T A A C T m H G_GGCAAAGGAGGTTGAGGGGAC
G T C G C T C T C C C T A T G C G G G T G C T G C T G A G A A G C C G T A G A T T A A A A C H B m B ^ B B I M H l ^ ^ M M M B M M T T T T i M M --
+  A A A A  A A A A A A A A  A A A  A A A A  A A A  A A A A A  A A A A A A A A  A A  A
HNF3B C/EBPa E2F-1 Spl p300 Spl
GTTTTATTCCCATCGAGGGAGGGAGAATGGGl
^ H H GGI H I ^ H H GGGTGCACGCCCTTGGGTl i H
A A A A  A A  A A A A A A  A A A  A A  A A A  A A  A A A A A A A A
C/EBP TATA box TATA box C/EBP
g g g c g g g g g H H I  AGGTGGAGTGCTACAGCCCCTCC
----------GATAGGAGGTGGGACGGTAlAGCCCCTCC
A A  A A A A A A A A A  A A A A A A A A A A A A A
Reverse Primer
CCGTTGGCTCTCKTGTT TTTATACTAATTTGACAACAiCCGCCTGTTGAGTCTCCTCCAGATCGCAGCTGAAGGAT
H T T GGC C T C T | ^ B B | ^ ^ m GAGGCGCGGCTGCTCTGCCCTGAGTTACAGCCCTGCTTAGCTCCGAACTAGTGTAGCAGCGCCCT 
* * * * * *  * * * * * * *  * + * * * * * * * * * * * *
Exon 1 (UTR)
CTGTTGAGCGCTTCAGGAAAGGCGGACAGGCGACAC TAACAGGTGAAGATCTCGGGAGACCATG
GAGCTGGTACCTCCCCGCGCCACGGACAAGTGACGCAGACCCAACCAGAGAAGCACTCTGGTGACCATG
A A A A A  A
- 6 0 2
- 5 1 2
- 4 4 2
- 3 3 2
- 2 4 2
- 1 5 2
- 6 2
3.5 Transfecting HepG2 cells
Lipofectamine LTX was chosen as a transfection reagent as it is purportedly less toxic than 
other lipofectamines (Promega website, www.promega.com). Although toxicity isn’t usually 
a problem when transfecting HepG2 cells, we also wanted to transfect primary mouse 
hepatocytes. In each case using the same DNA constructs, so using the same transfection 
reagent for both cell types was attractive (Figure 3.5.1 for cloning and transfection strategy).
The HepG2 cells were cultured in 24-well plates and the values for the conditions 
below are stated per well. Within the boundaries suggested by the manufacturer, different 
conditions were tested whereby the transfection time was 24 hours or 48 hours; the DNA 
concentration was 0.25 pg or 0.75 pg; and the amount of lipofectamine LTX was 1.75 pi, 2.5 
pi or 3 pi. The positive control, pGL3 control, and the four human FM05 constructs were 
transfected into HepG2 cells at 50-70% confluency. As mentioned in the Materials and 
Methods the FM05 promoter fragments have been cloned upstream of a firefly luciferase 
gene within the pGL3 Basic vector. The activity of the FM05 promoter is measured as 
luminescence using a luminometer. Hence any effects on the regulation o f FM05 gene 
expression is defined by the expression level of firefly luciferase. Another reporter plasmid 
containing Renilla, a sea pansy luciferase, is used as an internal standard to allow for 
differences in transfection efficiency and cell number, the resulting luminescence is 
described as relative light units (RLU).
Shown in Figure 3.6.1 are the RLU measured when the four FM05 promoter 
constructs (0.25 pg or 0.75 pg of DNA) were transfected into HepG2 cells for 24 or 48 hours 
using increasing amounts of Lipofectamine LTX (1.75, 2.5 or 3 pi per well). The RLU are 
approximately two-fold higher when using 0.75 pg compared to 0.25 pg o f DNA after 24 or 
48 hours of transfection time. Similarly the period of transfection time affects the RLU 
observed. There is a two- to four-fold greater level of RLU in those cells transfected for 48 
hours as opposed to 24 hours at both DNA concentrations. The change in Lipofectamine 
LTX makes a limited difference to the RLU observed for each construct. In summary those 
cells transfected with 0.75 pg of construct DNA for 48 hours show the greatest RLU 
measured. Figure 3.6.2 shows the effect of those same conditions as used for the promoter 
constructs on the positive control, pGL3-control vector. Using 0.75 pg of pGL3-control DNA 
for 48 hours with 2.5 pi of Lipofectamine LTX, seem the optimum conditions.
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3.5.1 The promoter cloning and transfection strategy
The promoter fragments as they sit in relation to each other and exon I o f  FM()5 (a). A 
promoter fragment is cloned into pGL3-Basic and transfected into HepG2 cells with a 
xenobiotic and incubated for 48 hours before measurement o f  luciferase (b).
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Using this indication of optimum conditions as a guide, in all subsequent 
transfections cells were transfected with 0.5 pg o f DNA, and 2.0 pL of lipofectamine LTX, 
left for 24 hours, then the cells were treated with xenobiotics, and left for a further 24 hours 
before analysis (i.e. 48 hours transfection time in total). The cells were transfected with 0.5 
pg of DNA instead of 0.75 pg because the amount o f Lipofectamine LTX could be reduced 
in line with this amount o f DNA and thus reduce the cost, whilst still obtaining a good 
response in luciferase activity.
To identify any modulation o f transcription by nuclear receptors, plasmids containing 
mouse pregnane-x-receptor (mPXR), human pregnane-x-receptor (hPXR) or mouse estrogen 
receptor a  (mERa) were co-transfected into cells with the different FMOS constructs. The 
total amount of DNA transfected was 0.6 pg (0.1 pg of nuclear receptor plasmid DNA and 
0.5 pg of FM05 reporter construct DNA).
In results described in the following sections each experiment was done 
independently at least 3 times. Within each experiment triplicate transfections were 
performed for each construct. The students t test (two-tail) was used to calculate statistical 
significance.
3.6 Failure to obtain expression of human FMOS reporter gene 
constructs in primary mouse hepatocytes
The protocol to isolate primary mouse hepatocytes was established so that they could be used 
as a source of primary cells to carry out reporter assays to examine the regulation of FM05 
expression. The hepatocytes transfected very well with the positive control a plasmid (pGL3- 
control) containing a retroviral enhancer. There was a clear relationship between the amount 
of transfection reagent used (Lipofectin and Lipofectamine LTX). However when the mouse 
hepatocytes were transfected with human FM05 reporter construct plasmids only very low 
reporter gene activity was detected. The activity of the experimental constructs being 
equivalent to cells transfected with a negative control plasmid, pGL3-Basic.
The lack of reporter activity in mouse hepatocytes transfected with human FM05 
constructs may be due to species-specific differences in the promoter regions of the gene.
As discussed in Section 3.3 the mouse and human 5’ flanking sequence o f the FM05 
gene have little sequence similarity beyond the first 500 bp.
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3.6.1 Luciferase assay development-constructs at 24 and 48 hours
The FM()5 constructs were transfected into HepG2 cells with varying amounts o f  
Lipofectamine LTX ( l . 75, 2.5 or 3 pL) for 24 hours with 0.25 pg DNA in a) and 0.75 pg 
DNA in b) and for 48 hours with 0.25 pg DNA in c) and 0.75 pg DNA in d).
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3.6.2 Luciferase assay development-pGL3 control
The expression o f  the positive control (pGL3 Control) in HepG2 cells after 24 and 48 hours 
o f  transfection, with 0.25 pg  or 0.75 pg o f  DNA and with three different volumes o f  
Lipofectamine LTX.
Transfection o f primary mouse hepatocytes was abandoned for this reason, but the 
induction of FM05 mRNA was also studied in the HepG2 cells and compared to the 
induction or repression seen in the primary mouse hepatocytes. As such this was a useful 
comparison between species and of the effects o f different chemicals on FMOS expression in 
different in vitro systems.
3.7 Effects of xenobiotics on FM05 promoter reporter constructs 
and FM05 mRNA expression
FM05 is the ‘black sheep’ of the FMO family, given its apparent limited substrate 
specificity. A comprehensive list o f FM05 substrates and inducers has been assembled (see 
Introduction, Section 1.15.1). There are just as many inducers as substrates but not many of 
either. So whilst this implies that FM05 can be refractive to environmental insult, the lack of 
substrates makes the role of FM05 in both xenobiotic and endogenous metabolism all the 
more tantalising.
3.8 Progesterone regulation of FM05 expression
HepG2 cells were dosed with a range of progesterone concentrations (0.1 pM to 100 pM). 
As can be seen from Figure 3.8.1a, at any concentration tested, progesterone increases 
reporter gene activity driven by FM05 sequences. At 0.1 pM and 0.5 pM progesterone, 
reporter gene activity is increased by a third. At concentrations of 5 pM and above, reporter 
gene activity is further increased. At 5 pM progesterone reporter gene activity driven by 
construct -531 increases 1.5-fold. Activity was increased 3- and 2.5-fold respectively in cells 
transfected with the constructs -1031 and -1723. This indicates a regulatory element located 
between -531 and -1031 that plays a role in the regulation by progesterone of the FMOS 
gene. A lower fold induction is seen when cells are transfected with construct -2443. This 
could be due to ‘large-construct’ effects, a phenomenon often seen in our laboratory when 
the size of an inserted fragment gets beyond an optimum point. At higher concentrations of 
progesterone (50 and 100 pM) the increase in reporter gene activity in cells transfected with 
the three larger constructs (-1031, -1723, -2443) is less than that seen at 5 pM. Reporter gene
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activity of cells transfected with the -531 construct (the shortest construct tested) is about 
two-fold higher at 50 and 100 pM than that observed with just the vehicle.
The lowest concentration of progesterone (0.1 pM) tested was selected for co­
transfection experiments. Each reporter gene construct was co-transfected with hPXR or 
mPXR (both 0.1 pg). Only hPXR increases reporter gene activity above that seen with 
progesterone alone (Figure 3.8.1b). This is probably because HepG2 cells are human cells in 
origin, and the constructs are derived from the human FMOS sequence. As well as having its 
own receptor, progesterone is a PXR ligand (Kliewer et al., 1998), and is able to induce PXR 
up to fifty times during pregnancy (Masuyama et al., 2001). Here we see that progesterone is 
able to increase FM05 reporter gene activity through hPXR.
As mentioned in the introduction section, mPXR and hPXR show only 80% similarity 
in their ligand-binding domains, this accounts for some of the differences in xenobiotic 
induction of CYP3A4 between the species. The two receptors however share about 96% 
amino acid sequence similarity in their DNA-binding domains (Lehmann et al., 1998). 
Progesterone is a ligand of mouse PXR (Kliewer et al., 1998), as well as human PXR which 
induced CYP3A4 four-fold (Lehmann et al., 1998).
The changes in FM05 mRNA expression were measured using real-time RT-PCR. 
When HepG2 cells were treated with progesterone, FM05 mRNA increased 165 % and 
222% at concentrations 0.5 pM and 5.0 pM respectively (Figure 3.8.2a) (FM05 mRNA 
expression from cells treated with the vehicle are zero percent). This increase in mRNA is 
similar to the increases observed in the reporter gene luciferase assays. For example, in cells 
transfected with the FMOS construct -2443, and treated with 0.5 pM and 5.0 pM 
progesterone, luciferase activity increased 98% and 289% respectively. When FM05 mRNA 
is measured in progesterone-treated primary female mouse hepatocytes (Figure 3.8.3), there 
is a dose-dependent increase in mRNA of 108%, 141% and 203% (i.e. 2-fold, 2.4-fold and 3- 
fold) at the concentrations of 0.1 pM, 0.5 pM and 1.0 pM respectively. The same does not 
apply with progesterone-treated primary male mouse hepatocytes, where FM05 mRNA 
amounts are decreased by 27% and 7%, at concentrations of 0.1 pM and 0.5 pM respectively 
(Figure 3.8.2b). The physiological concentration of progesterone is approximately 13-79 nM 
in the luteal phase of pre-menopausal women (Dabrosin, 2005) and in pregnant mice the 
concentration is 30-50 nM (Milligan and Finn, 1997). At 0.1 pM, the progesterone 
concentration is on the upper limits of the physiological range for women and at least twice
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as much for female mice. Lehmann et al., (1998) surmise therefore that progesterone is 
unlikely to be a natural ligand o f hPXR as the accompanying EC50 values are >10 pM.
As explained in the introduction progesterone has already been shown to have 
modulating effects on the FMOs. This is particularly obvious during pregnancy in rabbits 
(Lee et al., 1995) where FMOl is induced in the liver and FM02 in the lung. FMOS has been 
shown to be induced in a progesterone receptor-dependant manner in a breast cancer cell line 
(Miller et al., 1997). Perhaps progesterone is acting through its own receptor and this may be 
the pathway through which FM05 expression is increased. Although progesterone is thought 
of as the hormone of pregnancy it has many other roles, such as neuroendocrine control and 
mediation of sexual behaviour (Andersen and Tufik, 2006). The difference in response to 
progesterone by the male and female hepatocytes is interesting and could be due to 
differential expression of progesterone receptor isoforms (A or B) in males and females. 
Progesterone receptor B was found to be the predominant form in female rat brain (Guerra- 
Araiza et al., 2000), and progesterone receptor A was the predominant form in male rat brain 
(Guerra-Araiza et al., 2001). Given that there is a different response to progesterone by these 
two isoforms (B is inductive, A is able to repress the B isoform (Vegeto et al., 1993)), it is 
possible that this is the reason for the differential response in male and female mouse 
hepatocytes. This could be the reason for the limited repression of FM 05 mRNA via 
progesterone observed in male mouse hepatocytes. Estrogen is also able to induce 
progesterone receptors in female rat brain (Parsons et al., 1980; Scott et al., 2002), as well as 
inducing the B isoform in human breast cancer cells in culture (Graham et al., 1995). 
Although the induction of FM05 expression has already been described in a progesterone 
receptor B-dependent manner (Guerra-Araiza and Camacho-Arroyo, 2000), the progesterone 
receptor is expressed in low amounts in the liver (Perrot-Applanat et al., 1985). So although 
the effect of different concentrations of progesterone receptor is a credible reason for the 
differential induction of FM05, the mediation by a receptor that is highly expressed in the 
liver cannot be dismissed. But this does not explain the differential induction between the 
sexes, since PXR (and CAR) (both highly expressed in the liver (Kliewer et al., 2000)) is 
described as sex-independent (Honkakoski et al., 2003; Waxman, 1999).
In summary it is probable that there are male-female differences in response to 
progesterone generally, as seen behaviorally in rats (Heinsbroek et al., 1987) but a difference 
in progesterone metabolism could be the underlying cause (Kato et al., 1971).
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3.8.1 Progesterone effects on FM 05 promoter constructs in HepG2 cells
HepG2 cells were transfected with FM()5 constructs and dosed with various concentrations 
o f  progesterone (a). HepG2 cells were co-transfected with FM()5 constructs and mPXR or 
hPXR. the cells were then dosed with 0.1 pM progesterone (b). Significance is calculated 
from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.8.2 Progesterone effects on FM 05 mRNA in HepG2 and male mouse hepatocytes
HepG2 cells (a) and male mouse hepatocytes (b) were dosed with progesterone for 24 hours, 
the total RNA isolated; FM 05  mRNA measured using real-time RT-PCR. Zero % represents 
the expression o f  FM 05 mRNA when cells are treated with the vehicle. Significance is 
calculated from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.8.3 Induction of Fmo5 mRNA by progesterone in female mouse hepatocytes
Female mouse hepatocytes were dosed with progesterone for 24 hours, the total RNA 
isolated; FM 05 mRNA measured using real-time RT-PCR. Zero % represents the expression 
o f  FM 05  mRNA when cells are treated with the vehicle. Significance is calculated from the 
vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.9 Rifampicin induces FM05 expression, and FM05 mRNA in 
both human and mouse
Rifampicin is a well-known PXR ligand, although it is a much more efficacious activator of 
humamP450 enzymes than rodent P450 enzymes (Kocarek et al., 1995) this is because of the 
differences in PXR ligand-binding domains mentioned previously (Lehmann et al., 1998).
HepG2 cells were treated with rifampicin at 10 or 20 pM. At 10 pM it increases 
reporter gene activity 1.5- to 2- fold when cells were transfected with each of the four FM05 
reporter constructs (Figure 3.9.1a). Transfected cells treated with rifampicin at 20 pM 
showed no increase in reporter gene activity. The concentration o f 10 pM rifampicin is used 
almost ubiquitously by researchers, this is because the plasma concentration achieved by 
rifampicin when a patient is dosed with the typical 600 mg dose, reaches 10 pM on average, 
but can go as high as 40 pM (Physicians-Desk-Reference, 1992). 20 pM is also used in vitro, 
however the reason for it having little effect on the induction of FM05 may be due to the 
toxic effect of rifampicin in the hepatocytes. Hepatotoxicity has been described in patients on 
rifampicin monotherapy (Cancado et al., 1998; Prince et al., 2002). Toxic effects would be 
more pronounced in isolated cells because there is no real excretory mechanism. Although 
the cells appeared healthy, they were only dosed for 24 hours, had treatment continued, any 
toxic effects would have been observed in the morphology of the hepatocytes.
HepG2 cells were co-transfected with the FM05 reporter constructs and hPXR or 
mPXR and dosed with 0.5 pM or 10 pM rifampicin (Figure 3.9.1b). Both 0.5 and 10 pM 
rifampicin induce reporter gene activity in all four constructs. The two PXR homologs 
increase reporter gene activity even further, with mPXR inducing as much as hPXR. This is 
interesting given rifampicin is supposed to have very little effect on the induction of 
CYP3A4 through PXR in mice (Jones et al., 2000). There is a clear response to PXR in cells 
transfected with FM05 reporter gene constructs and most-importantly the increase in activity 
is via rifampicin, which is one of the most potent and specific PXR ligands (Kocarek et al., 
1995), with an EC50 value o f -800 nM (Lehmann et al., 1998).
FM05 mRNA isolated from rifampicin-treated (10 pM) female mouse hepatocytes 
and HepG2 cells was induced 206% and 231% respectively (Figure 3.9.2a). FM05 mRNA is 
increased only 35% in male hepatocytes treated with 10 pM rifampicin. Given the apparent 
lack of induction of CYP3A4 through PXR in mice with rifampicin (Jones et al., 2000), this
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profound increase in FM05 mRNA observed in female mouse hepatocytes is surprising. 
However, there are examples o f induction of the PXR responsive p-glycoprotein in mice after 
treatment with rifampicin (Schuetz et al., 1996; Wrighton et al., 1985). CYP3A11 and 
CYP3A13 are also induced in mouse liver after rifampicin treatment (Yanagimoto et al., 
1997).
PXR as explained is expressed in a sex-independent manner. The difference in 
xenobiotic metabolism between the sexes is complex, but overall the expression of 
metabolising enzymes can be mediated by growth hormone (Waxman and O'Connor, 2006). 
A greater induction of CYP3A4 has been observed in female human liver than in male 
(Gorski et al., 2003) which could account for the higher rate o f clearance for some drugs 
often seen in female patients (Hulst et al., 1994; Kahan et al., 1986). Interestingly in the same 
study CYP3A4 was induced to a greater extent in male intestine rather than female, further 
complicating the sex-dependent dichotomy o f xenobiotic metabolism.
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3.9.1 Effects of rifampicin on FM 05 promoter constructs in HepG2 cells
HepG2 cells were transfected with FM()5 constructs, and dosed with rifampicin (10 pM or 
20 pM) (a). HepG2 cells were transfected with FM()5 constructs alone or with O.l pg  hPXR 
or 0 .1 pg mPXR. then dosed with 0.5 pM or 10 pM  rifampicin (b). Significance is calculated 
from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.9.2 Effects of rifampicin on FM 05 mRNA and reporter gene constructs
HepG2 cells, female and male hepatocytes were dosed with rifampicin for 24 hours, the total 
RNA isolated; FM 05  mRNA measured using real-time RT-PCR. Zero % represents the 
expression o f  FM 05 mRNA when cells are treated with the vehicle (a). HepG2 cells were 
co-transfected with FM05 constructs and hPXR or mPXR (b). Significance is calculated 
from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.10 Ligand-independent effects of PXR on FM05 promoter 
reporter gene constructs
As shown in Figure 3.9.2b reporter gene activity increased when HepG2 cells were co­
transfected with FMOS promoter constructs and either mPXR or hPXR without the addition 
of a xenobiotic. The induction of a PXR target sequence-containing plasmid via PXR in a 
ligand-independent manner has been observed (Shah et al., 2007). Our results may represent 
the activation of PXR at a basal level. This activation may be via an endogenous ligand, 
resulting in induction of FM05 expression. The expression level of all four promoter 
constructs increase with the addition o f PXR, implying that a response element would lie 
early on in the sequence, within the first construct (-531). The induction via hPXR and 
mPXR varies from two- to four-fold, and is greatest with -1031 via both mPXR and hPXR. 
The expression for all four constructs is seen at a greater level via hPXR, probably due to the 
use of a human cell line and human promoter sequences.
3.11 Testosterone repression of the FM05 promoter but induction 
of FM05 mRNA
Testosterone is known to repress the expression o f Fmo3 in male mouse liver (Dannan et al., 
1986) via the androgen receptor (Chanden, 2004), so it would not be remarkable to discover 
that FM05 was affected in the same way by testosterone. In the HepG2 cells dosed with 
testosterone the FM05 promoter constructs are repressed at all concentrations tested (0.001, 
0.01 and 0.5 pM) (Figure 3.11.1a). The expression levels are reduced by 50% in the two 
smaller constructs (-531, -1031) by all testosterone concentrations. The expression of the two 
larger constructs is reduced by 75% by 0.5 pM testosterone. Dr Chandan found that FM03 
was repressed at 0.001 and 0.1 pM testosterone.
The repression of FM05 by testosterone is seen also when the mRNA is measured 
from HepG2 cells (Figure 3.11.2a). At the concentrations of 0.01 pM and 1.0 pM, FMOS 
expression is repressed 26% and 16% respectively. Comparing these values to those 
observed using the promoter assay, at 0.01 pM and 0.5 pM the FM05 promoter fragments 
were repressed to a greater extent, 40-50% and 50-80% respectively.
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Dosing primary mouse hepatocytes with testosterone had the opposite effect to the 
HepG2 cells with regard to FM05 expression. Mouse FM05 mRNA was induced 78%, 70% 
and 210% from the vehicle, at 0.001 pM, 0.01 pM and 0.5 pM testosterone respectively in 
male hepatocytes (Figure 3.11.2b) and induced 96% at 0.01 pM in female hepatocytes 
(Figure 3.11.1b). Clearly there is a great deal of difference in the response to testosterone in 
the human cell line and in the mouse ex vivo system. Testosterone is repressing FM05 
reporter gene activity and FM05 mRNA in the human cell line (HepG2), but testosterone is 
inducing FM05 mRNA in the primary mouse hepatocytes. These differences could be 
explained by differences in human versus mouse or cell line versus tissue culture. The 
different availability of liver-specific transcription factors to mediate this response by 
testosterone could be pertinent, the mouse hepatocytes being more closely related to an in 
vivo liver and therefore having a greater availability o f these factors than the HepG2 cells 
(Wilkening et al., 2003).
Androgens are known to be able to repress mRNA levels of genes such as the 
transforming growth factor (3 (Kyprianou and Isaacs, 1989) and the testosterone-repressed 
prostate message TRPM-2 (Leger et al., 1987) as well as Cypl7 in mouse MA-10 tumor 
Leydig cells (Burgos-Trinidad et al., 1997). The mechanism by which the androgen receptor 
is able to repress genes is unclear, but the binding of the receptor to the promoter is required 
for the repression, certainly in the case o f Cypl 7, in order to prevent cAMP associated up- 
regulation.
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3.11.1 Effects of testosterone on the FM 05 promoter and on Fmo5 mRNA
HepG2 cells were transfected with FM05 constructs, then dosed with 0 .0 0 1 pM , 0 .0 1 pM  or 
0.5 pM testosterone (a). Female mouse hepatocytes dosed with testosterone for 24 hours, the 
total RNA isolated; FM 05  mRNA measured using real-time RT-PCR (b). Zero % represents 
the expression o f  F M 05  m RNA when cells are treated with the vehicle. Significance is 
calculated from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.11.2 Testosterone effects on FM 05 mRNA in HepG2 and male mouse hepatocytes
HepG2 cells (a) and male mouse hepatocytes (b) were dosed with testosterone for 24 hours, 
the total RNA isolated; F M 05  mRNA measured using real-time RT-PCR. Zero % represents 
the expression o f  F M 05  mRNA when cells are treated with the vehicle. Significance is 
calculated from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.12 Dose-dependent mediation of FM05 by estradiol
It has been widely documented that some o f the FMOs are under sex specific regulation. In 
male and female rats, at maturity FM 03 is the predominant hepatic form for both, in the 
females because of the repression of FMOl by estradiol, and in males FM 03 is predominant 
because o f its induction by testosterone (Lattard et al., 2002). As explained in the 
introduction this is different from the situation in the mouse, where FM 03 is repressed by 
testosterone in the male liver (Duffel et al., 1981; Falls et al., 1997) by the androgen receptor 
(Chanden, 2004). This regulation is different again in female rat kidney, where FM03 is 
steadily induced by estradiol (Lattard et al., 2002). Hence the mechanism of hormonal 
control of the FMOs is complicated.
HepG2 cells were dosed with various concentrations of 17P-estradiol, with and 
without a plasmid containing the mouse homolog o f the estrogen receptor (mERa). As can be 
seen from Figure 3.12.1, at low concentrations (0.001 pM or 0.003 pM) 17p-estradiol 
induces the expression of FMOS. At 0.003 pM estradiol the construct containing the -1031 
fragment is induced by a third, and that o f the two larger fragments by about a half. There is 
no effect seen from the -531 fragment implying any regulatory elements may be further up­
stream, beyond -531 bp in the -1031 fragment.
At higher concentrations of estradiol (10 and 100 pM) there is a repressive effect 
upon all of the constructs by about 50%, but repression is only seen in the smallest construct 
(-531) at the highest estradiol concentration (100 pM). As seen in Figure 3.12.2, the 
repression is reversed when mERa is co-transfected into the cells. It is probable that there is 
enough endogenous estrogen receptor to be mediating the effects o f estradiol at low 
concentrations, at higher concentrations (10 and 100 pM) the addition of more estradiol has 
no effect.
FM05 mRNA was induced in HepG2 cells by 116% and 165% at 0.001 pM and 0.1 
pM estradiol concentrations respectively (Figure 3.12.3a). The FM05 promoter constructs 
are also induced in HepG2 cells by 22-85% and 46-129% at 0.001 pM and 0.003 pM 
respectively. In male hepatocytes FM05 mRNA was induced 52%, 25%, 55% and 140% at 
0.001 pM and 0.01 pM, 0.5 pM and 1.0 pM estradiol respectively (Figure 3.12.3b). The 
FM05 mRNA from female hepatocytes was induced 126 % but only at 0.003 pM. At the 
higher concentrations of 0.03 pM and 0.5 pM the mRNA is repressed 37% and 13%
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respectively (Figure 3.12.4). The promoter constructs were also repressed at the higher 
concentration of 0.1 pM. So in comparison, 0.5 pM estradiol represses FmoS in females, but 
induced Fmo5 expression in males. It is likely that this is due to the total levels of estradiol 
already within each male and female liver. In rats the circulating level o f estradiol is nearly 
twice as much in females than in males (Rahimian et al., 1997). So the addition of estradiol 
to female hepatocytes could result in an increased total concentration o f estradiol when 
compared to the males, leading to repression in females.
The estrogen receptor is able to repress transcription but its repressive effect has not 
been widely studied and is not fully understood. ER represses tumor-necrosis factor-a 
(TNFa) by binding to an AP-1 like site (TGTTTGT) in the TNFa promoter with co­
activators such as the glucocorticoid receptor interacting protein-1 (An et al., 1999).
With regard to ER consensus sites in the FM05 promoter, there are several half-sites 
(see Section 3.1.4). Although they are not complete sites this may not be a concern with 
regard to the promoter analysis, since it has been reported that ER will bind and meditate 
transcription of genes through Spl sites (Saville et al., 2000), o f which there are two within 
the first 200 bp, conserved between the mouse and human (Section 3.1.4). A third is 
approximately 1000 bp from the FMOS start site. Since any inductive response to estrogen is 
only seen in the larger three constructs this third Spl site would be the prime candidate. 
Although no inductive response is seen from the smallest fragment (-531), repression is 
observed in this fragment in cells dosed with a higher concentration o f estradiol (50 or 100 
pM). Implying the mediation by estradiol is through two different mechanisms.
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3.12.1 Effects of 17(S-estradiol on FM 05 promoter constructs in HepG2 cells
HepG2 cells were transfected with FM05 constructs and dosed with 0 .0 0 1 pM  or 0.003 pM 
l7p-estradiol. Significance is calculated from the vehicle where * is p<0.05. Error bars are 
SEM.
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3.12.2 Effects of estradiol on FM 05 promoter constructs in HepG2 cells co­
transfected with mERa
HepG2 cells were co-transfected with FM()5 constructs with and without m ERa, then dosed 
with 10 pM or 100 pM 17p~estradiol. Significance is calculated from the vehicle where * is 
p<0.05 and ** is p<0.005. Error bars are SEM.
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3.12.3 17p-estradiol effects on FM 05 mRNA in HepG2 and male mouse hepatocytes
HepG2 cells (a) and male mouse hepatocytes (b) were dosed with estradiol for 24 hours, total 
RNA isolated. FM 05 mRNA measured using real-time RT-PCR. Zero % represents the 
expression o f  F M 05  mRNA when cells are treated with the vehicle. Significance is 
calculated from the vehicle where * is p<0.05 and ** is p<0.005. Error bars are SEM.
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3.12.4 Effect of 17fS-estradiol on FM 05 mRNA in female mouse hepatocytes
Female mouse hepatocytes were dosed with estradiol for 24 hours, the total RNA isolated; 
F M 05  mRNA measured using real-time RT-PCR. Zero % represents the expression o f  
F M 05  mRNA when cells are treated with the vehicle. Significance is calculated from the 
vehicle where * is p<0.05. Error bars are SEM.
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3.13 Hyperforin and its effect on FM05 promoter constructs
Hyperforin is the active component o f the herbal supplement St Johns Wort, and is a PXR 
ligand (Chatterjee et al., 1998). Research on the effect o f hyperforin (1.0 pM) in HepG2 cells 
showed that FM05 was induced approximately 3-fold in a microarray and subsequent real­
time PCR (Rae et al., 2001). We treated HepG2 cells with hyperforin (0.5 or 1.0 pM) FMOS 
promoter expression was reduced 30% to 60% by 1.0 pM hyperforin (Figure 3.13.1). This 
repression was reversed upon co-transfection of human or mouse PXR (Figure 3.13.2). The 
induction of FMOS expression by hyperforin is clearly a PXR-dependent event, as might be 
expected. It appears that the quantity o f PXR within the HepG2 cells is not sufficient to 
mediate the effects of hyperforin, which is rectified with the co-transfection experiments.
In the HepG2 cells both PXR homologs mediate the induction of FMOS by 
hyperforin, there is an inductive response to both. Hyperforin has been proven to induce 
target PXR genes in both human and rodent systems (Durr et al., 2000; Moore et al., 2000). 
The addition of hPXR causes on average a 3-fold induction of FMOS expression across the 
promoter fragments whereas mPXR induces 2-fold across the fragments. The potency of 
hyperforin for hPXR over mPXR has been described (Vignati et al., 2004).
The treatment of HepG2 cells or primary mouse hepatocytes resulted in no induction 
of FMOS mRNA. It is possible that a longer treatment time is required to see a response. 
This has been described in mice treated with St John’s Wort, where an effect was only seen 
after three weeks of treatment (Bray et al., 2002), the original study saw an induction of 
CYP3A after two weeks of treatment (Durr et al., 2000). In an in vitro setting however, 
hyperforin was found to be a potent activator o f hPXR (more so than mPXR) in HepG2 cells 
(Vignati et al., 2004) only after 24 hours at 1 pM.
It is likely then that because an induction of FM05 reporter constructs by hyperforin 
is only observed when hPXR and mPXR is added that the amount of PXR in the HepG2 cells 
and hepatocytes is the cause of this lack o f induction of mRNA.
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3.13.1 The repression of FM 05 promoter constructs by hyperforin in HepG2 cells
HepG2 cells were transfected with FM05 constructs, then dosed with 0.5 pM or l pM 
hyperforin. Significance is calculated from the vehicle where * is p<0.05 and ** is p<0.005. 
Error bars are SEM.
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3.13.2 The effect of hyperforin and hPXR or mPXR on the FM 05 promoter
HepG2 cells were co-transfected with FM05 constructs with or without hPXR (a) or mPXR 
(b) and dosed with 0.5 fiM hyperforin. Significance is calculated from the vehicle where * is 
p<0.05. Error bars are SEM.
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3.14 Lipoic acid and its effect on FMOS promoter constructs
As explained in the introduction (Section 1.14), lipoic acid is a porcine liver FMO (FMOl) 
substrate (Taylor and Ziegler, 1987) and is one of the very few endogenous compounds 
metabolised by FMOs. Lipoic acid in the form of a lipoamide acts as a cofactor in the alpha- 
ketoglutarate dehydrogenase enzyme complex as well as the pyruvate dehydrogenase enzyme 
complex and is absolutely vital for the function of these enzymes. They are two important 
enzymes in the oxaloacetate cycle, obviously important for energy production.
We were interested to know if lipoic acid in its free form was able to modulate FMOS 
promoter expression. As can be seen from Figure 3.14.1 at low concentrations, lipoic acid 
has little or no effect on each promoter fragment, at 0.5 pM however, it does have an effect, a 
profound repression to at least 50% of the vehicle on the three larger constructs. The fact that 
this repression is not seen in the smallest fragment (531) is an indication that lipoic acid 
could be working through a nuclear receptor that is able to bind further upstream.
In HepG2 cells the mRNA reflects the results from the promoter assay. FM05 mRNA 
is repressed 57% upon treatment with 0.001 pM lipoic acid, the promoter constructs were 
repressed 22-40% at the same concentration. What is interesting though is that in male 
hepatocytes at the concentrations o f 0.001 pM and 0.01 pM, FM05 is induced 72% and 33% 
respectively and in female hepatocytes FM05 is induced 92% at 0.001 pM (Figure 3.14.2).
The relative abundance of steroid hormone receptors plays a large part in any 
differences in CYP3A4 induction (Swales et al., 2003) and the host cell environment dictates 
these effects (Barwick et al., 1996). So this may be the reason for the differences seen here 
between the hepatocytes and the HepG2 cells. The other possibility is it is a species-specific 
difference.
Lipoic acid is able to activate the peroxisome proliferator-activated receptor (PPAR), 
the alpha form (which is expressed in the liver), but more potently the gamma form, the 
isoform expressed most highly in adipose tissue (Venkatraman et al., 2004). Lipoic acid is 
also an activator of the insulin receptor (Diesel et al., 2007) and there is an insulin responsive 
sequence in the mouse FmoS promoter (Section 3.1.4).
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3.14.1 The effect of lipoic acid or ethanol on the FM 05 promoter
HepG2 cells were transfected with FM()5 constructs and dosed with 0 .0 0 1 pM or 0 .0 1 pM 
lipoic acid (a) or ethanol (b) for 24 hours. Significance is calculated from the vehicle where * 
is p<0.05. Error bars are SEM.
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3.14.2 The effect of lipoic acid on FM05 mRNA
Male mouse hepatocytes (a), female mouse hepatocytes and HepG2 cells (b) were dosed with 
lipoic acid for 24 hours, the total RNA isolated; F M 05  mRNA measured using real-time RT- 
PCR. Zero % represents the expression o f  F M 05  mRNA when cells are treated with the 
vehicle. Significance is calculated from the vehicle where * is p<0.05 and ** is p<0.005. 
Error bars are SEM.
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3.15 Ethanol induces FM05 promoter constructs
Something which I had not set out to study, but what I have observed is that ethanol induces 
the FM05 reporter construct expression. As shown in Figure 3.14.1b the expression of the 
three larger constructs are induced 2-3 fold. The lack of induction of the smallest construct 
could imply a modulation by ethanol through a transcription factor further upstream. Ethanol 
is able to induce genes involved in the stress response, signal transduction and gene 
regulation (Murphy et al., 2002). It is well known that CYP2E1 is induced by ethanol. It is 
induced with acute and chronic alcohol levels which increases ROS production leading to 
alcohol induced liver injury (Gong and Cederbaum, 2006). As a metabolising enzyme FM05 
could be induced to metabolise the ethanol but there is no evidence to support this. It could 
be induced as a response to stress, by affecting the redox status o f the cell. This possibility 
will be pursued in chapter five of this thesis.
3.16 Conclusions
It is quite clear that far from being uninducible, FMOS is profoundly affected at the level of 
transcription by the addition of xenobiotics. A summary of the results are shown in Figure 
3 .16.1. The results support a PXR binding site between -1 and -531, bom out by the 
induction of expression of all four constructs by rifampicin, hyperforin, progesterone and by 
the mouse and human PXR receptors alone. Any estrogen receptor sites or regulatory sites 
needed by the estrogen receptor are likely to lie between the -531 and -1031 construct in the 
promoter. This will only be confirmed by further experiments such as super-shift 
electromobility shift assays and DNase I footprinting.
There are two further questions that need to be answered. The first is: does this 
information have any relevancy in vivo? Given the use of primary mouse hepatocytes in 
determining some of the effects by the xenobiotics, it seems that the information gleaned is 
more relevant than that obtained from an immortalised cell line. Although the hepatocytes are 
a good in vitro model, they are only a model of mouse liver, not human and not any other 
tissue. As explained, the FMOs are subject to tissue-specific regulation, as well as hormonal 
control. But the use of human sequences and HepG2 cells, a human cell line, does provide a 
human slant to the information.
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The second question, and one which will not be answered fully by this thesis, is, what 
is the endogenous role of FM05?
FMOS is clearly under the control of PXR ligands, it is induced by rifampicin, 
progesterone, hyperforin and estradiol. Until an electromobility shift assay is carried out 
however, it is difficult to say whether FMOS is being mediated by PXR exclusively. The 
maintenance o f luciferase activity by the addition o f mERa seems to imply that at least one 
other receptor, as well as PXR, has some control over FMOS transcription.
PXR is renowned for its control over important xenobiotic metabolising enzymes, but 
it does have endogenous compounds as its ligands, and is able to regulate the metabolism of 
these as well as the exogenous drugs. PXR does have an important role in blocking bile acid 
production from cholesterol when cholesterol metabolism is in disarray or when bile acids 
accumulate. Bile acid metabolism and transport mechanisms are induced to clear the build-up 
(Goodwin et al., 2003). The famesoid-x-receptor (FXR) is able to induce the transcription of 
PXR (Jung et al., 2006) thus FXR which blocks the synthesis o f bile up-regulates PXR which 
increases the metabolism of bile, thereby protecting the liver.
PXR also appears to have some cross-talk with the glucocorticoid receptor (GCR) 
(Pascussi et al., 2000) in the role of inducing PXR-target genes. There are two GCR 
consensus sites in the FM05 promoter. GCR and C/EBPa also have some cross-over. 
Glucocorticoids are able to induce Gi cell cycle arrest in hepatoma cells, and C/EBPa is 
required for this arrest (Ramos et al., 1996). C/EBPa consensus sites are also found in the 
FM05 promoter. C/EBPa probably has a role in normal liver epithelial cell function, and 
appears to be required for normal differentiation of hepatocytes (Diehl et al., 1994).
Testosterone induces Fmo5 in primary male and female mouse hepatocytes, which is 
the opposite effect it has on Fmo3 in male mice. There are many examples o f testosterone- 
regulated gene induction but its role in the induction of lipogenic genes such as fatty acid 
synthase and acetyl-coA-carboxylase in androgen target tissues (Heemers et al., 2003) is 
especially pertinent to the status of the knock-out Fmo mice. The positive regulation by 
testosterone of FmoS has already been observed; it is expressed six-times more highly in 
male mouse kidney than in female (Janmohamed et al., 2004).
As mentioned testosterone has a role in lipid homeostasis, similarly estrogen has a 
role in glucose homeostasis. It seems to do this via the activation of ERa by changing the 
insulin sensitivity of hepatocytes. ERa knockout mice have higher fasting blood glucose and
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plasma insulin levels. The suppression o f glucose production by insulin was reduced and 
hepatic lipid biosynthesis genes were up-regulated (Bryzgalova et al., 2006). In ob/ob mice 
the treatment with estrogen led to a reduced insulin resistance and reduced plasma 
triglyceride levels. Lipid biosynthesis genes were down-regulated, an opposite effect to that 
seen in the ERaKO mice. Estrogen also induced signal transducer and activator of 
transcription 3 (Stat3) mRNA (Gao et al., 2006). STAT3 is required for normal glucose 
homeostasis in the liver (Inoue et al., 2004). FM 05 could have a role in these homeostatic 
functions, especially given the lower plasma cholesterol levels in the Fmo5 (-/-) mice. This 
will be explored further in chapter five o f this thesis.
The FM05 promoter contains many possible regulatory sequences which have not 
previously been associated with FMO gene transcription. As described in Section 3.1.4, 
potential C/EBPa sequences are found. In the C/EBPa knockout mouse, the animals died 
very early on due to their impaired energy homeostasis (Wang et al., 1995), this was 
overcome using Cre/lox-P technology to create a C/EBPa conditional knockout, where 
C/EBPa expression is inactivated only in the liver. The animals had impaired bilirubin 
detoxification due to the repression of bilirubin UDP glucuronosyltransferase expression 
(Lee et al., 1997). C/EBPa also appears to have a major role in adipocyte differentiation (Lin 
and Lane, 1994) and the C/EBPa (-/-) mice have severely impaired adipose generation 
(Flodby et al., 1996).
This has two notable involvements that may be pertinent to the role o f FMOs in general. 
Two possible USF sequences have been found in the FM05 promoter (Section 3.4). USF 
binds to the promoter of haem-oxygenase (HO) and regulates its transcription in human renal 
proximal tubular epithelial cells (Hock et al., 2004). FM05 and FMOl are both expressed in 
the human (Dolphin 1996, Janmohamed 2001) and mouse (Janmohammed 2004) kidney. HO 
breaks down haem, in addition it can be seen as cytoprotective whereby it shifts the redox 
state to a more antioxidant status (Applegate et al., 1991) and increases iron efflux (Ferris et 
al., 1999). Interestingly Fmo3 has been shown to respond to iron levels. Fmo3 was induced 
in transgenic mice with haemachromatosis, (HO was repressed in this mouse), but on 
addition of iron-dextran, Fmo3 was repressed (Muckenthaler et al., 2003). That perhaps is 
even more intriguing given the lower plasma iron concentration in the Fmo5 (-/-) mice (see 
Section 5.18). Also lipoic acid induces the expression of HO (Cheng et al., 2006; Ogbome et
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al., 2005), part o f lipoic acid’s antioxidant effect. The plasma iron concentration then 
increases on lipoic acid treatment in Fmo5 (-/-) mice (Section 5.19).
This is an interesting coincidence, given that porcine FMOl is able to metabolise 
lipoic acid (Taylor and Ziegler, 1987). Also, during the insulin regulation o f the fatty acid 
synthase (FAS) gene, upstream stimulatory factor (USF) is required to bind to the promoter 
o f the FAS gene for insulin regulation to have an effect (Wang and Sul, 1997). Clearly the 
transcriptional regulation o f FM05 has some intriguing similarities with the possible 
mechanisms involved in both of the Fmo knock-out mice, given the Fmol, 2, 4 (-/-) mice and 
their lack of fat, as well as the Fmo5 (-/-) mice and their intriguing low plasma lipid profile
which is covered in Chapter 5 o f this thesis.
Dual-reporter
assay
mRNA levels using real-time RT-PCR
HepG2 HepG2 Male mouse 
hepatocytes
Female mouse 
hepatocytes
Progesterone Increased 0.3 to 
3-fold over 
concentrations 
O.l, 0.5, 5.0, 50 
and 100 pM
Increased at 0.5 
and 5.0 pM, 1.5- 
2 fold
Decreased at 0.1 
and 0.5 pM by
75%
Increased at 0.1, 
0.5 and 1.0 pM, 
1 to 2-fold
Estradiol Increased 0.5- 
fold at 0.001 and 
0.003 pM. 
Decreased 50%
Increased 1 to 
1.5-fold at 0.001 
and 0.1 pM
Increased 0.2 to 
1.5-fold at 
0.001,0.01,0.5 
and 1.0 pM
Increased 1.5- 
fold at 0.003 
pM & decreased 
50% at 0.03 & 
0.5 pM
Testosterone Decreased 50% 
at 0.001, 0.01 
and 0.5 pM
Decreased at 
0.01 and 1.0 pM
Increased 1 to 2- 
fold at 0.001, 
0.01 and 0.5 pM
Increased 1-fold 
at 0.01 pM
Rifampicin Increased by 0.5 
to 2 fold at 10 
pM
Increased 2-fold 
at 10 pM
Increased 0.5- 
fold at 10 pM
Increased 2-fold 
at 10 pM
Hyperforin Decreased 50% 
at 0.5 and 1.0 
pM
ND ND ND
Lipoic-acid Decreased 50% 
at 0.5 pM
Decreased 50% 
at 0.001 pM
Increased 0.5 to 
1-fold at 0.001 
and 0.01 pM
Increased 1-fold 
at 0.001 pM
Ethanol Increased 2-fold ND ND ND
Ligand-
independent
Increased 1 to 2- 
fold with hPXR 
and mPXR
ND ND ND
Figure 3.16.1 Summary of results involving FM05 promoter studies and changes in
mRNA levels using various xenobiotics
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Chapter 4
Results and Discussion
Isolation and maintenance of primary 
mouse hepatocytes and their use to 
elucidate the genomic effects of liquorice
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4 Isolation and maintenance of primary mouse 
hepatocytes
The major organ involved in the metabolism and detoxification of xenobiotics is the liver and 
therefore it has the highest expression of metabolising enzymes in the body. Hence, the liver 
is an attractive site of study to learn more about the effects of xenobiotics, including 
nutritional supplements, upon these metabolising enzymes.
We required primary hepatocytes for the study of the promoter of FM05 using gene- 
reporter assays, as explained in the previous chapter this was unsuccessful due to the stark 
differences between the human and mouse promoters; and human FM05 promoter constructs 
were never successfully expressed in primary mouse hepatocytes. The hepatocytes were used 
instead to examine the gene expression level, using real-time RT-PCR, o f mouse Fmo5 after 
the addition of xenobiotics. Although cell lines derived from liver hepatomas (e.g. HepG2) 
may be employed, the gene expression levels observed may differ from the in vivo situation. 
For the study o f FMOS regulation these cells are very useful, as their inductive response 
appears similar to primary hepatocytes (Wilkening et al., 2003).
Primary hepatocytes can be termed ‘ex vivo’ and the functional capabilities of freshly 
isolated hepatocytes more closely mirror the capacities of a normal in vivo liver (Wilkening 
et al., 2003). HepG2 cells are representative of cancerous cells, a de-differentiated system, 
and so have less association with a normal healthy liver. For example in a recent study, 
researchers found, using genetic probe sets, that primary human hepatocytes (cultured in a 
sandwich system to increase the similarity to an actual liver) retained 77% similarity to liver 
biopsies, whereas HepG2 cells displayed less than 48% similarity (Olsavsky et al., 2007). 
Primary hepatocytes are also much better at biotransformation reactions than HepG2 cells, 
with increased levels of oxidation (phase I metabolism) as well as sulphation and 
glucuronidation (phase II metabolism) (Nyberg et al., 1994). Primary hepatocytes are not 
wholly representative o f a normal liver given that the cells are wrenched from their in vivo 
situation and forced to grow in vitro. The expression of enzymes involved in xenobiotic 
metabolism, as well as those involved in gluconeogenesis or glycolysis are greatly reduced 
over the first three days o f culture (Guguen-Guillouzo and Guillouzo, 1983; Sirica et al., 
1979; Steward et al., 1985) and even when supplemented with glucocorticoids and insulin the
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transcription of certain genes falls 3-10% in comparison to that in vivo (Jefferson et al., 
1984).
Primary hepatocytes nonetheless are a useful model in which to study changes in 
gene expression. Their use requires fewer animals than would be required to carry out a full 
in v/vo study, as well as being more closely related to a normal liver than cell lines.
4.1 Isolation of primary hepatocytes from mice
There is no standard procedure for isolating primary hepatocytes. There is much variation in 
the perfusion media used, the time taken to perfuse and the type o f collagenase. The method 
involves perfusion of the liver with collagenase through the vena porta (antegrade method; 
the portal vein to the hepatic vein) or the inferior vena cava, the so-called retrograde (reverse) 
way. Most methods are based on Seglen (Seglen, 1976) who perfused the liver in two steps. 
The liver is perfused in situ with dissociating agents to get a viable suspension of liver 
parenchymal cells. The first perfusion medium contains EGTA to chelate the calcium. 
Calcium is contained within desmosomes which form part o f the junctional complexes 
between cells. To isolate the hepatocytes chelating calcium irreversibly cleaves the 
desmosomes. This doesn’t happen immediately, so if calcium is restored too quickly the 
desmosomes will re-form. The second perfusion buffer contains collagenase which digests 
the collagen matrix between the cells. Collagenase requires calcium to function, so calcium 
must be re-introduced into the liver in the second perfusion buffer. Hence the requirement of 
two steps.
The isolation of primary hepatocytes is a very difficult procedure to master, since it is 
essentially microsurgery. The number of different factors to consider in the method, 
compounds this issue. Myself and Dr Edwards went through each aspect o f the method and 
made changes. In this way we discovered the parts of the procedure that were vital to its 
success, and which were less so.
Several methods were tried and the final protocol is an amalgamation of these. The 
first method (A in Table 1) was one used in our lab 10 years ago for the isolation of primary 
hepatocytes from transgenic mice by Dr. K Kramer. It in turn was based on the procedures 
used in the laboratories of Dr. P. Maurel (INSERM, Montpellier, France) who isolated rabbit 
hepatocytes and Prof. V. Rogiers (Vrije Universiteit Brussels, Belgium) who isolated rat
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hepatocytes. These methods had to be adapted due to the sheer size difference of the animals. 
For example whilst Prof. Rogiers favoured a glass cannula for the rat, the same device would 
be too fragile in a mouse. Dr. Kramer, who honed the method in the mouse, favoured a fine 
plastic pipette tip. When we began we used Dr. Kramer’s method and found that we had to 
make many more changes for the procedure to be reproducible.
4.2 Cannulation
To cannulate the portal vein, you must tie a loose ligature around it, make a small incision 
then insert the cannula. When we tried to cannulate the portal vein with a tip, it was prone to 
slip out of the ligature, or tear the fragile vessel. Cannulating the portal vein holds another 
problem. The vessel is so fine, that once it is cut, it collapses; making the procedure to insert 
the cannula almost impossible. It occurred so often that we moved on to an intravenous (I.V.) 
catheter for neonates. The very fine needle is sheathed in a thin plastic. The needle and its 
sheath are inserted into the portal vein and then the needle is removed, abolishing the need to 
cut the vessel. The problem with this instrument was that when the ligature was tightened, 
the plastic sheath would collapse and block the method of perfusion. The needle being so fine 
and the plastic so thin, it held very little physical strength. It became clear that perfusing the 
portal vein was too prone to failure to be of use. Many researchers, who I assume have come 
to the same conclusion, perfuse via the inferior vena cava (IVC) (Aiken et al., 1990; Bajt et 
al., 2004). Perivenous hepatocytes appear to contain a higher level o f metabolising enzymes 
(Bengtsson et al., 1987; Suolinna et al., 1989; Vaananen, 1986) so perfusing via the IVC may 
obtain hepatocytes more resembling the in vivo situation. After the advice from Dr. Rick 
Moore (NIEHS, North Carolina, USA) (Method B in Table 1) we purchased a 24 gauge, ball- 
tipped gavage needle (Popper and Son). Because the IVC is a much larger and robust vessel, 
cutting it does not result in its complete collapse, and we were able to cannulate and ligate 
the needle much more easily. The gavage needle is metal, so it doesn’t collapse when the 
ligature is tightened and the ball-tip keeps the needle above the ligature and stops it slipping 
out of the vein. However, this method was still prone to failure. The cutting of the IVC would 
flood the abdomen with blood and make inserting the cannula into the hole cut for it very 
difficult. Although we had more successes than failures, we considered going back to IV 
cannulas, but this time for use in the IVC. We acquired IV catheters of a larger gauge to
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insert into the IVC. Although the plastic sheath could withstand the tightened ligature, the 
cannula was still prone to slip out. This is because IV catheter plastic is designed to be 
entirely inert, so nothing will prevent the smooth removal of the catheter from the vein. 
Finally we found that securely taping this sturdier cannula to the mouse kept it in place. But 
because the catheter plastic is flexible, the cannula is much more difficult to place in the IVC. 
We have found that small movements of the cannula can help or hinder the perfusion of the 
liver. When the cannula is placed deep in the IVC close to the liver, the blood flow backs-up 
and bursts the IVC, or damages liver cells due to the proximity o f the flow. It is difficult to 
place the cannula further from the liver, since it becomes difficult to get the cannula to lie in 
a flat position so that it can be secured. The plastic cannula therefore is harder to get into the 
correct position and apt to coming out of the incision entirely. Once this happens it is very 
difficult to replace the cannula, as by this time the IVC has collapsed and all blood in it has 
been perfused away, making the incision very difficult to find again. It was for this reason 
that we began using the ball-tipped gavage needle again and contented ourselves with a 
securer perfusion and a better than average success rate, which improved with practice.
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4.2.1 Hepatocyte methods
The methods used to isolate primary mouse hepatocytes. A is from Dr K Kramer (Ph. D. thesis); B is from Dr R Moore, NIEHS (personal 
communication); and C is from Dr. Bajhat (Bajat, et al., 2000).
Buffer Solutions Collagenase Cannula Liver
disruption
method
Culture
media
Culture media 
after 3 hours
Collagen, 
plates and 
plating 
density
Additional
Informationl 2
A EBSS (Ca and 
Mg2+ free)
10 mM 
HEPES 
0.5 mM 
EGTA 
Total: 25 mL
EBSS alone 
(50 mL) 
followed by 
EBSS
5mM CaCl2 
(100 mL)
0.25%
collagenase H 
(Roche)
Plastic
catheter
Use of
curved
forceps to
scrape cells
from
Glissons
capsule
Dispersed in 
EBSS plus 
2% (w/v) 
BSA then 
plate in WE 
plus 5% 
(w/v) FBS
WE and
Glutamax I with 
10 pg/mL 
insulin,
0.1 pM DEX,
10 pg/mL 
transferrin,
25 pg/mL 
ascorbic acid, 
lOU/mL 
nystatin,
50 pg/mL 
gentamycin
1 X 10" on 
60mm 
plates 
(Iwaki) 
coated in 
collagen 
Type I 
(Sigma)
Cells were 
grown at 
33°C.
B HBSS (Ca2* 
and Mg2*
, free) plus 
1 0.3 mM 
EDTA 
1 pM insulin 
10 mM
HBSS (with 
Ca2+ and 
Mg2+)
1 pM insulin 
10 mM 
HEPES 
Total: 100 mL
Collagenase 
H (Roche)
Ball-
tipped
gavage
needle,
22G
(Poppin
and son)
Metal comb 
(48 x 48 
mm, teeth 
2mm 
length)
Disperse in 
WE, then 
plate in WE 
plus 7% 
FBS, 10 
mL/L ITS, 
30 mM
WE plus 7% 
FBS, 10 mL/L 
ITS, 30 mM 
pyruvate, 5 nM 
DEX, penicillin
1 x 105/ well 
on 12-well 
plates 
(Nunc) no 
collagen
Time from 
cannula 
insertion to 
perfusion 
should be 
70 secs. 
Collagenase
124
HEPES 
Total: 100 mL 
at 5 mL/min
at 5 mL/min pyruvate,
penicillin
digestion 
should take 
max 4 mins
c Krebs Ringer 
with glucose, 
0.1 mM 
EGTA
Total: 50 mL 
at 2 mL/min 
increase to 
7 mL/min
Krebs Ringer 
with glucose, 
1.37 mM 
CaCl2
Total: 50 mL 
at 7 mL/min
Blendzyme 
Type I 
(Roche)
22G x 1” 
catheter 
IV type
Cut liver
through
capsule,
disperse
cells with
large-bore
pippette
DMEM
with
10% FCS 
1% ABAM
DMEM with 
10% FCS 
1% ABAM
Collagen 
Type III 
(calf skin, 
Sigma) on 
Coming 
plates
Cover liver 
with
moistened 
gauze and 
place lamp 
over mouse 
for warmth
Final HBSS 
(without 
CaC12 and 
MgC12), 
containing 50 
mM EGTA, 
0.75 g glucose 
Total: 50 mL 
at 2 mL/min 
increase to 
7 mL/min
HBSS plus 
1.74 mM 
CaC12 
0.72% w/v 
BSA and 1.25 
g glucose 
Total: 100 mL 
at 7 mL/min 
until digestion 
is good (10 
mins)
Collagenase 
H (Roche) 
0.08 U/mL
Ball-
tipped
gavage
needle,
24G
(Popper
and son)
Use of
curved
forceps to
scrape cells
from
Glissons
capsule
Disperse 
cells and 
plate in WE 
plus 7% 
FBS, 10 
mL/L ITS, 
30 mM 
pyruvate, 
300 pg/ ml 
gentamicin
Plate cells in 
WE plus 7% 
FBS, 10 mL/L 
ITS, 30 mM 
pyruvate, 5nM 
DEX, 300 
pg/mL 
gentamicin
1 x lO5/w ell 
on 12/24- 
well Nunc 
plates 
coated with 
Matrigel 
(BD Bio­
sciences)
Fill the
cannula
with
50U/mL of 
heparin 
before 
insertion 
into IVC
All methods require the buffer solutions to be pH 7.4, at 37°C and have O2 and CO2 bubb 
filtered.
ed through them. All media is at pH 7.4 and
Abbreviations: ABAM-Anti-biotic Antimycotic; BSA-Bovine Serum Albumin; DEX-Dexamethasone; EBSS-Earl’s Balanced Salt Solution; 
FBS-Foetal Bovine Serum; HBSS-Hanks Balanced Salt Solution; ITS-Insulin Transferrin Selenium; WE -Wiliam’s E medium 
The methods used to isolate primary mouse hepatocytes. A is from Dr K Kramer (thesis); B is from Dr R Moore, NIEHS (personal 
communication); and C is from Dr. Bajhat (Bajat, et al., 2000).
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4.3 Liver removal
The initial method from Dr. Kramer involved removing the liver from the animal before 
perfusion began. We found this very cumbersome. The cannula is in such a fragile position 
that it became folly to then cut around the liver while the blood within it begins to clot. Cell 
viability seemed to improve the quicker we moved through the procedure. Clearly the cells 
need nourishing media as soon as possible. The two subsequent protocols we used (method C 
(Bahjat et al., 2000); method B kindly provided by Dr R Moore) advocated ‘whole body’ 
perfusion of the liver. The cannula was inserted the same way, via the IVC, but the liver was 
left where it was, giving the cannula a much sturdier base. Merely clamping the superior 
vena cava below the heart negated the problem of disturbing the cannula. It also limited the 
path of the perfusion buffer so it was directed at the liver and not the whole body.
4.4 Perfusion buffers
Few detailed methods on mouse hepatocyte isolation are available. Many isolation 
procedures are based on the rat, and a particular worry that the media used for rat would not 
be suitable for mouse hepatocytes. The two available detailed methods were tested by us. Dr. 
Bajhat (Method C in Table 1) provided great detail specifically about mouse hepatocyte 
isolation. She used Krebs Ringer solution as her perfusion buffer and DMEM as her dispersal 
buffer and culture medium. In contrast Dr. Moore uses HBSS to perfuse then Williams E 
medium to disperse and culture the hepatocytes. We tried out both methods. The use of 
different perfusion buffers seems to make no difference to the perfusion or the culturing of 
the cells. But pH appears to be very important. Gao et al. found that the viability o f the 
hepatocytes at pH 6.4 was about 63%, whereas at pH 7.2 it was 75% (Gao et al., 2005). 
Maintaining a physiological pH is obviously important so the pH indicator in HBSS enabled 
us to check the pH and re-adjust it to pH 7.4 once 95% O2 and 5% CO2 was bubbled through 
the buffer.
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4.5 Perfusion flow rate
Initially we tried to perfuse the liver via gravity. Having measured the flow rate, the buffer 
was running at about 2 to 3 mL/min. This pressure was insufficient to exclude the blood from 
the mouse liver. This method works in rats where the flow rate is inevitably higher because 
the cannula is much larger. However, the fine cannula used in mice precludes the use of 
gravity flow. We therefore connected the cannula to a peristaltic pump and initially used a 
flow rate of 15 mL/min. Our cell viability was 50%. A flow rate of 7 mL/min was used by 
Bajhat (2001) and when we reduced the flow rate to 7 mL/min viability improved to 60%. It 
is clear that flow rate is important. Perhaps the mechanical (sheer) stress o f such a high rate 
reduces the viability.
4.6 Collagenase
I would say that finding the correct collagenase is the most important factor to get right in 
hepatocyte isolation. Once we found a batch that worked for us, the method was consistently 
successful and viability was maintained at at-least 65%. Collagenase is made up of a crude 
preparation of a bacterial culture from Clostridium histolyticum. Other proteases in this 
preparation include clostripain, trypsin, neutral protease and aminopeptidase. Hence 
collagenase activity varies from batch to batch. We purchased collagenase H and Blendzyme 
3 both from Roche and collagenase I from Sigma. The collagenase from Sigma looked very 
crude and the procedure resulted in low viability even at a low collagenase activity. 
Blendzymes from Roche are produced to have no lot to lot variability. They are much less 
crude. However, again the viability was very low with Blendzyme 3 at 0.1 U/mL. The 
procedure would probably have benefited from some method development, but Blendzymes 
are very expensive, and by this time we had found collagenase H to give a good viability and 
cell number. We found that using 0.08 U/mL of collagenase H (Roche) was the ideal activity 
for our procedure although we tried several batches to get this right. We typically achieved 
65-70% viability and 65 - 75 x 106 cells per liver.
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4.7 Maintenance of mouse primary hepatocytes-use of media
Williams and Gunn (1974) investigated the long-term culture o f adult epithelial cells and 
developed Williams’ Medium E. We tried DMEM and Williams’ E media. The type o f media 
used did not appear to improve or hinder the culturing of the cells. Guguen-Guillouzo (1983) 
also found that few differences resulted from the choice o f medium.
4.8 Plate coatings
Dr Moore’s protocol specifies he uses uncoated plates on which to culture the hepatocytes. 
When we tried this the cells did not attach onto the plate very well, and they lived for only a 
day or so. So we coated the plates with collagen Type I (Sigma) as used by Dr Kramer. This 
worked very well; the cells attached onto the plate at a greater density and maintained their 
pavement-like morphology. The cells also have a rounded healthy-looking shape when they 
initially attach, which is very pleasing. Although collagen was an excellent base for the 
hepatocytes, the cells have a short life span of only a couple o f days (Figure 4.9.1). To 
improve their survival we plated the cells onto Matrigel™-coated plates. It is a biomatrix 
extracted from the Engelbreth-Holm-Swarm mouse sarcoma. Matrigel™ is a mixture of 
collagens, designed to give a support structure more like that in vivo. Various matrix 
components are found in the liver including collagens I, III, IV, V and VI, noncollagenous 
glycoproteins such as laminin and fibronectin (Clement et al., 1986). Indeed the cells 
cultured on Matrigel™ attached very well, and survived for at least 5 days when cultured on 
this substratum. Although it is difficult to be definitive purely on microscopic observations, 
the cells appeared to have a less flattened and a more “polygonal” morphology. However, 
even so we found that the concentration of Matrigel to layer onto the plates required some 
method development. The protocol provided by the supplier of Matrigel specifies using it at a 
3:1 concentration, the greater part made up from the culture media, such as Williams E. 
When used at this concentration however, the cells were inclined to get too entrenched in the 
Matrigel™, not change their morphology or make contacts with their neighbours (Figure 
4.9.2). Subsequently we found that a 9:1 dilution combined a longer survival time with a 
liver-like morphology.
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4.9 Plating density
We tried plating cells at several densities on 12-well plates, from 1 million cells per well (per 
mL) down to 0.1 million cells per well. At the level of 1 million, the cells did not attach at all 
to the plate. They appear to crowd each other out and die in suspension. But at 0.5 million 
cells per well, the cells attach to the plate immediately. We plated 0.4, 0.3, 0.2, 0.1 million 
cells per well also. The cells also attach at these lower densities. However after 24 hours, 
when plated below 0.3 million cells, the hepatocytes appear to be stretched beyond their 
means, (Figure 4.9.3), and hepatocyte characteristics are no longer like those of an intact 
liver in which cells are in contact with other cells (Koji et al., 1988).
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(a)
(b)
4.9.1 Primary mouse hepatocytes plated onto collagen
Primary male mouse hepatocytes plated on collagen, hepatocytes after 20 hours, X20 
magnification (a), hepatocytes plated for 40 hours, X40 magnification (b).
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(a)
n>
(b)
4.9.2 Primary male mouse hepatocytes plated on Matrigel™
Hepatocytes plated on Matrigel™ diluted 1:3 (a); Cells plated on Matrigel™ diluted 1:5 (b) 
(X20 magnification)
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4.9.3 Primary male mouse hepatocytes plated onto Matrigel™ and cell density
Primary male mouse hepatocytes plated onto Matrigel™ 1:5 (X10 magnification) (a). Cells 
plated at 0.2 million cells per mL (X 20 magnification) (b).
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(a)
(b)
4.9.4 Primary male mouse hepatocytes-plating density
Primary male mouse hepatocytes plated at 0.3 million cells per mL (a). Cells plated at 0.5 
million cells per mL(b) (x 20 magnification).
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4.10 Defining a differentiated system-examples of healthy cultured 
mouse hepatocytes
Mouse hepatocytes were cultured as described in the methods section. In Figure 4.10.1 I have 
chosen to display the same cells, but the photographs are taken with a different light source 
to show the rounded morphology of the cells. This is important; because as the cells become 
de-differentiated, they lose their shape and become flatter. You can also see that the majority 
of the cells are bi-nucleate. This is also indicative o f a differentiated system, implying the 
cells are healthy. Similarly the defined junctions between cells and the pavement-like shape 
they acquire show the cells are well. Unhealthy or de-differentiating cells will expel 
pseudopodia and the barriers between cells become less-well defined.
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(a)
4.10.1 Demonstration of healthy morphology
Cells are shown with the light source from below (a) to demonstrate defined gap junctions 
and pavement morphology, and a light source from above (b) to show the rounded and 
therefore healthy morphology.
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4.11 C o n f i r m a t io n  o f  a  P 4 5 0  r e s p o n s e  u s i n g  p h e n o b a r b i t a l
To confirm that the hepatocytes maintained healthy responses to stimuli and maintained 
transcriptional activity, they were dosed with PB. In healthy cells CYP2B should be induced. 
As shown in Figure 4 .11.1 CYP2B1/2 is inducible in the mouse hepatocytes and that they 
have therefore maintained crucial factors required for induction o f  the mouse CYP2B gene. 
A concentration o f  ImM phenobarbital was found to give the highest induction. Previous 
studies also show that induction o f  CYP2B by phenobarbital is greatest at similar 
concentrations (0.75-ImM ) (Kocarek et al.. 1990).
CYP2B induction in primary mouse hepatocytes
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4.11.1 Induction of CYP2B in phenobarbital-treated primary mouse hepatocytes
Flepatocytes were treated with phenobarbital for 24 hours. Cells were scraped from the plates 
and protein concentration measured. The graph is a quantitation o f  the resulting bands from a 
Western blot using an anti-CY P2Bl/2  antibody. This is a representative result from three 
different cultured male mouse livers and their western blots.
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4.12 Investigating hepatocyte genetic response to glycyrrhetinic 
acid using microarray
Microarray enables the investigator to look at the up- or down-regulation of genes in a whole 
organism in response to a treatment or environmental condition. Two discrete cell 
populations are used and the experiment is usually carried out using triplicate microarray 
slides.
Hepatocytes were treated with a component of liquorice, glycyrrhetinic acid (lOpM) 
for 24 hours. 56 genes were up-regulated in total, but only two were above the two-fold cut 
off, in all 3 slides. The rest of the ’up-regulated’ genes were increased above 2-fold but in 
only 2 out of 3 slides, or above l.5-fold and in 3 or 2 out of 3 slides. No genes were down- 
regulated. The ‘upregulated’ genes can be split into general functions and this is what I will 
attempt to do here. The full list of genes up-regulated are shown in Figure 4.14.1.
4.13 Xenobiotic metabolism
We were looking for an induction in genes involved in xenobiotic metabolism, and 
transportation. Phase I enzymes Cyp3al 1, Cyp3a25 and Cyp2c29 were up-regulated, as were 
glutathione-s-transferases (GST) mu3 and mu4, members of phase II metabolism. There were 
no increases in any transcription factors, especially those known to regulate the CYPs such as 
PXR, CAR, AhR and PPAR. This may not be of concern since phosphorylation as opposed 
to an increase in transcriptional levels may be how these receptors are being modulated.
4.14 Glycolysis
Three genes involved in glycolyis were up-regulated. Pyruvate kinase (Pkm2), enolase and 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh).
Pyruvate kinase was up-regulated more than 2-fold in all 3 slides and converts 
phosphoenolpyruvate (PEP) to pyruvate. Enolase is the enzyme that produces PEP from 2- 
phosphoglycerate. Gapdh is involved in an earlier step of glycolysis, converting 
glyceraldehyde-3-phosphate to l ,3-bisphosphoglycerate. Clearly glycolysis in this system is 
being up-regulated. The reaction catalysed by pyruvate kinase produces ATP by direct 
phosphorylation of ADP.
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Function/
Process
Common
Name Name
Fold
Incr
ease
Pkm2 pyruvate kinase, muscle 2.06
Glycolysis Gapdh glyceraldehyde-3-phosphate dehydrogenase 1.42
Enol enolase 1, alpha non-neuron 1.66
C yp3al1 cytochrome P450, family 3, subfamily a, polypeptide 11
2.11
Xenobiotic
Cyp3a25 cytochrome P450, family 3, subfamily a, polypeptide 25
1.91
metabolism Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29
1.60
Gstm3 glutathione S-transferase, mu 3 4.07
Gstm4 glutathione S-transferase, mu 4 1.49
Bnip3 BCL2/ adenovirus E 1B 19kDa-interacting protein 1,NIP3
1.69
Apoptosis Ddit4 DNA-damage-inducible transcript 4 1.75
Itm2b integral membrane protein 2B 1.62
Rnase4 ribonuclease, RNase A family 4 1.55
Ndrgl N-myc downstream regulated gene 1 2.34
Stress response Higl hypoxia induced gene 1 1.51
Hspa8 heat shock protein 8 1.67
Egln3 EGL nine homolog 3 1.79
Signalling Bmp8a bone morphogenetic protein 8a 3.14
Protein Lgals3 lectin, galactose binding, soluble 3 1.72
binding nebulin nebulin 1.75
Amine
transporter Slc30al
solute carrier family 30 (zinc transporter), 
member 1
1.63
Hormone Prl prolactin 1.98
Glycosylation Pmml Phosphomanno-mutase 1 1.47
Blood
coagulation Fgg fibrinogen, gamma polypeptide
1.56
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Metal ion 
binding
Loxl2 lysyl oxidase-like 2 1.44
Mt2 metallothionein 2 1.98
Plekhel pleckstrin homology domain containing, family E (with leucine rich repeats) member 1
1.92
Calcium ion
Gsn gelsolin 1.77
binding Calb2 calbindin 2
1.48
Nell2 nel-like 2 homolog (chicken) 1.70
Interleukin
receptor II17rb interleukin 17 receptor B
1.58
G-protein
coupled
receptor
Olfr82l olfactory receptor 821 1.46
Transport Fabpl
fatty acid binding protein 1, liver 1.46
Crabpl cellular retinoic acid binding protein I 1.43
MGC54-
896 similar to CTCL tumor antigen se57-l
1.37
Unknown Attp signaling molecule ATTP
1.54
ScalO spinocerebellar ataxia 10 homolog 1.31
9230109-
N16 hypothetical protein 9230109N16
1.46
DNA-binding
(stress) Nuprl nuclear protein 1
1.66
Mitosis Mapre2 microtubule-associated protein, RP/EB family, member 2
1.43
Angiogenesis
Vegfa vascular endothelial growth factor A 1.64
Serpinel serine (or cysteine) proteinase inhibitor, clade E, member 1
1.73
Protein Rpll2 ribosomal protein L I2 1.83
biosynthesis Rpl23a ribosomal protein L23a 1.79
Differentiation Sprrl7 small proline rich-like 7 2.73
4.14.1 Table of the genes up-regulated in glycyrrhetinic acid-treated hepatocytes
This table contains the genes up-regulated when primary male mouse hepatocytes were dosed 
with 10 pM glycyrrhetinic acid for 24 hours. The total RNA was isolated, and mRNA was 
analysed using microarray.
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This is substrate-level phosphorylation and is especially important for providing 
energy for a tissue when they are lacking oxygen (Salway, 1999). Pkm2 is the only pk 
isozyme detectable in early fetal tissues. The other isoforms, L-, R-, and M l-type gradually 
replace M2 as development progresses. However, when tissues are de-differentiated or are 
developing a neoplasm, M2 is reactivated or increased (Asai et al., 2003). It also appears that 
during increased cell proliferation pkm2 increases energy production.
This is a key point when elucidating the consequences of dosing GTA to hepatocytes, 
especially when it is known that all three enzymes are under transcriptional control of 
hypoxia-inducible factor 1 (HIF-la).
4.15 Hypoxia and apoptosis
As well as glycolysis, other genes are up-regulated in these treated hepatocytes that are 
acutely related to hypoxia. HIF-la is the transcription factor that mediates hypoxia and 
modulates the transcription of genes involved in angiogenesis, glucose transport and 
metabolism, inflammation, apoptosis and cellular stress. As part of a cell’s response to 
hypoxia, HIF-la is stabilised, it forms a heterodimer with HIF-lp and the pair target hypoxia 
response elements in a plethora of genes. It is clear that H IF-la has a large part to play in the 
fate of these glycyrrhetinic-dosed cells, although H IF-la wasn’t induced in the microarray.
H IF-la’s role is to prepare the cell for survival against hypoxia, as cells are able to 
grow and proliferate normally in hypoxia. This perhaps is especially true in solid-tumours, 
where the growth tissue often becomes hypoxic, and what is often observed associated with 
these cancers is angiogenesis. A normal or cancerous cell increases the blood flow to that 
tissue to increase the flow of oxygen, the first step o f which is to up-regulate vascular 
endothelial growth factor (VEGF), directly under the control o f HIF-la. VEGF is up- 
regulated in this system, and is obviously part of a normal cell’s response to hypoxia. 
Prolactin is also induced in this system and has also been implicated in angiogenesis (Jackson 
etal., 1994).
Another gene under the control of H IF-la is Ddit4 (DNA-damage-inducible 
transcript 4) it was induced and is activated in response to cellular stresses such as DNA 
damage and hypoxia (Lin et al., 2005). It activates the mTOR signalling pathway which in 
turn also activates HIF-la, and ultimately up-regulates angiogenesis. Already there are
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control mechanisms in place whereby hypoxia induces H IF-la and then Ddit4, but also Ddit4 
itself responds to hypoxia, giving two levels of control. The inactivation of H IF-la is also 
being regulated in the form of EGL nine homolog 3 (Egln3). H IF-la contains independent 
oxygen degradation domains, which Egln3 targets, flagging H IF-la for proteasomal 
degradation (Villar et al., 2007). Egln3 catalyses oxygen-dependent hydroxylation of H IF-la 
and is up-regulated by hypoxia at the mRNA level and appears to be involved in the negative 
feedback of HIF-la (Epstein et al., 2001).
Heat shock protein 70 (HSP70/Hsp8a) is increased in hypoxic hepatocytes at an early 
stage (Tokyol et al., 2005) and Hsp70 was also induced in this system. Heat shock proteins 
have a cytoprotective effect, an example being the inhibition o f lipopolysaccharide-mediated 
apoptosis in cultured sheep pulmonary artery endothelial cells over-expressing Hsp70 (Wong 
et al., 1996). Cultured murine lung epithelial cells under thermal stress were protected by 
Hsp70 from oxidant-mediated injury (Wang et al., 1996).
Higl (hypoxia-induced gene 1) was characterised in hypoxic cervical epithelial cells, 
and could be involved in pro-apoptotic signalling (Bedo et al., 2005). Ndrgl (N-myc down- 
regulated gene 1) was also up-regulated in this system and is regulated during cell 
proliferation, differentiation, and in response to stress. It modulates the response to hypoxic 
injury in human trophoblasts (Chen et al., 2006). The RNase4 level was increased, it is as yet 
unclear what RNase4’s role is, but its promoter is dependent on an intact H IF-la consensus 
binding site (Dyer and Rosenberg, 2005). Bone morphogenic 8a (Bmp8a) is an intracellular 
signaling molecule that is released when there are changes in cell proliferation, cell survival, 
differentiation and cell fate (Zhao et al., 1998). The up-regulation of Hsp70, H igl, Ndrgl and 
RNase4, Itm2b and Bmp8a is perhaps indicative of the cell adapting to hypoxia, but also in 
preparation for apoptosis. This is because there is another side to H IF-la, whilst it is able to 
protect against hypoxia it can also prepare the cell for destruction and be pro-apoptotic. 
BNIP3 (BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3) was induced and is under 
direct control of HIF-la. BNIP3 is a pro-apoptotic mediator and is important in hypoxia- 
induced death in normal as well as malignant cells (Lee and Paik, 2006). Bnip3 binds to Bcl- 
2/Bcl-XL, repressing them and inducing cell death. Integral membrane protein 2B (Itmb2) is 
also able to inhibit Bcl-2, and is up-regulated in this system. Itm2b appears to have a p53- 
independent apoptotic role (Fleischer and Rebollo, 2004).
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Clearly the cells are under some stress. In an hypoxic environment, where the lack of 
oxygen means less ATP will be obtained from oxidative phosphorylation, glycolysis is up- 
regulated to try to compensate. Cell proliferation is increased to produce more ATP- 
providing units in an effort to maintain the energy level, and in whole systems, genes to 
increase angiogenesis are transcribed to increase the flow o f oxygen. If these measures fail to 
lift the cells out of an hypoxic environment, then pro-apoptotic mediators are up-regulated in 
preparation for cell suicide. This appears to be the environment the hepatocytes are in. The 
question as to why the cells are becoming hypoxic seems to be resolved by Salvi (Salvi et al., 
2003) who investigated the effects o f glycyrrhetinic acid (lOpM), on rat liver microsomal 
mitochondria. They found that glycyrrhetinic acid caused swelling o f the mitochondria, 
enhanced oxygen uptake and mitochondrial membrane potential collapse. To uncover the 
reasons for this, in their follow-up paper (Salvi et al., 2005), they used carbenoxolone, the 
glycyrrhetinic acid derivative, which has been used more widely in the past clinically. They 
found that carbenoxolone produced oxidative stress which opens up the transition pore in 
mitochondria. The possible mechanism being that carbenoxolone produces H2 O2 which 
reacts with thiol groups that are critical in opening the mitochondrial pore. The increased 
uptake in oxygen leads to a greater production of H2 O2 and more thiol group oxidation. This 
could explain the hypoxic conditions we observe in the GTA-treated hepatocytes. 
Carbenoxolone causes an increase in the permeability o f mitochondrial membrane which can 
result in the release of critical proapoptotic intermembrane space effectors into the cytosol 
such as cytochrome c.
In a more recent paper Pivato (Pivato et al., 2006) found that carbenoxolone 
stimulated state IV respiration, which led to the uncoupling of oxidative phosphorylation and 
the induction of membrane pore transition.
The system may not be descending into apoptosis just yet, as the interplay o f signals 
to decide the cell’s fate is not clear-cut. Interestingly there is up-regulation of the anti-oxidant 
glutathione (GSH) by the hepatocytes to try to minimise the damage, as well as up-regulating 
gelsolin, a protein that appears to be involved in closing the transition pore (Kusano et al., 
2000). The up-regulation of Egln3 may also be in preparation for a normoxic environment 
where HIF-la can be degraded.
There is also no sign of up-regulation of the ‘executioner caspases’ -3, -6 and -7 
which are typically required for full-blown apoptosis. So although the cells are under a
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condition of stress, it may not be too severe, given that the level o f induction of the genes 
involved is fairly slight, only just over the two-fold cut-off. The cells also weren’t obviously 
morphologically different otherwise the RNA wouldn’t have been isolated.
Unfortunately I was unaware of the mitochondrial effects of carbenoxolone and hence 
glycyrrhetinic acid before the cells were dosed at 10 juM, which incidentally is a similar 
concentration to the plasma concentration derived after liquorice ingestion (de Groot et al., 
1988), the reason for the hepatocytes being dosed at that concentration in the first place. This 
mitochondrial action may also explain some o f the beneficial effects observed when people 
take liquorice for inflammation and cancer, promoting the safety mechanism of the body, 
apoptosis, to dispose of the damaged cells.
Although the microarray doesn’t tell us any more about the control o f xenobiotic 
metabolism when glycyrrhetinic acid is applied, it does show what can be inferred from the 
induction of genes and the ‘cross-talk’ between transcription factors and effector genes that 
may ensue.
These results do show rather elegantly however, what does happen at a genomic level 
when the cell is under a condition of stress and if nothing else, this experiment does validate 
the process o f microarray.
4.15.1 Diagram 1: The response of genes and their inter-relationship when primary 
male mouse hepatocytes are treated with glycyrrhetinic acid
On the next page is a diagram showing the relationship of genes induced by glycyrrhetinic 
acid (10 pM) in primary male mouse hepatocytes. The blue genes are those induced by the 
microarray. Black arrows indicate an inductive effect of one gene on another, or upon a 
process. Red arrows are inhibitive.
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5 Investigation into FMO knock-out mouse models and 
implications for the endogenous role(s) of FMOs
FMOs are drug-metabolising enzymes, but presumably they originally had an endobiotic role 
and have evolved to metabolise xenobiotics. Their possible endogenous role has to this day 
remained elusive. To study the likely endogenous function(s) of FMOs two knock-out mouse 
models had previously been created by the laboratory o f Professor Elizabeth Shephard. The 
first mouse to be made was the Fmol, 2, 4 (-/-) mouse (also referred to as the ‘cluster’ knock­
out) which was created according to Hernandez et al., (2006). The second was an Fmo5 (-/-) 
mouse, created by removing exon two o f the transcript, resulting in a non-functional enzyme. 
Using these two models we have undertaken extensive study to uncover the endogenous role 
of FMOs.
In the following chapter I will describe the research into these two knock-out (KO) 
mouse models separately. The interesting results seen with the Fmol, 2, 4 (-/-) mice will be 
described first; the investigations into the Fmo5 (-/-) mice will be set out in the second half of 
the chapter.
5.1 Weight analysis of male Fmol, 2, 4 (-/-) knock-out mice
Once homozygous knock-outs had been produced, it was observed that the body weight of 
the male Fmol, 2, 4 (-/-) mice was less than that of wild-type (WT) males o f the same age 
(Figure 5.1.1). The body weight of these animals was measured for 15 weeks from 4 weeks 
of age (Figures 5.3.1). At 4 weeks of age the WT male weight (16g) is less than that of the 
Fmol, 2, 4 (-/-) males, being about 23g. This is clearly a large difference, but the WT mice 
gain 5g in weight on average and the Fmol, 2, 4 (-/-) lose 2g to become the same weight as 
each other from 5.5 to 6.5 weeks of age. Between 6.5 and 7 weeks of age the WT males on 
average put on 1.5g in weight, whilst the Fmol, 2, 4 (-/-) males gain no weight. Shown in 
Figure 5.3.3 are the percentage weight gains over periods of time for comparison between 
male Fmol, 2, 4 (-/-) mice and male WT mice. From 4.5 to 6 weeks the WT males gain 38% 
in weight, whilst the Fmol, 2, 4 (-/-) males gain 7.5% weight over the same time. From 6 to 
10 weeks, the WT males gain 32% in weight, but the Fmol, 2, 4 (-/-) males gain only 14%.
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5.1.1 Picture of Fmol, 2, 4 (-/-) male mouse and WT male mouse
Photographs o f  a representative WT male mouse (a) and a male Fmol, 2, 4 (-/-) mouse (b) 
are shown.
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Between 10 and 14 weeks the WT males gain just over 6% and the Fmol, 2, 4 (-/-) males 
gain a similar amount over the same period. From 14 to 17.5 weeks o f age the male Fmol, 2, 
4 (-/-) mice gain 2.5% in weight whilst the WT males gain twice that (5%) in weight.
5.2 Weight analysis of female Fmol, 2, 4 (-/-) knock-out mice
The influence of gender in FMO weight gain and phenotype is observed in female Fmol, 2, 4 
(-/-) mice who weigh more than the WT females. At 5 weeks o f age the WT females weigh 
I5.8g, but the Fmol, 2, 4 (-/-) females weigh nearly 3 grams more. The percentage weight 
gain of the Fmol, 2, 4 (-/-) and WT females are quite similar. From 4.5 to 6 weeks of age the 
Fmol, 2, 4 (-/-) females gain approximately 7% in weight, whilst the WT females gain about 
11% in weight. From 6 to 10 weeks the Fmol, 2, 4 (-/-) females gain 18% in weight and the 
WT females gain 20% in weight. From 10 to 14 weeks o f age the Fmol, 2, 4 (-/-) females 
gain only 7.5% and the WT females gain 12% in weight (Figure 5.3.3). Our results indicate 
that the Fmol, 2, 4 (-/-) females start life weighing more, then maintain the weight gain at a 
similar level to the WT females. But from 10 to 14 weeks of age the weight gain in Fmol, 2, 
4 (-/-) females is slightly less than that seen in WT females.
5.3 Food intake of Fmol, 2, 4 (-/-) knock-out and WT mice
The intake of food was measured in the same cohort of mice analysed for changes in 
bodyweight. The feed put into cages was weighed and the remaining feed was measured 
twice a week. This value was divided by the number o f mice in the cage.
All mice ate a similar amount of food (Figure 5.3.2). Thus the lower bodyweight in 
the Fmol, 2, 4 (-/-) males is not due to decreased food consumption compared to WT males. 
Similarly the increased bodyweight observed in the Fmol, 2, 4 (-/-) females compared to WT 
females is not due to an increased consumption o f food.
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5.3.1 Bodyweights of Fm ol, 2, 4 (-/-) and WT mice
The bodyweight o f  Fmol, 2, 4 (-/-) and WT males (a) and females (b) on a normal chow diet 
from 4 to 18 weeks o f  age. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.3.2 Food consumption of Fmo1, 2, 4 (-/-) and WT mice
Food consumption per mouse per day o f  Fmol, 2, 4 (-/-) and WT males (a) and females (b) 
on a normal chow diet.
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5.3.3 Percentage weight gain of Fmo1, 2, 4 (-/-) and WT mice
The percentage weight gain o f Fmol, 2, 4 (-/-) and WT males (a) and females (b) on a
normal chow diet. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.4 Fmol, 2, 4 (-/-) males have less gonadal fat than WT males
It was clear from the dissections o f the Fmol, 2, 4 (-/-) and WT males that there was a 
difference in amount of fat between the two (Figure 5.5.1). The liver, spleen, brown fat, heart 
and front adipose tissue (gonadal fat) were weighed in 4, 10 and 22 week old males.
The dissection and weighing confirmed that there is a reduced amount of gonadal fat 
in the Fmol, 2, 4 (-/-) males (Figure 5.5.2 and 5.5.3). At 4 weeks the Fmol, 2, 4 (-/-) males 
have over 26% less fat on average than the WT, when taking body weight into account. At 10 
weeks this difference increases, the Fmol, 2, 4 (-/-) males have nearly 47% less fat than the 
WT. At 22 weeks the difference continues and the Fmol, 2, 4 (-/-) males have 43% less fat 
then the WT. The weight o f the gonadal fat is a good estimate of total body fat according to 
Rogers and Webb (1980). So it can perhaps be assumed that in general the total body fat for 
the Fmol, 2, 4 (-/-) males is lower than the WT mice, leading to a mouse with reduced body 
weight. The fat around the kidney was also reduced as shown in Figure 5.5.1, which backs 
this theory up.
5.5 Fmol, 2, 4 (-/-) males have smaller hearts
The second difference between WT and cluster KO mice in organ weight concerns the heart. 
Compared to the WT male hearts, the absolute organ weight of the Fmol, 2, 4 (-/-) male 
hearts is 6% larger at 4 weeks, then 17% smaller at 10 weeks and 21% smaller at 22 weeks of 
age (Figure 5.5.4). However, when you take body weight into account, compared to the male 
WT hearts, the Fmol, 2, 4 (-/-) male hearts are 16.5% larger at 4 weeks, 7.8% smaller at 10 
weeks and 23.5 % smaller at 22 weeks. None o f these values are significant. There is clearly 
a difference in the heart weight, but whether this should be given credence is a matter of 
discussion. Hearts tend to be a representation o f body size in general (Janz et al., 2000; 
Vlasov and Volkov, 2004). So any changes should have body weight taken into account. 
Perhaps the more interesting aspect is that the KO heart weight as a percentage o f body 
weight plummets at 22 weeks, whereas the WT hearts remain fairly consistent across the 
ages.
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. /
WT male Fmol, 2, 4 (-/-) male
5.5.1 Abdominal and kidney photos from Fm ol, 2, 4 (-/-) and WT male mice
Representative photographs o f  the in situ gonadal fat (a) and the kidney with associated fat 
(b). The WT images on the left o f  the page, Fmol, 2, 4 (-/-) images on the right.
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5.5.2 Organ weights at 4 and 10 weeks of age-Fmo1, 2, 4 (-/-) males
The organ weights as a percentage o f  body weight o f  Fmol, 2, 4 (-/-) and WT males on a 
normal diet at 4 weeks o f  age (a) and 10 weeks o f  age (b). * is p<0.05. Error bars are SEM.
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( a )  7Qo Organ weights in Fmol, 2, 4 (-/-) and WT males at 22 weeks of age
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5.5.3 Organ weights and gonadal fat weight
Organ weights at 22 weeks o f  age (a) and gonadal fat weight at 4, 10 and 22 weeks o f  age (b) 
in Fmol. 2, 4 (-/-) and WT males. * is p<0.05, ** is p<0.005.
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(a) Absolute heart weights of Fmol, 2, 4 (-/-) and WT males
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5.5.4 Heart weights
Absolute heart weight (a) and heart weight as a percentage o f body weight (b) in Fmol, 2, 4
(-/-) and WT males at 4, 10 and 22 weeks o f age. Error bars are SEM.
5.6 Fmol, 2, 4 (-/-) males have less fat in the liver than WT males
The liver histology o f both WT and Fmol, 2, 4 (-/-) male mice were analysed at 4, 10 and 22 
weeks of age (Figures 5.7.1, 5.7.2, 5.7.3). The livers were frozen and cut using a cryostat, 
and stained using Oil Red O, which stains all fats red. A secondary stain, Gil’s haematoxylin, 
was used to highlight nuclei, which stain blue.
At 4 and 10 weeks o f age, the Fmol, 2, 4 (-/-) males have very little or no observable 
fat in the liver. In contrast the WT males do have some fat in the liver, visible as red dots. At 
22 weeks of age the amount o f fat in the livers of the male Fmol, 2, 4 (-/-) mice increases, 
and the WT mice have a similar amount o f fat in the liver at this age.
5.7 Fmol, 2, 4 (-/-) males have smaller adipocytes than WT males
To investigate the morphology of the adipocytes, gonadal fat was removed for histology. All 
adipose fixing and staining was done by Mr Omar. It became clear that the adipocytes from 
the Fmol, 2, 4 (-/-) male mice were much smaller than the WT adipocytes (Figures 5.7.4 and 
5.7.5). The sizes were measured using the Openlab 6.0 program, and the volumes calculated 
with the assumption that the cells were spheres. As can be seen from Figure 5.7.6 the 
adipocytes from the Fmol, 2, 4 (-/-) mice at 10 weeks of age are approximately 50% of the 
size of the WT mice. At 22 weeks this difference increases to approximately 25% of the WT 
adipocytes.
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5.7. •/ Liver histology in Fmol, 2, 4 (-/-) and WT males at 4 weeks of age
A representative photograph o f the liver histology in Fmol, 2, 4 (-/-) males (a) and WT males
(b) at 4 weeks o f age.
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5.7.2 Liver histology in Fm ol, 2, 4 (-/-) and WT males at 10 weeks of age
A representative photograph o f the liver histology in Fm ol, 2, 4 (-/-) males (a) and WT males
(b) at 10 weeks o f age.
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5.7.3 Liver histology in Fm ol, 2, 4 (-/-) and WT males at 22 weeks of age
A representative photograph o f  the liver histology in Fm ol, 2, 4 (-/-) males (a) and WT males
(b) at 22 weeks o f age.
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5.7.4 A dipocyte histology-10 week males
Representative images o f  the adipocyte histology o f  10-week old male mice, Fmol, 2, 4 (-/-) 
(a), and WT (b), both on a normal chow diet. Scale bar represents 75 pm.
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5.7.5 Adipocyte histology-22 week males
Representative images o f  the adipocyte histology o f  22-week old male mice, Fmol, 2, 4 (-/-)
(a), and WT (b), both on a normal chow diet. Scale bar represents 75 pm.
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F m o l ,  2,  4  (-/-)
(b)
F m o l ,  2,  4  (-/-)
5.7.6 Adipocyte volumes-normal diet
The adipocyte volumes o f  10-week (a) and 22-week (b) old male Fmol, 2, 4 (-/-) and WT
mice, both on a normal chow diet. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.8 Analysis of blood plasma lipids and solutes in Fmol, 2, 4 (-/-) 
male mice
The total cholesterol, HDL cholesterol and LDL cholesterol were measured at 8, 15 and 22 
weeks of age in male Fmol, 2, 4 (-/-) and WT mice. At the three ages the Fmol, 2, 4 (-/-) 
males had 18.5%, 25% and 7.5% more total cholesterol than the WT respectively (Figure
5.8.1).
The HDL cholesterol was consistently higher at the three ages (8, 15 and 22 weeks) in 
the Fmol, 2, 4 (-/-) males than the WT males at 23%, 28% and 9% respectively; as was the 
LDL at 8%, 27% and 16% respectively (Figures 5.8.1, 5.8.2). The triglyceride concentration 
in the blood was also measured (Figure 5.8.2). The triglyceride concentration in Fmol, 2, 4 (- 
/-) male mice is very similar to that of the WT male mice at 8, 15 and 22 weeks o f age.
Along with the plasma lipids, some plasma solutes were measured, glucose, iron, 
calcium and urea. There were no significant changes in plasma solutes observed in the Fmol, 
2, 4 (-/-) male mice (Figures 5.8.3 and 5.8.4), although the level o f iron in the plasma is 
slightly higher (20%) than that in the WT males at 9 and 15 weeks o f age.
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(a) Plasma total cholesterol in Fmol, 2, 4 (-/-) and WT males
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5.8.1 Total cholesterol and HDL cholesterol
The blood plasma lipids in Fmol, 2, 4 (-/-) and WT males, total cholesterol (a) and HDL
cholesterol (b) at 8, 15 and 22 weeks o f age. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.8.2 LDL cholesterol and triglycerides
The blood plasma lipids in Fmol, 2, 4 (-/-) and WT males. LDL cholesterol (a) and
triglycerides (b) at 8, 15 and 22 weeks o f  age.* is p<0.05, ** is p<0.005. Error bars are SEM.
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(a) Plasma solutes in Fmol, 2, 4 (-/-) and WT males at 9 weeks of age
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5.8.3 Blood plasma solutes at 9 and 15 weeks of age
The blood plasma solutes in Fm ol, 2, 4 (-/-) and WT males at 9 weeks o f  age (a) and 15
weeks of age (b). Error bars are SEM.
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5.8.4 Blood plasma solutes at 20 weeks of age
The blood plasma solutes in Fmol, 2, 4 (-/-) and WT males at 20 weeks o f  age. Error bars are 
SEM.
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5.9 On a high-fat diet Fmoi, 2, 4 (-/-) mice gain body weight, fat 
mass and adipocyte size
To see if the Fmol, 2, 4 (-/-) male mice were able to put on weight and gonadal fat weight 
they were put on a 35% fat diet for 7 weeks. Once again the bodyweight and organ weights 
were measured. The histology of the gonadal fat was also analysed again.
As can be seen from Figure 5.9.1a, the Fmol, 2, 4 (-/-) male mice put on weight 
readily. Their bodyweight increases from 25.8g just before being put on a high fat diet, to 
38.6g at the end of the diet. Similarly the WT males increase their weight over the same 
period from 29. lg  to 49.5g. The Fmol, 2, 4 (-/-) males consistently weigh less than the WT 
males. They are on average 92% of the weight o f the WT males over the period of the high 
fat diet. This has changed little from the percentage difference in weight between the two on 
a normal diet, where at 16.5 weeks of age the Fmol, 2, 4 (-/-) males weighed 89% of the WT 
males.
The organ weights of the Fmol, 2, 4 (-/-) males were measured (Figure 5.9.1b). The 
gonadal fat weight is now similar to that of the WT male mice. Another difference on the 
high-fat diet is seen in the liver weights, where the in the Fmol, 2, 4 (-/-) males the livers 
weigh 14% less than those of WT males. The spleens of the Fmol, 2, 4 (-/-) males were 
slightly larger (35%) than the WT male spleens on a high-fat diet.
The histology of the Fmol, 2, 4 (-/-) male adipocytes was checked, this time the cells 
were a similar size to the WT cells (Figure 5.9.2). So the Fmol, 2, 4 (-/-) male mouse 
adipocytes are not incapable o f gaining size and storing fat. Perhaps putting these animals on 
a high-fat diet has made them more like the WT mice, similar body weight and a similar 
adipocyte size.
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Weight of Fmol, 2, 4 (-/-) and WT males on a high-fat diet
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5.9.1 Bodyweight and organ weights on a high-fat diet
Bodyweight (a) and organ weights (at 2 1 weeks o f  age) (b) o f  Fmol, 2, 4 (-/-) and WI males
on a high-fat diet. * is p<0.05. Error bars are SEM.
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5.9.2 Adipocyte histology-high fat diet
The adipocyte histology o f  Fmol, 2, 4 (-/-) (a) and WT males (b) at 22 weeks o f  age 
high-fat diet. Scale bar represents 75 pm.
5.10 Plasma lipid and solute analysis in Fmol, 2, 4 (-/-) males on a 
high-fat diet
The plasma lipid concentration was measured in the WT and Fmol, 2, 4 (-/-) males 
on a high-fat diet at 22 weeks o f age (Figures 5.11.1). The Fmol, 2, 4 (-/-) males have 
increased plasma lipids compared to the WT males. The Fmol, 2, 4 (-/-) males on a high fat 
diet have higher plasma total cholesterol (39%), HDL cholesterol (34%) and LDL cholesterol 
(53%) than the WT males on a high fat diet. The Fmol, 2, 4 (-/-) males have reduced plasma 
triglycerides (-40%) on a high fat diet compared to WT males on the same diet.
At 22 weeks of age, the plasma lipids on a high-fat diet in the KO males are all much 
higher than the WT mice, more so than on a normal diet at the same age. The plasma 
triglyceride concentration which was very similar between WT and KO on a normal diet is 
much lower in the KO males than the WT males on a high-fat diet.
There are no significant differences in plasma solute concentrations between Fmol, 2, 
4 (-/-) males and WT males on a high-fat diet. Although the iron concentration on average is 
20% higher in the KO than the WT males.
5.11 Liver histology on a high-fat diet in WT and KO mice
The histology of the livers from males on a high-fat diet was examined. As shown in Figure 
5.11.2, there is much more fat in the livers o f both WT and Fmol, 2, 4 (-/-) mice on a high- 
fat diet, compared to animals on a normal diet at 22 weeks of age, as demonstrated by the 
markedly increased staining o f Oil Red O in both samples.
The amount of fat in the WT males on a high-fat diet appears to be slightly more than 
that contained within the livers o f the Fmol, 2, 4 (-/-) males. Clearly the trend of reduced 
hepatic fat in the Fmol, 2, 4 (-/-) males is continued. This may account for the lower liver 
weight in Fmol, 2, 4 (-/-) males compared to WT males on a high-fat diet.
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5.11.1 Plasma lipid and solutes on a high-fat diet
The plasma lipids (a) and plasma solutes (b) were measured in Fm ol, 2, 4 (-/-) and WT
males on a high-fat diet. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.11.2 Liver histology in Fm ol, 2, 4 (-/-) and WT males on a high-fat diet
A representative photograph o f  the liver histology in Fmol, 2, 4 (-/-) males (a) and WT males
(b) at 22 weeks o f  age on a high-fat diet.
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5.12 Analysis of bodyweight, organ weight, plasma lipids and 
plasma solutes in Fmo1, 2, 4 (-/-) males on a lipoic acid diet
To try to narrow down the possible reasons for the observed weight reduction in male Fmol, 
2, 4 (-/-) mice, we turned to the known endogenous substrates of the FMOs. Lipoic acid has 
been shown to be a substrate for porcine FMOl (Taylor and Ziegler, 1987). In its lipoamide 
form it is an important cofactor for enzymes o f the Krebs cycle. Mice fed lipoic acid show a 
reduction in weight via an increase in energy expenditure and reduction in food intake. 
Lipoic acid does this by reducing the activity o f AMP-activated protein kinase (AMPK) an 
important fuel-sensor in the cell (Kim et al., 2004). Our hypothesis was that without FMOl 
to metabolise lipoic acid, any weight reduction in the animals would be more pronounced in 
the Fmol, 2, 4 (-/-) mice as any lipoic acid would not be metabolised as efficiently. Hence 
that could be the underlying cause of the phenotype observed o f the male Fmol, 2, 4 (-/-) 
mice. To see if any differences could be seen, the Fmol, 2, 4 (-/-) and WT male mice were 
put on a 0.1% lipoic acid diet for 4 weeks (from 7 weeks o f age to 11 weeks of age). Their 
weight was measured over this time. Shown in Figure 5.12.1a are the weights of the animals 
on the lipoic acid diet compared to their weights on a normal chow diet. All o f the animals 
lose weight compared to what they weighed on a normal chow diet. At the beginning of the 
diet the Fmol, 2, 4 (-/-) mice weigh 9% less than they did at the same time on a normal chow 
diet. At the end of the diet they weigh 2.3% less than they did at the same time on a normal 
diet.
The organ weights o f the 0.1% lipoic acid-treated mice were also measured at the end 
of the 4 weeks (Figure 5.10.3). There was a slight reduction in liver weight in the Fmol, 2, 4 
(-/-) (-8.5%) mice compared to the WT, but this wasn’t statistically significant.
Blood plasma lipids were analysed from the lipoic acid-treated mice (Figure 5.12.1b). 
The total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were all higher 
(15.9%, 15.8%, 10.2% and 18.4% respectively) in the Fmol, 2, 4 (-/-) mice than the WT 
mice, but none of these values are significant. When compared to those values on a normal 
diet, there is very little change in cholesterol concentration from a normal to a lipoic acid diet 
in any of the mice.
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Plasma solutes were also measured in the lipoic acid-treated mice (Figure 5.12.2). 
Chloride was lower in Fmol, 2, 4 (-/-) mice, -2.1% (p<0.05) and potassium was 10.4% 
higher (p<0.05) compared to the WT males. The level of iron in the plasma increased in the 
KO animals compared to the WT. The Fmol, 2, 4 (-/-) males had 42% more iron (p<0.05) 
than the WT mice.
The histology of the male livers is shown in Figure 5.12.4. Both have little or no fat in 
the liver, i.e. no red dots where Oil Red O has stained. Another example o f how the WT and 
KO response to lipoic acid is very similar.
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ra \ Bodyweight of Fmol, 2, 4 (-/-) and WT males on a normal or 0.1% lipoic acid diet
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5.12.1 Bodyweight and plasma lipids on a lipoic acid diet
Bodyvveights (a) and plasma lipids (b) o f  Fm ol. 2, 4 (-/-) and WT males on a 0.1% lipoic
acid diet. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.12.2 Plasma solutes on a lipoic acid diet
Plasma solutes of Fmol, 2, 4 (-/-) and WT males on a 0.1% lipoic acid diet at 10 weeks of
age. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.12.3 Organ weights on a lipoic acid diet
Organ weights o f  Fmol, 2. 4 (-/-) and WT males on a 0 .1%  lipoic acid diet at 10 weeks o f  
age. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.12.4 Liver histology in Fmol, 2, 4 (-/-) and WT males on a lipoic acid diet
A representative photograph of the liver histology in Fmol, 2, 4 (-/-) males (a) and WT males
(b) at 10 weeks of age on a 0.1% lipoic acid diet. Error bars are SEM.
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5.13 Organ weight analysis of Fmol, 2, 4 (-/-) females
The liver, spleen, brown fat, heart and front adipose tissue (gonadal fat) were weighed in 4 
week old females (Figure 5.14.1). They have a pronounced reduction in gonadal fat 
compared to the WT females, 61% less fat. This is interesting given the increased 
bodyweight in the Fmol, 2, 4 (-/-) females.
The Fmol, 2, 4 (-/-) female mice at 4 weeks are shorter (15%) than that of the WT 
female mice of the same age. This difference is not seen in the male Fmol, 2, 4 (-/-) mice at 
all at any age. Unfortunately we don’t have data for the older female mice, but at 22 weeks of 
age on a high fat diet, there is no length difference.
5.14 Analysis of plasma lipids and solutes in Fmol, 2, 4 (-/-) 
females
Plasma lipids were measured in Fmol, 2, 4 (-/-) females on a normal diet at 8 and 15 weeks 
of age (Figure 5.14.2). The Fmol, 2, 4 (-/-) females had 39% and 42% more total cholesterol 
at 8 and 15 weeks respectively than the WT females. Similarly HDL cholesterol was 44% 
and 48% higher than the WT at 8 and 15 weeks respectively; the LDL cholesterol being 33% 
and 43% higher in the KO females at those same two ages.
Along with the plasma lipids, some plasma solutes were measured, glucose, iron, 
calcium and urea. There was a significant difference between female Fmol, 2, 4 (-/-) mice 
and WT females at 8 weeks o f age in iron concentration (Figure 5.14.4). The female Fmol, 
2, 4 (-/-) mice had 45 pMol/L of iron compared to the WT females who have 32 pMoI/L. The 
level remains higher than the WT at 15 weeks (not significant). Iron homeostasis is tightly 
regulated and is mainly controlled by the absorption o f iron through the intestine. A high 
plasma iron level can be due to certain anaemias (e.g. thalassemia), an increase in food 
intake, haemochromatosis (an uncontrolled absorption o f iron through the intestine), or liver 
disease. The measurement of plasma iron alone is not sufficient to imply iron overload. In 
view of this plasma ferritin would have to be measured as well to define the total iron 
binding capacity. What is really interesting is that the female Fmol, 2, 4 (-/-) mice also have 
more calcium (2.43 mMol/L) than the WT females (2.34 nMol/L) at 9 weeks of age. Calcium
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has been shown to reduce iron absorption in the intestine (Barton et al., 1983; Hallberg et al., 
1992) and this may be a response by the females to get iron levels in check, which could be 
thought o f  as successful given that the iron elevation at 15 weeks is not significant, and there 
is no longer an increased calcium concentration. The Fmol, 2, 4 (-/-) females at 15 weeks 
also show a slightly higher blood glucose concentration (not significant) compared to the WT 
females.
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5.14.1 Organ weights of Fm ol, 2, 4 (-/-) females at 4 weeks of age
The organ weights as a percentage o f  body weight o f  Fmol, 2, 4 (-/-) and WT females at 4 
weeks o f  age. ** is p<0.005. Error bars are SEM.
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5.14.2 Plasma total and HDL cholesterol
The plasma lipids in Fmol. 2, 4 (-/-) and WT females on a normal diet, total cholesterol (a);
HDL cholesterol (b) at 8 and 15 weeks o f  age.*is p<0.05,**is p<0.005. Error bars are SEM.
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5.14.3 Plasma LDL cholesterol and triglycerides
The plasma lipids in Fmol, 2, 4 (-/-) and WT females on a normal diet, LDL cholesterol (a)
and triglycerides (b) at 8 and 15 weeks o f  age. * is p<0.05, ** is p<0.005. Error bars are
SEM.
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(a) Plasma solutes in Fm ol, 2, 4 (-/-) and WT females at 9 weeks of age
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5.14.4 Plasma solutes
The plasma solutes in Fmol, 2, 4 (-/-) and WT females on a normal diet at 9 (a) and 15 (b)
weeks o f  age. * is p<0.05, ** is p<0.005. Error bars are SEM.
185
5.15 Analysis of Fmol, 2, 4 (-/-) females on a high-fat diet
Female Fmol, 2, 4 (-/-) and WT mice were put on a high-fat diet (35% cholesterol) diet for 7 
weeks. Their bodyweight, organ weights, plasma lipids and plasma solutes were all 
measured.
The female mice all gain weight (Figure 5 .15 .1), the Fmol, 2, 4 (-/-) females start the 
high fat diet weighing 22.9g and end it weighing 33.73g. The WT females start at 22.35g and 
after the high fat diet they weigh 32.94g. The Fmol, 2, 4 (-/-) females weigh on average 5% 
more than the WT females throughout the diet.
The female mice were dissected and their organs measured. There were no 
differences seen in female organ weights on a high-fat diet between KO and WT (Figure 
5.15.2). The gonadal fat weight which was much less in the Fmol, 2, 4 (-/-) females at 4 
weeks of age on a normal diet, now weighs a similar amount to the WT females on a high-fat 
diet.
The plasma lipids in the Fmol, 2, 4 (-/-) females are higher on a high fat diet (Figure
5.15.1) compared to the WT females. The females have higher total cholesterol (40%), HDL 
cholesterol (39%) and LDL cholesterol (41%) than the WT females on a high fat diet. There 
is no observable difference in triglyceride levels between WT and KO females.
Once again the plasma lipids are higher on a high-fat diet in the Fmol, 2, 4 (-/-) 
females than the WT females, even more so than on a normal diet. This is the same pattern as 
the male Fmol, 2, 4 (-/-) mice. What is different to the males is there is no lowering of 
plasma triglycerides on a high-fat diet in the Fmol, 2, 4 (-/-) females. Whereas the plasma 
triglycerides are 40% lower in Fmol, 2, 4 (-/-) males than WT males on a high-fat diet.
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(a) Weight of Fmol, 2, 4 (-/-) and WT females on a high-fat diet
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5.15.1 Bodyweight and plasma lipids of females on a high-fat diet
The bodyweight (a) and plasma lipids (b) o f  Fm ol, 2, 4 (-/-) and WT females on a high-fat
diet. * is p<0.05, ** is p<0.005. Error bars are SEM.
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5.15.2 Organ weights of Fmol, 2, 4 (-/-) females on a high-fat diet
The organ weights o f  Fmol, 2, 4 (-/-) and WT females on a high-fat diet. Error bars are SEM.
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5.16 Investigation into Fmo5 (-/-) mice on a normal diet
In this part of the chapter I will set out our research into the Fmo5 (-/-) mice. Their 
bodyweights and blood analyses were carried out, on normal, high-fat and lipoic acid diets.
On a normal diet at 4.5 weeks o f age the Fmo5 (-/-) males weigh about 23g whereas 
the WT males weigh 16g. The percentage weight gain o f the mice at certain ages is shown in 
Figure 5.17.2. From 4.5 weeks they are a very similar weight to the WT males, the 
percentage weight gain from 6.5 to 10 weeks o f age is 24% in Fmo5 (-/-) males compared to 
31% in the WT males. Between 10 and 17 weeks of age the percentage weight gain is very 
similar in WT and KO males.
The Fmo5 (-/-) females weight at 4.5 weeks is 16.3g on average, just over a gram 
heavier than the WT females. The percentage gain of the Fmo5 (-/-) females compared to the 
WT females is very similar (Figure 5.17.2). From 4.5 to 6 weeks of age the Fmo5 (-/-) 
females gain 14% in weight whilst the WT females gain only 10% in weight. Between 6 and 
10 weeks this pattern reverses and the WT females gain more weight (20%) than the Fmo5 (- 
/-) females (12%). This pattern continues but is less pronounced from 10 to 14 weeks where 
the WT females gain 12% in weight and the Fmo5 (-/-) females gain 9.5% in weight. Overall 
the weight of Fmo5 (-/-) females is very similar to that o f WT females.
t,
5.17 Blood plasma lipids in Fmo5 (-/-) mice
The Fmo5 (-/-) males have 22% and 16% lower HDL cholesterol at 15 and 22 weeks 
respectively. Whilst their LDL cholesterol is 16% lower at 15 weeks, but 38 % higher at 22 
weeks of age. The Fmo5 (-/-) females have slightly lower HDL cholesterol at 15 and 22 
weeks (9% and 5% respectively) and higher LDL cholesterol at 15 weeks (22%) but slightly 
lower (2%) at 22 weeks (Figure 5.17.3).
In the Fmo5 (-/-) females, the same applies; there is no difference in the triglyceride 
concentrations between them and the WT females at 15 and 22 weeks of age (Figure 5.17.4). 
There is a difference between Fmo5 (-/-) males and WT males (Figure 5.17.4). At 15 weeks 
their triglyceride content is very similar (0.8 and 0.85 mMol/L respectively), but whilst the 
WT male mice triglyceride concentration increases at 22 weeks of age to 1.8 mMol/L, the
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Fmo5 (-/-) male mice concentration stays at a similar level to that of 15 weeks (0.84 
mMol/L).
Fmo5 (-/-) males have less iron (22 pMol/L) compared to the WT males (29 pMol/L) 
at 22 weeks of age (Figure 5.17.7 and 5.17.8). The Fmo5 (-/-) females also have a reduced 
iron level (not significant) at the same age.
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5.17.1 Bodyweights of Fmo5 (-/-) and WT males and females
The bodyweight o f  Fmo5 (-/-) and WT males (a) and females (b) on a normal diet. Error bars
are SEM.
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5.17.2 Percentage weight gain of Fmo5 (-/-) mice
The percentage weight gain o f  Fmo5 (-/-) and WT males (a) and females (b) on a normal
diet. * is p<0.05. Error bars are SEM.
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Plasma total cholesterol in Fmo5 (-/-) and WT males
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5.17.3 Plasma total and HDL cholesterol in male Fmo5 (-/-) mice
The plasma total cholesterol (a) and HDL cholesterol (b) o f Fmo5 (-/-) and WT males on a
normal diet. * is p<0.05. Error bars are SEM.
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5.17.4 Plasma LDL cholesterol and triglycerides in Fmo5 (-/-) mice
The plasma LDL cholesterol in Frno5 (-/-) and WT males (a) and triglycerides (b) in Fmo5 (-
/-) and WT males and females on a normal diet. * is p<0.05. Error bars are SEM.
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5.17.5 Plasma total and HDL cholesterol in female Fmo5 (-/-) mice
The plasma total cholesterol (a) and HDL cholesterol (b) o f  Fmo5 (-/-) and WT females on a
normal diet. Error bars are SEM.
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5.17.6 Plasma LDL cholesterol in female Fmo5 (-/-) mice
The plasma LDL cholesterol o f  Fmo5 (-/-) and WT females on a normal diet. Error bars are 
SEM.
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5.17.7 Plasma solutes in Fmo5 (-/-) mice at 15 weeks of age
The plasma solutes o f  Fmo5 (-/-) and WT males (a) and females (b) on a normal diet. Error
bars are SEM.
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5.17.8 Plasma solutes in Fmo5 (-/-) mice at 22 weeks of age
The plasma solutes of Fmo5 (-/-) and WT males (a) and females (b) on a normal diet. * is
p<0.05. Error bars are SEM.
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5.18 Analysis of Fmo5 (-/-) mice on a high-fat diet
The Fmo5 (-/-) mice, were put on a 35% cholesterol diet (high-fat) to see if they were 
responsive to changes in fat in the diet. The Fmo5 (-/-) males put on weight, they start the 
high fat diet weighing 28. lg  and end it weighing 40.5g. They begin the diet weighing on 
average the same weight as the WT males, but end it weighing 95% o f the WT weight. The 
same pattern occurred on a normal diet where the Fmo5 (-/-) male weight gain appears to be 
tailing off sooner than the WT males (Figure 5.18.1).
The Fmo5 (-/-) females start at 21.1 g then end the high fat diet weighing 26.9g, 
although they are culled two weeks before the other females. Towards the end the Fmo5 (-/-) 
female weight looks like it is tailing off, starting the diet being 97.6% of the weight of the 
WT, reducing to 92%. None of the high fat diet body weight differences are significant, the 
weights become more variable but also more similar to the WT body weight.
The plasma lipids were measured in the Fmo5 (-/-) mice on a high-fat diet. The Fmo5 
(-/-) males have reduced plasma total cholesterol (-17%), HDL (-15%) and LDL cholesterol 
(-35%) whilst the females have slightly reduced total cholesterol (-12%) and HDL 
cholesterol (-14%) compared to their WT counterparts (Figure 5.18.3).
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5.18.1 Bodyweight in Fmo5 (-/-) mice on a high-fat diet
The bodyweight o f  Fmo5 (-/-) and WT males (a) and females (b) on a high-fat diet.
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5.18.2 Plasma lipids in Fmo5 (-/-) mice on a high-fat diet
The plasma lipids o f  Fmo5 (-/-) and WT males (a) and females (b) on a high-fat diet. * is
p<0.05. Error bars are SEM.
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5.18.3 Plasma solutes in Fmo5 (-/-) mice on a high-fat diet
The plasma solutes o f Fmo5 (-/-) and WT males (a) and females (b) on a high-fat diet. * is
p<0.05. Error bars are SEM.
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5.19 Fmo5 (-/-) males on a lipoic acid diet
To see the effects of lipoic acid on the Fmo5 (-/-) mice, Fmo5 (-/-) males were put on a 0.1% 
lipoic acid diet. The bodyweights o f the Fmo5 (-/-) mice were measured and compared to that 
o f WT mice on a lipoic acid diet. At the end of the diet compared to animals on a normal 
chow diet, on a 0.1% lipoic acid diet there is a reduction in weight in the Fmo5 (-/-) (-6%) 
and WT (-3%) mice. None o f these weight differences are statistically significant.
The organ weights o f the 0.1% lipoic acid-treated mice were also measured at the end 
of the 4 weeks (Figure 5.19.2). The only significant difference seen was a reduction in liver 
weight in the Fmo5 (-/-) mice (-2.8%), compared to the WT mice.
Plasma lipids were measured in Fmo5 (-/-) males on a 0.1% lipoic acid diet. The total 
cholesterol, HDL cholesterol, LDL cholesterol and triglycerides in the Fmo5 (-/-) mice were 
18%, 15.5%, 21.5% and 15.3% lower respectively than those in the WT mice (Figure 5.19.1).
Plasma solutes were also measured in the lipoic acid-treated mice (Figure 5.19.3). 
Calcium and phosphorous were significantly lower in the Fmo5 (-/-) mice, -3% and -20.4% 
respectively. Chloride was also lower in Fmo5 (-/-) mice (-1.6%) compared to the WT males. 
Potassium was 17.9% higher (p<0.005) in Fmo5 (-/-) males than WT males. The level o f iron 
in the plasma also increased in the KO animals compared to the WT. The Fmo5 (-/-) mice 
had 51.4% more iron (p<0.0005) than the WT mice.
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(a ) Bodyweight of Fmo5 (-/-) and WT males on a normal or 0.1% lipoic acid diet
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5.19.1 Bodyweight and blood plasma lipids on a lipoic acid diet
Bodyweight (a) and blood plasma lipids (b) in Fmo5 (-/-) and WT males on a 0.1% lipoic
acid diet at 10 weeks of age. The iron concentration is in pMol/L. * is p<0.05, ** is p<0.005.
Error bars are SEM.
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5.19.2 Organ weights on a lipoic acid diet
Organ weights in Fmo5 (-/-) and WT males on a 0.1% lipoic acid diet at 10 weeks o f  age. * is 
p<0.05.
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(a) Plasma solutes of Fmo5 (-/-) and WT males on lipoic acid diet
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5.19.3 Blood plasma solutes on a lipoic acid diet
Blood plasma solute concentration in Fmo5 (-/-) and WT males (a) and (b) on a 0.1% lipoic
acid diet at 10 weeks o f age. The iron concentration is in pMol/L. * is p<0.05, ** is p<0.005.
Error bars are SEM.
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5.20 Discussion
As shown in Figure 5.1.1 the Fmol, 2, 4 (-/-) male mice look leaner. At 10 weeks of 
age the Fmol, 2, 4 (-/-) male mice have nearly 50% less gonadal fat than the WT males. 
Leanness essentially can fall into two categories, a deficiency in stored energy or a lack of 
adipocytes to store fat (Reitman, 2002). Initially it appears the Fmol, 2, 4 (-/-) males do have 
an impaired ability to store fat, given that they have smaller adipocytes (50% smaller), shown 
by histology (Figures 5.7.4 and 5.7.5). This size though, is increased on putting the mice on a 
high-fat diet (Figure 5.9.2) where their adipocyte size becomes very similar to that o f WT 
mice on a high-fat diet. So the adipocytes cannot be described as non-functional. Both 
leanness and obesity result from an imbalance between energy intake and expenditure. The 
energy intake for the mice appears to be very similar as shown by the similarity in feed 
intake profiles (see Figure 5.3.2). The energy expenditure is something yet to be evaluated in 
these mice, but on the basis that feed intake is the same, it must be increased, through a 
general increase in metabolic turnover or increase in physical activity. Smaller adipocytes 
have been shown able to take-up increased concentrations of glucose in response to insulin 
compared to larger adipocytes (Olefsky, 1976).
The female Fmol, 2, 4 (-/-) mice do not look thinner, but at 4 weeks o f age they do 
have less gonadal fat than the WT females. As further analysis o f female mice was not 
undertaken we can only infer to the reasons behind this difference in weight. There are sex- 
differences in energy homeostasis as well as different regulation of fat depending on where in 
the body it is. More leptin is secreted from the subcutaneous fat (Casabiell et al., 1998), 
whilst insulin is more closely correlated with visceral fat and in humans it is increased 
visceral fat that is the risk factor for diabetes (Bjomtorp, 1997). Women carry fat more 
subcutaneously whilst men carry it more viscerally (Legato, 1997) hence why men tend to 
get diabetes more when they put on weight than women (Despres, 1998). Like humans, 
female rats have more circulating leptin and more total fat than males (Woods et al., 2003). 
The male rats have a greater sensitivity to low concentrations of insulin than female rats, who 
in turn have a greater sensitivity to low concentrations of leptin than male rats (Clegg et al., 
2003). Although we have no fat data on the female mice after 4 weeks o f age, we do know 
that the Fmol, 2, 4 (-/-) female mice have a greater body weight than the WT females 
whereas the Fmol, 2, 4 (-/-) males weigh less than WT males. We can therefore propose a
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reason for this difference. The possibility is that the effect we are seeing is visceral fat 
specific, which is why the males have shown a pronounced reduction in weight whereas the 
females have not. Females carry more fat subcutaneously, which perhaps is unaffected, 
although their visceral fat is still reduced, certainly at 4 weeks of age. Therefore we could 
come to the conclusion that the difference in weight and fat we are observing is down to 
insulin regulation, or lack o f it. This does not preclude a role for leptin, given the increased 
weight in the Fmol, 2, 4 (-/-) females.
There were no bodyweight differences between WT and Fmo5 (-/-) animals on a 
normal diet, in either sex. This is a stark difference to that seen in the Fmol, 2, 4 (-/-) 
animals, where bodyweight is lower in males and higher in females compared to the WT 
mice.
The differences between KO mouse models continue regarding the plasma lipids on a 
normal diet. The Fmol, 2, 4 (-/-) males and females had higher total-, HDL- and LDL- 
cholesterol than the WT males at the same age. Surprisingly the Fmo5 (-/-) males and 
females had less total- and HDL-cholesterol than the WT mice. Although it is well publicized 
that HDL cholesterol is the “good cholesterol” and LDL cholesterol is the “bad cholesterol” 
as an indicator o f coronary artery disease, this view is over-simplistic, since both have vital 
roles in the body. LDL transports cholesterol from the liver to tissues for use e.g. in 
membrane synthesis, whilst HDL accompanies old/used cholesterol back to the liver for 
recycling or excretion. The causes o f this dichotomy o f lipid homeostasis between the KO 
mouse models are unknown. But adipocytes are one of the largest pools in the body for 
cholesterol storage and exchange (Angel and Farkas, 1974). So a reduction in adipocyte size 
could cause a rise in plasma cholesterol levels in the Fmol, 2, 4 (-/-) mice.
Seeing the changes in body fat and lipid levels in the KO mice, they were put on a 
high-fat diet to investigate further the apparent dysregulation of energy homeostasis. On a 
normal diet there is no difference in the plasma triglyceride concentration between KO and 
WT animals. High plasma triglycerides do have an association with incidence of 
cardiovascular disease (Despres et al., 1996), and also insulin resistance (Reaven et al., 
1967). But this is not the case here, there is no change to triglycerides on a chow diet, but 
interestingly on a high-fat diet the plasma triglyceride level in Fmol, 2, 4 (-/-) male mice is 
much lower than that in WT male mice (Figure 5.11.1). In line with this reduction in plasma 
triglycerides is an increase in plasma total- and HDL-cholesterol. In the WT males only a
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steady increase in total-cholesterol is observed, but a marked increase in triglycerides is seen, 
the concentration almost doubles. Whereas on a normal or high-fat diet in Fmol, 2, 4 (-/-) 
males, the plasma triglycerides stay remarkably the same. Triglyceride levels in plasma are 
greatly influenced by the intake o f dietary fats (as well as endogenous production by the liver 
and to a lesser extent liberation from adipose) (Weatherby, 2002). So this large increase of 
triglycerides in the WT males could be thought of as ‘normal’ given the mice are eating a 
high-fat diet; the ability of the WT mice to excrete fat is dwarfed by the fat concentration 
being taken in. Again this isn’t seen in Fmol, 2, 4 (-/-) male mice on a high-fat diet. They are 
either successfully using the extra energy they are taking in, or excreting it.
The Fmo5 (-/-) mice on a high-fat diet have similar or slightly lower plasma lipids 
than the WT mice. Again this is counter-intuitive, given the amount of fat being eaten. Whilst 
there is a steady increase in plasma lipid in the WT mice, the reduction in Fmo5 (-/-) mice 
again shows a lack o f control in lipid homeostasis.
As shown in the liver histology o f mice on a normal chow diet, the Fmol, 2, 4 (-/-) 
male mice have fewer triglycerides, stored fat, in the liver than the WT mice at 4 and 10 
weeks of age, and at 22 weeks o f a age they have a similar amount of fat. It would then make 
sense that the Fmol, 2, 4 (-/-) mice have higher lipids in the blood plasma. The fat is being 
circulated, not stored in the liver or adipocytes. In the liver histology from the Fmol, 2, 4 (-/- 
) mice on a high-fat diet, they have much more fat in the liver, a similar amount to the WT 
mice. A fatty liver is caused by an imbalance in hepatic triglycerides for export and the 
disposal system of the liver (Malnick et al., 2003). The main sources of hepatic fatty acids to 
make triglycerides are those made by the liver itself and those found in the plasma, the free 
fatty acids. In more recent work by the laboratory the free fatty acids appeared unchanged in 
the mice, this leaves us with the possibility o f a problem with hepatic de novo lipogenesis. 
Hepatic lipogenesis is controlled by two main transcription factors, the sterol regulatory 
element-binding protein (SREBP)-lc which is controlled by nutritional stimulus and the 
action o f insulin (Yokoyama et al., 1993), and the carbohydrate response element-binding 
protein (CREBP) which is governed by glucose levels (Dentin et al., 2006). Since the high- 
fat feed was very crumbly and difficult to weigh accurately once in the cages, we are unable 
to know if the Fmol, 2, 4 (-/-) mice ate more high-fat diet than their WT counterparts. So the 
nutritional stimulus and subsequent effects o f glucose and insulin could be the mechanisms 
involved to increase the amount of fat in the liver but lower plasma triglycerides in the Fmol,
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2, 4 (-/-) male mice on a high-fat diet. However, on a normal diet there is no difference in 
triglyceride levels in the plasma between Fmol, 2, 4 (-/-) and WT mice, so a problem with 
the synthesis of triglycerides by the liver is probably not the case.
At 8 weeks of age on a normal diet the Fmol, 2, 4 (-/-) mice have increased levels of 
iron in their plasma. The Fmol, 2, 4 (-/-) female mice have 30% more iron than the WT 
females and the Fmol, 2, 4 (-/-) male mice have more iron than the WT males (20%, not 
significant). Van Lenten (Van Lenten et al., 1995) suggests a possible correlation between 
lipid levels and iron homeostasis. In his study the C57BL/6J strain which is more susceptible 
to fatty streak formation appeared less able to maintain iron homeostasis when challenged 
with lipid-induced oxidative stress. Liver apoferritin (sequesters iron) was induced in the 
fatty-streak resistant mice (C3H/HeJ) to a greater level than that observed in the C57BL/6J 
mice. The increased amount of LDL cholesterol in the Fmol, 2, 4 (-/-) mice could perhaps be 
the cause o f the iron dysregulation. This effect is transient because the older mice do not 
have this difference in plasma iron concentrations. As explained in the results section, an 
increased calcium concentration in the Fmol, 2, 4 (-/-) females could have combated this 
increase in plasma iron.
The biggest changes for the Fmo5 (-/-) mice are seen on a 0.1% lipoic acid diet. All 
o f the mice, both o f the KO mouse models and the WT each lose about 5% weight on 
average on this diet. The liver weights in the Fmo5 (-/-) mice are lighter (-11%) than that of 
the WT mice. The Fmol, 2, 4 (-/-) mice also have a lighter liver than the WT males (-8%, not 
significant). There are no other differences with regard to organ weights on the lipoic acid 
diet.
There is a reduction in total-, HDL- and LDL- cholesterol as well as triglycerides in 
the Fmo5 (-/-) mice, which is significant, but doesn’t appear to vary much from the 
concentrations on a normal diet at 15 weeks o f age. The most interesting alteration in mice 
on a lipoic acid diet is the change in some of the plasma solutes. There is a 30% increase in 
plasma iron in the Fmol, 2, 4 (-/-) males and a 35% increase in Fmo5 (-/-) males compared to 
the WT mice. As discussed in Chapter 3, the promoter of FM05 contains a potential 
upstream-stimulatory factor (USF) binding site. USF is also known to bind to the promoter of 
haem-oxygenase (HO). HO breaks down haem and is able to shift the redox state of a cell to 
a more antioxidant status and increase iron efflux (Ferris et al., 1999). Lipoic acid is known 
to induce the expression of HO (Cheng et al., 2006; Ogbome et al., 2005). What is interesting
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then is the increased plasma iron level in both o f the KO mouse models compared to the WT 
on 0.1% lipoic acid diet.
What we had expected to see was a more pronounced reduction in weight in the 
Fmol, 2, 4 (-/-) mice on a lipoic acid diet, presuming that these mice would be less able to 
metabolise lipoic acid than the WT mice, thus the effects o f lipoic acid would be more 
manifest. But this is not the case, and so lipoic acid and its lack o f metabolism is probably 
not the cause o f the gonadal fat reduction in the Fmol, 2, 4 (-/-) mice.
5.21 Current work
Work currently being carried out in the laboratory of Prof Elizabeth Shephard has delved a 
little deeper into questions thrown up by the Fmol, 2, 4 (-/-) and Fmo5 (-/-) mice.
The expression of several fat storage and fat oxidation genes have been studied in the 
gonadal fat using real-time RT-PCR by Mr Bilal Omar, and there are several differences 
between WT and Fmol, 2, 4 (-/-) males (Figure 5.21.1). PPARy is a regulator of genes 
involved in glucose and lipid metabolism, and is highly expressed in adipose tissue. There 
were no PPARy expression changes seen between Fmol, 2, 4 (-/-) and WT male adipose. 
This may not be of importance, since phosphorylation is often used to activate nuclear 
receptors. Activation o f PPARy enhances the uptake o f lipids (Martin et al., 1997; Martin et 
al., 1998) and up-regulates transcription o f genes involved in fatty acid uptake (Motojima et 
al., 1998). Adipocyte fatty acid binding protein (AP2, or FABP4) expression is 2-fold and 9- 
fold higher in Fmol, 2, 4 (-/-) than WT adipose at 10 and 22 weeks o f age respectively. 
Lipoprotein lipase is two-fold higher in the KO male adipose than the WT but only at 10 
weeks o f age. Fatty acid transport protein 1 (FATP1) expression was similar in WT and KO 
adipose. Leptin is expressed at a similar level in WT and KO mice until they are fed a high- 
fat diet, where leptin is expressed 2-fold higher in WT than Fmol, 2, 4 (-/-) adipose.
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Part 1 of Figure 5.21.1
Lipid regulatory and oxidation genes in Fm ol, 2, 4 (-/-) and WT male adipose.
For full figure legend see next page.
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5.21.1 Fat regulatory and fat oxidation genes in WT and KO white adipose
Fat regulatory and fat storage genes were measured using real time RT-PCR from WT and 
Fmol, 2. 4 (-/-) male white adipose tissue (gonadal fat) at 10 and 22 weeks o f  age on a 
normal diet, as well as 22 weeks o f  age on a high-fat diet. n=WT:3, KO:3 for each gene.
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Acyl coA synthetase converts fatty acids to acyl coA for beta-oxidation. The 
expression of this gene is similar at 10 weeks o f age in WT and KO adipose, and on a high- 
fat diet acyl coA synthetase is repressed to a similar level in both WT and KO adipose. 
Interestingly, at 22 weeks of age on a normal diet, acyl coA synthetase is 5-fold higher in the 
Fmol, 2, 4 (-/-) male adipose than the WT.
PPARy-co-activator-la (PGCla) appears to be expressed over 100 times more in the 
KO male adipose compared to the WT at 10 weeks of age and also at 22 weeks o f age on a 
high-fat diet. However the relative expression levels of PG Cla are very low in both WT and 
KO, so the emphasis that can placed on this result is unclear.
Caution should be taken in attaching too much weight to gene expression values 
where the relative expression is very small. Hence the changes stated above which are most 
interesting are those related to the adipocyte fatty acid binding protein (FABP4) and acyl coA 
synthetase (ACS).
FABP4 is a target gene of PPARy whereby activators o f PPARy lead to up-regulation 
of FABP4 (Rival et al., 2004). Adipocytes from FABP4 (-/-) mice show a reduction in 
lipolysis and increased cellular fatty acid levels (Coe et al., 1999). Fatty acid binding proteins 
are involved in the trafficking o f lipid mediators (Hertzel and Bemlohr, 2000), although the 
precise role o f FABP4 is unknown. A study where FABP4 expression levels were measured 
semi-quantitavely in obese and lean individuals suggested a greater expression o f FABP4 in 
the lean (Fisher et al., 2001). This is interesting when considering the lean Fmol, 2, 4 (-/-) 
male mice. However it has also been up-regulated in patients with ‘metabolic syndrome’ (a 
collection o f disorders that increase the risk o f cardiovascular disease and diabetes) and is 
secreted during adipogenesis (Cabre et al., 2007).
FABP4 is also known to associate with hormone sensitive lipase (HSL) (Shen et al., 
2001; Smith et al., 2004a). HSL hydrolyses triacylglycerol to monoacylglycerol, which 
eventually becomes glycerol. Glycerol is then exported to the liver and other tissues for the 
production of glucose. Free fatty acids are esterified using the co-factor acyl CoA to form 
triacylglycerol. Acyl CoA synthetase is up-regulated in the Fmol, 2, 4 (-/-) males, clearly the 
production of triacylglycerol can have two outcomes, storage or mobilisation to form energy 
via p-oxidation. Since the fat is not being stored in the Fmol, 2, 4 (-/-) male adipose, it is 
probably being used for energy. Whether P-oxidation is up-regulated in Fmol, 2, 4 (-/-) male 
adipose is currently being investigated.
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The expression o f  all five FM Os has been examined in white adipose in WT male 
mice, something which has not been investigated before. Fmol is highly expressed at 10 
weeks o f  age and is expressed 3-fold lower at 22-weeks o f  age. It is expressed 3-fold lower at 
22 weeks o f  age on a high-fat diet than at 22 weeks on a normal diet. Fmo3 shows the same 
pattern but to a much lower extent, the 10 week expression o f  Fmo3 is 7-fold lower than the 
Fmol expression at the same age. Fmo5 is not expressed at all at 10 or 22 weeks o f  age on a 
normal diet, but interestingly seems to be up-regulated on a high-fat diet. There is no 
expression o f  Fmo2 and Fmo4 at all in white adipose.
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5.21.2 The expression of Fmos in WT male adipose
The expression o f  Fmos was analysed using real-time RT-PCR in WT male adipose at 10 and 
22 weeks o f  age on a normal diet, and at 22 weeks o f  age on a high-fat diet.
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In a series o f preliminary experiments the ventricles o f the Fmol, 2, 4 (-/-) and Fmo5 
(-/-) and WT male hearts have been analysed. When normalised to bodyweight there is a 
slight reduction in right ventricle weight in the Fmol, 2, 4 (-/-) males compared to the WT 
males. The Fmo5 (-/-) male right and left ventricles weight is very similar to the WT. When 
the ventricles are normalised to femur length the left ventricle weights in both Fmol, 2, 4 (-/- 
) and Fmo5 (-/-) mice are heavier than the WT male ventricles. The right ventricle in the 
Fmo5 (-/-) hearts are heavier than the WT, whilst in the Fmol, 2, 4 (-/-) males, the right 
ventricles are a similar weight to the WT. This is an interesting development which requires 
further study.
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5.21.3 Ventricle weights vs bodyweight or femur length
The ventricles o f 10 week old Fmol, 2, 4 (-/-), Fmo5 (-/-) and WT males were measured and 
normalised to bodyweight or femur length. Where ‘FMO’ is Fmol, 2, 4 (-/-) mice and K 02  
is Fmo5 (-/-) mice.
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5.22 Conclusions
Studying the removal o f  FMOs from mice has thrown up some interesting and 
unexpected results, made all the more intriguing for the similarities and differences in the 
response by the separate KO models. What also confuses the issue is the apparent gender- 
specific effects. Clearly these results could be considered the tip o f the iceberg, as a lot more 
work needs to be undertaken to really understand the, what appears to be, fundamental role in 
energy homeostasis o f  FMOs. In the following paragraphs I will set out two possible 
explanations for these effects in an attempt to clarify our observations.
It has long been speculated that FMOs have a role in the production o f  reactive 
oxygen species (ROS). It has been shown that as FAD-OOH in the FMO catalytic cycle 
breaks down, superoxide anions and hydrogen peroxide are released (Rauckman et al., 1979). 
Additionally purified porcine liver FMOl produced superoxide anions at a rate o f about 4% 
o f the oxidised NADPH, and FM 02 (purified from rabbit lung) released H2O2 from, at most, 
40% o f the total NADPH oxidised (Tynes et al., 1986). It has thus been surmised that FMOs 
may have a role in the regulation o f  redox potential within a cell. This has not been fully 
investigated so far, but recently the only yeast FMO (yFMO) has been shown to regulate the 
thiol:disulfide ratio by oxidising glutathione (Suh et al., 1999). The expression levels of 
yFMO and its activity are modulated by changes in the redox state o f  the cell (Suh et al., 
2000) therefore substantiating a possible role for yFMO in redox regulation and also perhaps 
other FMOs. We could conclude that the removal o f  FMOl, 2 and 4 has somehow disrupted 
the redox status o f the cells (hepatocytes and/or adipocytes) causing a disruption in lipid 
homeostasis. Fmol is up-regulated in the glycerol kinase KO in brown adipose (Rahib et al., 
2007). Glycerol kinase catalyses the transfer o f  phosphate from ATP to glycerol. Adipocytes 
do not have this enzyme so they cannot metabolise glycerol produced from the breakdown o f  
triacylglycerol. Instead glycerol travels to the liver to be used in glycolysis or 
gluconeogenesis. The up-regulation o f  FMO 1 in the glycerol kinase KO further points to an 
association to energy homeostasis.
There are a limited number o f known endogenous substrates for FMOs, this is not to 
say that there are not more. Lipoic acid is one o f the known endogenous substrates for 
porcine FMOl (Taylor and Ziegler, 1987). It has been shown to reduce weight and increase 
energy expenditure in rats (Kim et al., 2004). This was the reason for using this substrate as a
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basis for part o f  this research, to see if  without certain FMOs, the Fmol, 2, 4 (-/-) mice would 
lose more weight than the WT mice. This was not the case. Although subsequent increases in 
plasma iron concentrations are intriguing and require further research. It is feasible that there 
could be another unknown endogenous substrate that goes un-metabolised when FMOl, 2 
and 4 are knocked-out. This possibility also has to be further investigated and is no doubt no 
easy task, as nearly 50 years o f  research has not thrown up many candidates.
The role for FM 05 remains elusive. FM 05 mRNA levels are similar or higher than 
FM03 or FMOl levels in human and mouse liver respectively. Its degree o f  expression 
implies that it has a fundamental role in the liver, if  not an endogenous role, than a distinct 
xenobiotic metabolism role. We need to learn more about the substrate specificity o f FM 05 
to further our knowledge o f its role.
There is a pattern o f lower lipid levels in the Fmo5 (-/-) mice, distinctly lower HDL- 
cholesterol. Low concentrations o f  bile salts such as cholate have been shown to induce 
expression o f FMO in mouse and rat liver (Dixit and Roche, 1984; Pettit et al., 1964), but 
repress it in rabbit (Williams et al., 1985) and pig (Gorrod et al., 1975) liver. Interestingly 
cholic acid reduces HDL-cholesterol in mice, and this effect is even more pronounced in 
PXR-null mice (Masson et al., 2005), PXR is known to have a role in bile acid regulation 
(Handschin and Meyer, 2005). It would be interesting if  the reduction o f  HDL-cholesterol in 
Fmo5 (-/-) mice was in any way related to an increased level o f  cholic acid, perhaps because 
FM05 is not there to metabolise it. This would tie in very well with the apparent regulation 
o f FM05 by PXR and is certainly worth further study.
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Appendix
Primers
hFM05 -2443 F ggggtacCAGTTCCACATGCATGTGCATC (11/22) 
hFM05 -1723 F ggggtaccGACCAGCTTGAGCAACATAGTG (11/22) 
hFM05 -1031 F ggggtaCCTCACTATACTCCAGCACTCAG (12/23) 
hFM05 -531 F ggggtaccGCTCGGCTCTTAAGACGCGAGTC (12/23) 
hFM05 +9 R ggagatctGCGCTCAACAGATCCTTCAGCTG (12/23)
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